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ABSTRACT 
Delineating Human Dendritic Cell Development 
Jaeyop Lee 
 
 The origin of human dendritic cells (DCs) has long been debated. DCs are a subset of 
innate immune cells that are essential for initiating adaptive immune responses. Determining 
their ontogeny is critical for vaccine development and for unveiling the molecular mechanism of 
DC insufficiency, which underlies many primary immune deficiency disorders and leukemia. 
Like all blood cells, human DCs develop from hematopoietic stem cells through a sequence of 
increasingly restricted progenitors. Initially it was assumed that DCs should derive exclusively 
from myeloid progenitors. However, during the past few decades, a number of myeloid and 
lymphoid progenitors have been described and shown to have DC potential, instigating the 
debate of the myeloid vs. lymphoid origin of DCs. Hindering the resolution of this debate, 
human DC-restricted progenitors had not been identified. Further, the potential of known 
progenitors could not be interrogated due to the lack of a culture system that supports 
simultaneous differentiation of all human DCs subsets, in conjunction with other myeloid and 
lymphoid cells. In this work, we establish a culture system that supports the development of the 
three major subsets of DCs (plasmacytoid DCs or pDCs, and the two classical DCs, cDCs) as 
well as granulocytes, monocytes and lymphocytes. This system combines mitomycin C-treated 
murine stromal cell lines, MS5 and OP9, together with human recombinant cytokines, FLT3L, 
SCF and GM-CSF, and supports the differentiation of progenitor cells at a population and single 
cell level. Using this culture in combination with a phenotypic characterization of CD34+ 
progenitor cells, we identify four consecutive DC progenitors with increasing degree of 
commitment to DCs and describe their anatomical location of development. We show that DCs 
develop from a granulocyte-monocyte-DC progenitor (GMDP), which produces granulocytes 
and a monocyte-DC progenitor (MDP), which then generates monocytes and a common DC 
progenitor (CDP), which produces pDCs and a cDC precursor (pre-cDC), which finally produces 
cDCs only. Lastly, we establish a staining panel that allows the phenotypic identification and 
separation of newly found DC progenitors as well as all previously described myeloid and 
lymphoid progenitors. We investigate their inter-developmental relationship and DC potential at 
the single cell level. We show that each progenitor population with homogeneous phenotype is 
heterogeneous in developmental potential and prove that cell surface marker expression cannot 
be directly equated to a specific developmental potential. In order to resolve the unreliability of 
phenotype to draw developmental pathways, we propose to use the quantitative clonal output in 
order to delineate the DC developmental pathway. In summary, our studies provide a new tool to 
determine DC potential in vitro, identify new stages of DC development, and propose a new 
method for tracing the developmental pathway for DC lineage. This will generate a new model 
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Chapter I. Introduction 
 
1. Classical hematopoiesis model and conflicts. 
 Human blood cells, including dendritic cells (DCs), develop from hematopoietic stem 
cells (HSCs) in the bone marrow through a series of progenitors that sequentially lose lineage 
potential. Blood cells are mainly categorized into two groups according to their function. One 
category includes all myeloid cells, which are comprised of red blood cells, megakaryocytes, 
granulocytes (G), monocytes (M) and DCs; G, M and DCs together they create the first barrier of 
immunity or innate immunity. These are relatively short-lived1, 2, 3, 4 and need constant 
replenishment from bone marrow progenitor cells5. The other category of blood cells, lymphoid 
cells, is comprised of B, NK and T cells, which are responsible for forming the adaptive immune 
response and they are longer lived than innate cells6, 7, 8. Due to the significant difference in their 
function, it was originally postulated that myeloid and lymphoid cells comprise two separate 
lineages, originating from either a common myeloid progenitor or a common lymphoid 
progenitor, respectively, both downstream from HSCs (Fig 1.1). 
This model was supported in humans and mice by prospective isolation of committed 
progenitors that are restricted to lymphoid and myeloid lineages, respectively. Common 
lymphoid progenitors (CLPs)9 and common myeloid progenitors (CMPs)10 were first identified 
in mice by the Weissman group. Shortly after finding the murine CMPs, Manz et al. identified 
the human CMP counterpart in cord blood and bone marrow within the CD34+ hematopoietic 
progenitor compartment11. Human CMPs were characterized by the expression of CD123, CD38 
and lack of CD45RA (CD34+CD38+CD123+CD45RA-). Single CMP cells cultured on 
methylcellulose together with IL-3, IL-6, IL-11, stem cell factor (SCF), FMS-tyrosine kinase 3 
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ligand (FLT3L), granulocyte/monocyte-colony stimulating factor (GM-CSF), thrombopoietin 
(TPO) and erythropoietin (EPO), generated colonies that could produce granulocytes, 
macrophages and megaerythrokaryocytes simultaneously. However, when more than 2x103 cells 
were co-cultured with Sys-1 stromal cells supplemented with human SCF, FLT3L, IL-7 and IL-2, 
supporting the development of B and NK cells, CMPs failed to produce lymphocytes12. This 
proves that CMPs are the clonogenic progenitor that has the potential to produce strictly to 
myeloid cells. Furthermore, this study also showed that upon culture, CMPs can give rise to cells 
having the phenotype of megaerythrokaryocyte progenitors (MEKs) and granulocyte-
macrophage progenitors (GMPs) that are restricted to megaerythrokaryocytic and myeloid (G 
and M) lineages, respectively11, 13. Based on these results, it was concluded that the 
megaerythrokaryocytic and myeloid (G and M) lineages bifurcate at the CMP. Therefore, the 
identification and characterization of the CMP showed that the human myeloid cell lineage 
originated from a common progenitor, distinct from the lymphoid lineage, and supported the 
classical model of hematopoiesis. 
Another piece of evidence that seemed to support the classical model was the 
identification of the human CLP14. Analysis of human bone marrow revealed the presence of a 
progenitor population with CD34+CD10+ phenotype. These cells exhibited robust B and NK cell 
potential, and T cell potential when cultured on Sys-1 and OP9-DL stromal cells, respectively. 
Additionally, CLPs failed to produce granulocytes, macrophages or megaerythrokaryocytes in 
methylcellulose CFU assay, thus are committed to lymphoid lineage and lack myeloid potential. 
The identification of human CMPs and CLPs supports that myeloid and lymphoid lineages 
diverge very early into two mutually independent trajectories. 
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The premise of the classical model is that progenitor populations isolated based on a 
homogeneous phenotype should also have homogeneous potential. Candidate progenitors were 
placed on the hematopoietic map based on their progenitor-progeny relationship with other 
known progenitors and based on their capacity to produce terminally differentiated cells. CMPs, 
for example, produced megaerythrokaryocytes, granulocytes and macrophages in 
methylcellulose cultures, as well as DCs in vivo15. Although there was no experimental evidence 
that these four cell types are generated from the same clone, it was assumed that all CMP cells 
had the uniform potential to produce all myeloid cells, and hence was considered the common 
progenitor of the myeloid lineage. 
However, the classical tree-like model and this premise have frequently been challenged. 
First, irreversibly separated myeloid and lymphoid lineages appear to be able to “converge” and 
do not seem to be completely mutually exclusive. For example, analysis of Sys-1 stromal cell 
cultures showed that single CD34+CD10+ CLPs consistently produced CD33+ myeloid cells with 
DC morphology that expressed MHC II (HLA-DR) and CD1a14, 16, 17, 18, suggesting that DC and 
lymphoid lineage potential is shared by the same clone. When CLPs and CMPs were plated onto 
Sys-1 stromal cells in parallel, they both produced human DCs19. Furthermore, when human 
CLPs and CMPs were transferred into immunodeficient mice to assess their in vivo potential15, 
they produced DCs that had identical gene expression signature irrespective of the progenitor of 
origin. Therefore, these results indicated that DCs could arise from mutually exclusive 
progenitors and questioned the reliability of the classical model in explaining human DC 
development. 
Second, recent studies in humans have provided evidence that progenitor populations are 
highly heterogeneous in phenotype and clonal potential. Human CLPs are a mix of two 
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populations, which could be further fractionated based on their CD38 expression18, 20. CD38+ 
CLPs only produced B and NK cells and were termed B/NK progenitors (BNKP), and the CD38- 
CLPs produced both B/NK lymphocytes, monocytes and DCs, and termed multilymphoid 
progenitor (MLPs). Additionally, single GMP cells from cord blood cultured on OP9-DL stromal 
cells displayed robust T cell potential20. Although whether they also produced myeloid cells 
simultaneously was not determined, it suggested that the GMPs, as a population, may not be 
restricted to myeloid lineage alone. Furthermore, work on patients with AML leukemia also 
revealed the presence of an expanded cell population with CD34+CD38-CD45RA+CD10- 
phenotype that could produce B, NK, T cells and myeloid cells, such as granulocytes21, which 
was consequently termed lymphoid-primed multipotent progenitor (LMPP). Interestingly, this 
population was also able to produce GMPs without going through CMP stage, suggesting that 
GMPs could be a mixed population arising from different sources. 
Moreover, in contrast to what is predicted by the tree-like bifurcation model, that is 
multiple myeloid lineages or lymphoid lineages descend from one common progenitor cell, 
different lineages very rarely descend from the same progenitor in vivo. By labeling mouse 
CMPs and LMPPs (the mouse CLP counterpart) with bar-coded viruses to trace the fate of single 
progenitors in vivo, Perié et al. and Naik et al. found that DCs and other myeloid or lymphoid 
cells rarely descend from the same cell22, 23. That is, a differentiated DC rarely shared the same 
barcode with another myeloid or lymphoid cell. This suggested that DC lineage is imprinted at 
early stages and distinct from lymphoid and myeloid lineages. Therefore, increasing data appears 




However, understanding DC development through single cell fate tracing has been 
hampered in humans by two main factors: (1) human DCs are comprised of three main subsets24 
and a system that can faithfully support the development of all three cell types is missing, (2) a 
culture system that can simultaneously support DC and multilineage cell development is missing. 
Therefore a system that can evaluate granulocyte, monocyte, lymphocytes and all three DC 
subset potential at the single cell level is required in order to conclusively prove whether the DC 



















Figure 1.1 Classical model of hematopoiesis. Schema shows the hierarchical ordering of 
progenitor cells and lineage bifurcation. Current model of hematopoiesis postulates that the first 
lineage commitment decision is made at the MPP stage between myeloid vs. lymphoid. LT-HSC, 
long-term hematopoietic stem cells; ST-HSC, short-term hematopoietic stem cell; MPP, 
multipotent progenitor; CMP, common myeloid progenitor; MkEP, Megaerythrokaryocyte 
progenitor; GMP, granulocyte-macrophage progenitor; CLP, common lymphoid progenitor; B 

























Figure 7. Current and Alternative Models for Hematopoietic Stem Cell and Blood Lineage Commitment
(A) Current model (Reya et al., 2001) for hematopoietic lineage commitment and development, postulating that the first lineage commitment
step of HSCs results in a strict separation of myleopoiesis and lymphopoiesis as supported through the identification of CMPs and CLPs,
respectively (Akashi et al., 2000; Kondo et al., 1997).
(B) Alternative model, based on the present studies, in which a pluripotent HSC upon loss of Mk and E potential develops into a lymphoid
primed multipotent progenitor (LMPP) that upon loss of GM potential generates the CLP (Adolfsson et al., 2001).
(C) Composite model, incorporating the experimental evidence for models (A) and (B). Also shown are expression of key genes in ST-HSCs
and LMPPs based on Q-PCR data.
LT-HSC, long-term hematopoietic stem cell; ST-HSC, short-term hematopoietic stem cell; MPP, multipotent progenitor; LMPP, lymphoid-
primed multipotent progenitor; CLP, common lymphoid progenitor; CMP, common myeloid progenitor; GMP, granulocyte/macrophage
pronenitor; MkEP, megakaryocyte/erythroid progenitor; B, B cell; T, T cell.
Our findings are particularly intriguing in light of re- didate progenitors in question have not been pro-
spectively purified and characterized and therefore pre-cent gene profiling studies of HSCs (with full myeloid
and lymphoid lineage differentiation potentials), reveal- sent at low frequencies and assayed along with other
progenitors showing additional lineage potentials in theing wide expression of myeloid (MkE and GM) but not
lymphoid gene programs (Delassus et al., 1999; Miya- utilized assays. Thus, under such conditions it has not
been possible to conclude whether or not progenitorsmoto et al., 2002). Combined with our finding, this ob-
servation strongly supports that HSCs might initially be showing restricted lineage development are in fact lin-
eage restricted or whether it rather reflects the inabilityprimed to undergo myeloid (Mk, E, and subsequently
GM) commitment (Figure 7B) and that lymphoid com- of the utilized assays to efficiently support the full lin-
eage potentials of all progenitors investigated. For in-mitment through an LSK Flt3+ LMPP stage depends on
subsequent activation of lymphoid genes. In that re- stance, the granulocyte potential of a multipotent pro-
genitor might go unnoticed if investigated at the wronggard, it is noteworthy that LSK Flt3+ cells upregulate
gene expression for FLT3 and IL-7Ra, the two cytokine time or under suboptimal conditions, as granulocytes
are very short lived in vitro, whereas monocytes accu-receptors critically involved in lymphoid and B cell
commitment (Peschon et al., 1994; Sitnicka et al., mulate with time in such cultures. Thus, to prove the
existence of other lineage-restricted progenitors, pro-2002). Furthermore, in agreement with their sustained
G and M potential, multiplex single cell PCR analysis spective purification must be combined with character-
ization of their lineage potentials in efficient in vitro anddemonstrates that IL-7Ra+ LSK Flt3+ cells also sustain
expression of the G-CSFR. in vivo assays for all lineage potentials, as demon-
strated for LSK Flt3+ cells in the present studies. Pro-In fetal (but not adult) hematopoiesis, a number of
previous observations have implicated the potential spective purification of such populations will also be
required to obtain meaningful genetic information re-existence of lympho-myeloid lineage-restricted pro-
genitors, primarily with a combined B cell, monocyte garding the genetic determinants of lineage com-
mitment.(Cumano et al., 1992; Mebius et al., 2001), and in some
cases also T cell (Lacaud et al., 1998; Lu et al., 2002) In conclusion, we have in the adult mouse bone mar-
row LSK HSC compartment identified a prominent LSKpotential. However, as emphasized by others (Ema and
Nakauchi, 2003; Katsura, 2002), definitive conclusions Flt3+ LMPP, which in contrast to true ST- and LT-HSCs
lacks significant Mk and E potential but sustains otherhave been difficult to reach based on these studies,








2. Dendritic cells: subsets and functions 
DCs are immune sentinel cells, prevalent throughout the body, essential for initiating the 
adaptive immune response and for maintaining self-tolerance. DCs were originally identified 
from mouse splenic preparations26, 27 and distinguished from macrophages by their dendritic 
morphology, lack of phagocytic vacuoles and superior capacity to prime T cells for antibody 
production28 (Fig 1.2).  Advancing from this historical point, many studies have identified 
additional DC subsets and expanded our understanding of their surface molecule expression, 
functional specialization and transcriptional regulation during development. There are currently 
three main classes of DCs in mice and humans, and together they finely orchestrate the immune 
system. 
 
Classical DCs (cDCs): There are two major subsets of cDCs in mice, called cDC1 and cDC229, 
which can be identified in lymphoid30 and non-lymphoid organs31 throughout the body. In 
lymphoid organs, they are distinguished from other mononuclear phagocytes by the expression 
of CD11c and MHCII32. Within the CD11c+MHCII+ cells, these two populations can be 
identified based on their mutually exclusive expression of CD8 and CD11b33, 34: CD8+CD11b- 
cDCs and CD8-CD11b+ESAMhi cDCs35, which correspond to cDC1s and cDC2, respectively. 
cDC1s and cDC2s differ from each other not only in phenotype but also in their functional 
capacities36. 
cDC1s are known for their superior capacity to cross-present antigens found in apoptotic 
cells in the context of MHC class I to cytotoxic CD8 T cells (CTLs)37, 38, 39, which is essential for 
combating intracellular pathogens. This was first demonstrated when cDC1s isolated from mice 
that had been immunized with OVA-loaded cells were superior to cDC2s at inducing the 
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proliferation of OT-I Rag-/- CD8+ T cells in vitro. cDC1s also induce the polarization of T cells 
into Th1 cells in vivo in an IL-12 dependent manner40, 41. cDC1s injected into wild-type mice 
after in vitro priming with Keyhole limpet hemocyanin (KLH) induced T cell division and 
secretion of IL-2 and IFNγ, characteristic of Th1 response42. Furthermore, cDC1s specifically 
express TLR343, 44, which is a conserved pathogen recognition receptor (PRR) that recognizes 
endosomal double-stranded RNA45, and induces the secretion of antiviral interferon-λ upon 
stimulation46. cDC1s can also be identified in non-lymphoid organs as CD103+CD11b- cDCs47, 
48, 49. 
cDC2s, on the other hand, are professional antigen presenters, primarily in the context of 
MHC class II50, 51. Transcriptional profile comparison between cDC1s and cDC2s showed that 
cDC2s had more transcripts of genes associated with the MHCII antigen processing pathway, 
such as LAMP1/2, Cathepsin Z and H2-DMb151, 52. Different from cDC1s, cDC2s are also better 
inducers of Th2 subset polarization53, 54, 55, 56, which is specific for combatting extracellular 
pathogens and inducing antibody immunity. Mice receiving CD8- cDCs, or cDC2s, primed with 
KLH demonstrated increased IL-4, IL-5 and IL-10, cytokines necessary for polarizing Th2, in 
their lymph nodes compared to those receiving cDC1s42. cDC2s are also present in non-
lymphoid organs and can be identified as CD103+CD11b+ cells35. 
cDCs are indispensable for successful clearance of pathogens and regulating 
hematopoiesis. Mice lacking cDCs by conditional ablation using diphtheria toxin (DT) cannot 
mount an effective adaptive immune response57, 58. In particular, these mice fail to activate CTLs 
against lymphocytic choriomeningitis virus (LCMV) or mouse hepatitis virus (MHV)59, resulting 
in chronic infections. More importantly, DT-induced, cDC-less mice displayed a 
myeloproliferative disorder syndrome, whereby peripheral numbers of neutrophils, eosinophils 
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and monocytes significantly increased as well as their respective progenitors in the bone marrow. 
Therefore, cDCs are not only important in regulating immune responses against pathogens, but 
also in regulating leukopoiesis. 
It is important to note, and distinguish, that cDCs are different from another type of 
mononuclear phagocytes that share similar phenotype with cDCs. These are the monocyte-
derived DCs. Although monocyte-derived DCs comprise the majority of CD11c+MHCII+ cells in 
the periphery, such as in the intestine60 and skin29, 61, and can equally activate naïve T cells62, 63, 
they are ontologically different from cDCs64. Monocyte derived DCs, as their name suggests, 
develop from Ly6Chi monocytes circulating in the blood61, while cDCs differentiate from 
specific cDC precursors (more in detail below). 
 
Plasmacytoid DCs (pDCs). pDCs were initially identified in human tonsils65, and later in the 
blood66, 67, 68. Although pDCs receive their name from their plasma cell-like morphology, they 
are functionally distinct from B cells. pDCs are glass adherent and have the capacity to produce 
interferon alpha (IFNα), which distinguishes them from B cells69, 70. Further studies in mouse 
identified the murine pDC counterpart in the lymph nodes, which is characterized by 
CD11c+B220+Gr-1+ expression71, 72, 73. pDCs are round and lack dendritic processes, have 
extensive ER subcellular structure and their main function is to produce copious amounts of 
IFNα in response to different signals74, 75. pDCs express TLR7 and TLR976, 77, both of which 
sense different forms of nucleic acid material. TLR9 binds to CpG-rich DNA material, which is 
commonly found in DNA viral genomes. pDCs respond to cytomegalovirus (CMV)78 and herpes 
simplex virus 2 and 1 (HSV2/1)79. However, when TLR9-/- pDCs were exposed to RNA viruses, 
they were still able to produce IFNα, suggesting the expression of a separate sensor for RNA 
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molecules80. This lead to the search and identification of TLR7 on pDCs, which recognizes 
single-stranded RNA from viral sources, such as influenza81, 82 and vesicuolstomatitis virus 
(VSV)83. Despite the functional and morphological difference from cDCs, extensive 
transcriptional analysis and developmental studies (described below) have shown that pDCs are 



















Figure 1.2 First dendritic cells in history. Phase-contrast microscopy of a representative glass-
adherent DC isolated from (A) mouse spleen26 or (B) human blood85 fixed with glutaraldehyde. 



























FIG. 1. Phase-contrast micrographs of dendritic cells isolated from peripheral lymphoid 
organs and fixed in glutaraldehyde. Figs. 1 a-d are from spleen, (e) from cervical lymph 
node, and (f) from Peyer's patch. The nucleus is large, irregular in shape, and has a refractile 
quality. The cytoplasm is arranged in processes of varying sizes and shapes, many of which 
contain spherical phase-dense mitochondria. Occasional refractile lipid granules are also 
present. A medium size lymphocyte in Fig. 1 b can be used as a size comparison. (a) X 4,500; 
(b) X 3,500; (c) X 3,200; (d) X 4,600; (e) X 3,200; (f)  X 3,200. 
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and human thymus grafted subcutaneously44–46. During adult life,
pDCs are produced constantly in the bone marrow and migrate from
the bone marrow to lymph nodes, mucosal-associated lymphoid tis-
sues and spleen in steady-state conditions. Kinetic studies indicate that
pDCs in mice have an average turnover of about 2 weeks21.
Human blood pDCs express L-selectin13, which is downregulated
in lymphoid organs, where pDCs are particularly abundant in the T
cell–rich areas around high endothelial venules2,10 (Fig. 1). Thus,
pDCs may constitutively emigrate from the blood into lymph nodes
through high endothelial venules, like naive T lymphocytes.
Consistent with this hypothesis, noninflamed lymph nodes and
spleens of L-selectin-deficient mice show a substantial reduction in
pDCs18. However, other studies have suggested that circulating pDCs
preferentially accumulate in lymph nodes when they are exposed to
an inflammatory stimulus13,23,47. In addition, pDC attachment to
inflamed high endothelial venules is dominated by E-selectin- rather
than L-selectin-mediated interactions47. Thus, the relative impor-
tance of constitutive and inflammation-induced pDC migration into
the lymph nodes is still controversial.
Chemokines and their receptors mediate leukocyte trafficking. The
pDCs express the chemokine receptor CXCR3 (refs. 13,47–50), which
promotes migration in response to interferon-γ (IFN-γ)–inducible
chemokines such as CXCL9 and CXCL10. CXCR3 is required for
most pDC migration into inflamed lymph nodes47. However, pDCs
express at least three additional receptors, CCR1, CCR2 and CCR5,
for the inflammatory chemokines CCL2, CCL3, CCL4 and CCL5.
They also express two receptors, CXCR4 and (after activation) CCR7,
for the constitutive chemokines CXCL12 and CCL21 (refs. 47–49).
CCR7 can mediate migration of mouse pDCs in in vitro chemotaxis
assays47,49, and CXCR4 is involved in pDC migration in vivo, at least
into tumors 51. Moreover, pDCs express the G protein–coupled recep-
tor ChemR23, which drives their migration in response to chemerin,
a peptide chemoattractant that is released by inflamed tissues and
tumors (S. Sozzani, unpublished data). Thus, CXCR3 may not be
solely responsible for pDC migration; at least some redundancy
seems likely in vivo in steady-state and/or inflammatory conditions.
In vitro studies have shown that CCR2, CCR5, CCR7 and CXCR3
are not functional in human pDCs48. However, CXCR3 and CXCR4
can mediate pDC migration when simultaneously engaged49,50, sug-
gesting that chemokine receptor function may require cooperation
between distinct receptors. Studies in T cells have demonstrated
that chemokine receptors can heterodimerize, delivering intracellu-
lar signals through pertussis toxin–insensitive pathways that trigger
cell adhesion but not chemotaxis52. Thus, CXCR3, CXCR4 and
other chemokine receptors on pDCs may heterodimerize, stabiliz-
ing pDC adhesive interactions with high endothelial venules. A pos-
sible requirement for LFA-1 or other integrins expressed on pDCs,
such as VLA4 and VLA5, for firm adherence of pDCs to high
endothelial venules remains to be explored. However, involvement
of VLA5 has already been found in pDC migration into tumors, as
tumor microvasculature expresses a counter-ligand for VLA-5,
VCAM-1 (ref. 51).
Pathogen sensing
The ability of pDCs to secrete type I interferons depends on cellular
sensors that promptly detect the presence of DNA and RNA viruses.
Initial clues regarding the identity of pDC viral sensors came from the
demonstration that pDCs express a subset of Toll-like receptors
(TLRs), including TLR7 and TLR9 (ref. 53). TLR9 expression
accounts for pDC responses to CpG oligonucleotides, which mimic
bacterial DNA53. TLR7 is responsible for pDC responses to guanosine
analogs as well as imidazoquinolines, which are used as antiviral com-
pounds in the treatment of human papilloma virus infections53,54. All
TLRs expressed in pDCs signal through the adaptor molecule
MyD88, which recruits signaling mediators to activate the transcrip-
tion factor NF-κB54. Unlike DCs, pDCs do not express TLR2, TLR4,
TLR5 or TLR3, which explains why pDCs do not respond to bacterial
products such as peptidoglycans, lipopolysaccharide and flagellin, or
poly(I:C), which mimics viral double-stranded RNA.
Because DNA viral genomes contain CpG-rich regions, TLR9 was a
likely candidate for pDC recognition of viral DNA. The generation of
MyD88- and TLR9-deficient mice54 allowed the demonstration that
pDCs require TLR9 to respond to DNA viruses, including herpes sim-
plex virus 2 and 1 and mouse cytomegalovirus24,55,56. Although
TLR9-deficient pDCs respond to RNA viruses (such as influenza),
MyD88-deficient pDCs do not. This observation, along with the
structural homology between some TLR7 ligands and ribonu-
cleotides57, indicated that TLR7 is a likely candidate for pDC recogni-
tion of RNA viruses. This has been demonstrated with
single-stranded RNA (ssRNA) viruses such as influenza58,59 and
vesiculostomatitis virus60, as well as synthetic ssRNA sequences rich
in uridine that mimic ssRNA viruses58,59.
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Figure 2 Morphology of pDCs. (a) By electron microscopy, pDCs appear as lymphoblasts with a medium-to-large diameter, a slightly eccentric, indented,
round or oval nucleus, lightly stained perinuclear areas and well developed rough endoplasmic reticulum. (b,c) By scanning electron microscopy, resting
pDCs have a spherical shape (b), whereas CD40L-activated pDCs have a dendritic cell–like morphology (c). Original magnifications, ×7,000 (a) and ×3,000




































1176 HUMAN DENDRITIC CELLS 
Co., Orangeburg, NY, 6 Ci /mM) at 104-120 h (MLR) and 56-72 h (periodate). Cells were 
harvested in a multisample harvester, and the data displayed as ean counts per minute ___ 
sta dard deviation of he m an.
R e s u l t s  
A small  percentage  (1-2%) of  adheren t  h u m a n  P B M C  had  s imilar  morphologic  
features to the DC isolated from mouse l y m p h o i d  organs (1). These  features inc luded:  
i r regular  shape,  a b u n d a n t  phase-dense  granules  (mi tochondr ia) ,  i r regular  nucleus 
wi th  small  nucleoli ,  and  a p rominen t  r im of  he te rochromat in .  There  were few surface 
ruffles, p inocyt ic  vesicles, or  lysosomes, organelles that  were a b u n d a n t  in ad jac n t  
monocytes  (Fig. 1 a). We  first devised a mul t i s tep  p rocedure  for enr iching  these 
" c a n d i d a t e "  DC.  This  involved successive deple t ion  o f T  cells, monocytes ,  and  B cells. 
W e  could then show tha t  the cytologic,  surface, and  funct ional  proper t ies  of  h u m a n  
DC were s imi lar  to their  counte rpar t s  in rodents.  
Enriched Prepa ati  of Human DC. T h e  pur i f ica t ion  of  h u m a n  DC was moni to red  
by  phase-contras t  microscopy of  specimens fixed in g lu ta ra ldehyde .  At each stage of  
the protocol  (Table  I), samples  were a t t ached  to PLL-coa ted  cover slips and  incuba ted  
at  37°C to al low cells to spread.  D  exhib i ted  m a n y  processes, mi tochondr ia ,  and  
i r regular  nuclei  (Fig. 1 b, c). Monocytes  spread  c i rcumferent ia l ly  and  had  clear  ruffles, 
p inocyt ic  vesicles, lysos m s, and  oval-  or k idney-shaped  nuclei  (Fig. 1 d). Smal l  
lymphocytes  showed li t t le sp read ing  (Fig. 1 c), except in the case of  B cells, which 
Fro. 1. Phase-contrast microscopy of glutaraldehyde-fixed, adherent mononuclear cells (× 1,080). 
(a) Fresh mononuclear cells adherent t  glass. A DO is surrounded by four monocytes, which exhibit 
typical ruffles, lysosomes, and pinocytic vesicles. (b, c) DO from DC-enriched fractions, after 
attachment and spreading on PLL-coated glass cover slips. Dendrites extend in several directions, 
and the cytoplasm is full of granules that are mitochondria. At the top of Fig 1 c is a typical small 
lymphocyte, which does not have processes or ruffles when attached to PLL. (d) Monocytes adherent 
to PLL-coated glass. The cells spread more actively than on non-PLL-coated glass or plastic, and 





















3. Human dendritic cells 
Shortly after the identification of mouse DCs in 1973, the quest for identifying and 
classifying human DCs began. Elegant methods for human blood fractionation by density 
gradient centrifugation allowed the first identification of human DCs (<1% of total mononuclear 
cells)85. As in mice, DCs found in the human blood had extended dendritic processes on the cell 
surface when observed by confocal microscopy. Human blood DCs were drastically different 
from blood monocytes in their morphology and their capacity to prime T cells. 
However, it wasn’t until more than a decade later that all three DC counterparts were 
thoroughly phenotypically and functionally characterized in human blood24. The main reason 
DCs in humans could not be directly isolated from blood using the murine phenotype was due to 
the poor translation of mouse surface markers to humans. A characteristic of mouse DCs is their 
expression of CD11c and MHCII (HLA-DR, in humans). CD11c in human blood is not restricted 
to DCs and is also present on neutrophils87 and monocytes88, 89. HLA-DR, which is the receptor 
in which foreign antigen is presented to CD4 T cells, and DEC-205 or CD205, a marker that 
specifically recognizes cDC1s in mouse, are expressed by DCs, monocytes, and even circulating 
CD34+ hematopoietic progenitor cells24. This indicated that markers utilized to study mouse DCs 
could not be directly translated to the study of human DCs, and additional markers were needed. 
Further studies with human blood showed that the human DC counterparts could be 
detected in lineage negative, (non-T, B, NK, CD14, CD16 monocytes) CD11c+HLA-DR+ cells 
by the differential expression of four blood-DC antigens (BDCAs); BDCA3 (CD141) 
distinguishes human cDC1s, BDCA1 (CD1c) labels cDC2s, and BDCA2 (CD303) and 4 
(CD304) are expressed on pDCs24, 90, 91. Isolation and functional assays have revealed great 
conservation between human and mouse DCs. Human pDCs express TLR7 and 9 and respond to 
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CpG by producing high levels of IFNα92 while human cDCs are superior to pDCs, monocytes 
and macrophages in their antigen presentation capacity93, 94, 95. Human cDC1s also detect 
apoptotic cells by CLEC9a receptor96, 97, 98 and efficiently cross-present antigens after 
processing99, 100, 101. Furthermore, TLR3 is specifically expressed on human cDC1s, which 
secrete IFNλ upon polyI:C stimulation46, 102. 
Further transcriptional analysis between mouse and human DCs showed that DCs across 
species were more transcriptionally similar to each other than are other cell populations within 
the same species103, 104, 105. Subset-specific transcriptional factors were identically expressed in 
human and in mouse DCs. Human and mouse pDCs express high levels of SPIB and E2-2106, 107, 
a master regulator of pDC development; cDC1 cells from mice and humans both expressed IRF8 
and BATF3, essential transcription factors for cDC1 commitment; both cDCs subsets expressed 
ID2 and CIITA, which are a transcription factor that promotes cDC differentiation and a 
coactivator that regulates the expression of genes involved in antigen presentation96. Additionally, 
all three DCs express high levels of FMS-tyrosine kinase 3 (FLT3), which is a cytokine receptor 
essential for DC development. In fact, human subjects injected with FLT3 ligand (FLT3L) 
showed dramatic increase of DC numbers in the periphery, mimicking the response to Flt3L 
injection described in mouse.  
Therefore, the high degree of conservation of transcriptional profile and function across 
species provides strong evidence that human DC development may occur through conserved 
progenitor stages108. However, while the developmental stages for mouse DCs have been 
relatively well characterized, defining the process of human DC development has met major 
challenges. The main issue for such a delay is the lack of a system that supports the unbiased 
interrogation of DC potential.  
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Figure 1.3 Surface marker phenotype comparison between human and mouse DCs. Human 
and mouse DC are compared side by side. Boxes show the surface phenotype signature for 
human and mouse DCs as well as their primary biological function. Top left, cDC1s or CD141 










































































































precursors that develop in the bone marrow7,8. In the 
mouse, a series of progressively restricted progenitor 
cells has been described, including macrophage and DC 
precursors (MDPs), which give rise to both monocytes 
and DCs, and common DC precursors (CDPs), which 
have restricted DC potential. As in other haematopoietic 
lineages, the differentiation of DCs is controlled by the 
sequential expression of growth factor receptors coupled 
to transcription factors that direct cell fate6,26. The bone 
marrow origin of human tissue DCs has been formally 
proven by haematopoietic stem cell transplantation27, but 
whether there is indefinite self-renewal of Langerhans 
cells cannot be tested in this setting as they are replaced 
by donor cells within a few months of transplantation28. 
Transplanted limbs, however, maintain their own local 
Langerhans cell populations, consistent with a process 
of local self-renewal29.
Known unknowns in humans. It is still unclear whether 
committed DC progenitors exist in the human bone 
marrow, and DC precursors have yet to be identified 
in human blood. In the haematopoietic compartment 
of the bone marrow, monocytoid DCs can be gener-
ated from both granulocyte–macrophage progenitors 
(GMPs) and the recently identified multi-lymphoid 
progenitors (MLPs), which retain myeloid potential30. 
However, distinct precursors with restricted DC poten-
tial, equivalent to MDPs and CDPs in mice, have not 
been found. Another major puzzle is the nature of 
human DC precursors in blood. Logically, a ‘pre-classical 
DC’ or precursor of human myeloid tissue DCs must 
exist. However, the mononuclear fraction of human 
blood has been analysed exhaustively and there is no 
room for the discovery of novel compartments31. Rather, 
human DC precursors must share identity with a known 
cell, such as one of the existing human blood DC sub-
sets or perhaps circulating CD34+ cells that are found 
in human blood in the steady state32. The identification 
of immunodeficiency conditions in which spontaneous 
deletion of one or more of these precursors occurs might 
help to decipher DC lineages in humans and, in par-
ticular, might reveal the relationship between monocytes 
and DCs. Current models of DC ontogeny in mice and 
humans are summarized in BOX 1.
Discovering DC deficiency. Without defined examples 
of DC deficiency it has been difficult to tackle the sim-
ple question of whether DCs have a non-redundant 
role in resistance to infections in humans in vivo or to 
explore more complex aspects of their biology, such as 
their developmental origin, relationship to monocytes 
and homeostatic influence on regulatory T (TReg) cells. 
It is perhaps surprising that DC deficiency has not been 
described previously, given that severe defects in cell-
mediated immunity would be expected if there is an 
absolute requirement for DCs in in vivo T cell prim-
ing. At least part of the problem is that the antigen-
presenting cell compartment is often overlooked, and a 
lack of DCs might simply have gone undetected in quite 
severely immunocompromised infants. Alternatively, 
the phenotype of DC deficiency might be less severe 
than anticipated owing to overlapping and redundant 
functions of antigen-presenting cells. In this case, the 
deletion of one or more DC subsets passes undetected 
if it does not dramatically compromise resistance to 
infection and survival. Interpolating the evidence from 
inducible DC depletion experiments in mice, specific 
immune response parameters are attenuated when a 
subset is depleted, but this does not always translate 
into an increase in the mortality rate of infection with 
complex pathogens4.
Figure 1 | DC classification in mice and humans. Human ‘myeloid’ dendritic  
cells (DCs) are equivalent to mouse ‘classical’ DCs. Plasmacytoid DCs (pDCs) are 
functionally closely equivalent in both species. Human blood contains at least three 
DC subsets: CD141+ myeloid DCs, CD1c+ myeloid DCs and pDCs. The non-classical 
CD16+ human monocyte is also sometimes considered a blood myeloid DC18 (not 
shown). In particular, a subset of CD16+ monocytes that express 6-sulpho LacNAc 
(SLAN; a carbohydrate modification of P-selectin glycoprotein ligand 1) has been 
characterized as a DC subset83,84. The CD141+ myeloid DCs found in human blood are 
thought to have equivalent antigen cross-presenting function to mouse DCs that can 
be identified by CD103 expression in most tissues and by CD8 expression in lymphoid 
organs; in both species C-type lectin 9A (CLEC9A), XC-chemokine receptor 1 (XCR1) 
and Toll-like receptor 3 (TLR3) are conserved markers of these cells21–24. Tissue 
equivalents of the blood CD141+ DC have not yet been described in humans, but most 
organs contain a sizeable proportion of migratory CD1c+ myeloid DCs that are distinct 
from macrophages85,86 and a second subset of ‘monocytoid’ DCs that express CD14 
and CD209 (also known as DC-SIGN)87. Their origin from monocytes remains unproven 
but they are similar in many ways to the DCs derived from classical monocytes that 
have been described in mice19,20. Human lymphoid tissues also contain CD1a+ 
lymphoid-resident myeloid DCs and CD14+ monocytoid DCs88. There is a paucity of 
information on mouse blood DCs. The only candidates appear to be pDCs and the 
precursor of classical DCs (pre-classical DCs), but the frequency of these cells in 
mouse blood is approximately tenfold lower than the frequency of DCs in human 





C-chemokine receptor 1; FLT3, FMS-related tyrosine kinase 3; iNOS, inducible 
nitric oxide synthase; M-CSFR, macrophage colony-stimulating factor receptor;  
TIP, TNF and iNOS producing; TNF, tumour necrosis factor.
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precursors that develop in the bone marrow7,8. In the 
mouse, a series of progressively restricted progenitor 
cells has been described, including macrophage and DC 
precursors (MDPs), which give rise to both monocytes 
and DCs, and common DC precursors (CDPs), which 
have restricted DC potential. As in other haematopoietic 
lineages, the differentiation of DCs is controlled by the 
sequential expression of growth factor receptors coupled 
to transcription factors that direct cell fate6,26. The bone 
marrow origin of human tissue DCs has been formally 
proven by haematopoietic stem cell transplantation27, but 
whether there is indefinite self-renewal of Langerhans 
cells cannot be tested in this setting as they are replaced 
by donor cells within a few months of transplantation28. 
Transplanted limbs, however, maintain their own local 
Langerhans cell populations, consistent with a process 
of local self-renewal29.
Known unknowns in humans. It is still unclear whether 
committed DC progenitors exist in the human bone 
marrow, and DC precursors have yet to be identified 
in human blood. In the haemat poietic compartment 
of the bone marrow, monocytoid DCs can be gener-
ated from both granulocyte–macrophage progenitors 
(GMPs) and the recently identified multi-lymphoid 
progenitors (MLPs), which retain myeloid potential30. 
However, distinct precursors with restricted DC poten-
tial, equivalent to MDPs and CDPs in mice, have not 
been found. Another major puzzle is the nature of 
human DC precursors in blood. Logically, a ‘pre-classical 
DC’ or precursor of human myeloid tissue DCs must 
exist. However, the mononuclear fraction of human 
blood has been analysed exhaustively and there is no 
room for the discovery of novel compartments31. Rather, 
human DC precursors must share identity with a known 
cell, such as one of the existing human blood DC sub-
sets or perhaps circulating CD34+ cells that are found 
in human blood in the steady state32. The identification 
of immunodeficiency conditions in which spontaneous 
deletion of one or more of these precursors occurs might 
help to decipher DC lineages in humans and, in par-
ticular, might reveal the relationship between monocytes 
and DCs. Current models of DC ontogeny in mice and 
humans are summarized in BOX 1.
Discovering DC deficiency. Without defined examples 
of DC deficiency it has be n difficult to tackle the sim-
ple question of whether DCs hav  a non-redundant 
role in resistance to infections in humans in vivo r to 
explor  more complex asp cts of their biology, such as 
their developmental origin, relationship to m ocytes 
and homeostatic influence on regulatory T (TReg) cells. 
It is perhaps surprising that DC deficiency has not be n 
described previously, given that severe defects in cell-
mediated immunity would be expected if there is an 
absolute requirement for DCs in in vivo T cell prim-
ing. At least part of the problem is that the antigen-
presenting cell compartment is often overlooked, and a 
lack of DCs might simply have gone undetected in quite 
severely immunocompromised infants. Alternatively, 
the phenotype of DC deficiency might be less severe 
than anticipated owing to overlapping and redundant 
functions of antigen-presenting cells. In this case, the 
deletion of one or more DC subsets passes undetected 
if it does not dramatically compromise resistance to 
infection and survival. Interpolating the evidence from 
inducible DC depletion experiments in mice, specific 
immune response parameters are attenuated when a 
subset is depleted, but this does not always translate 
into an increase in the mortality rate of infection with 
complex pathogens4.
Figure 1 | DC classification in mice and humans. Human ‘myeloid’ dendritic  
cells (DCs) are equivalent to mouse ‘classical’ DCs. Plasmacytoid DCs (pDCs) are 
functionally closely equivalent in both species. Human blood contains at least three 
DC subsets: CD141+ myeloid DCs, CD1c+ myeloid DCs and pDCs. The non-classical 
CD16+ human monocyte is also sometimes considered a blood myeloid DC18 (not 
shown). In particular, a subset of CD16+ monocytes that express 6-sulpho LacNAc 
(SLAN; a carbohydrate modification of P-selectin glycoprotein ligand 1) has been 
characterized as a DC subset83,84. The CD141+ myeloid DCs found in human blood are 
thought to have equivalent antig n cross-pres nting fu ction to mo se DCs that can 
be identified by CD103 expression in most tissues and by CD8 expression in lymph id 
organs; in both species C-type lectin 9A (CLEC9A), XC-chemokine receptor 1 (XCR1) 
and Toll-like receptor 3 (TLR3) are c nserved markers of these c lls21–24. Tissue 
equivalents of the blood CD141+ DC have not y t been described in humans, but most 
organs contain a sizeable proportion of migratory CD1c+ myeloid DCs that are istinct 
from macrophages85,86 and a second subset of ‘monocytoid’ DCs that express CD14 
and CD209 (also known as DC-SIGN)87. Their origin from monocytes remains unproven 
but they are similar in many ways to the DCs deriv d from cl ssical m nocytes that 
have been described in mice19,20. Human ly phoid tissues also contain CD1a+ 
lymphoid-resident myeloid DCs and CD14+ monocytoid DCs88. There is a paucity of 
information on mouse blood DCs. The only candidates appear to be pDCs and the 
precursor of classical DCs (pre-classical DCs), but the frequency of these cells in 
mouse blood is approximately tenfold lower than the frequency of DCs in human 
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4. Dendritic cell-restricted progenitors 
In mice, DCs in the periphery are very short lived and need constant replenishment from 
bone marrow precursors110. After the identification of the aforementioned mouse CMPs, finding 
the macrophage-dendritic cell progenitor (MDP) that has lost granulocyte potential was a 
landmark111. Mouse MDPs can be characterized by their Lin-Sca-KithiFlt3+CD115+ CX3CR1+ 
phenotype and lack lymphoid, megakaryocyte, and granulocyte activity but can generate 
monocytes, macrophages and DCs, which are the three main mononuclear phagocyte cell types 
that connect the innate to the adaptive immune response. Downstream MDPs, monocyte and DC 
developmental pathways split. MDPs generate a common monocyte progenitor (cMOP), which 
lacks Flt3 ligand receptor, loses DC potential and gives rise to monocytes only112. Toward the 
DC branch, MDPs give rise to a common dendritic cell progenitor (CDP)113, which expresses 
Flt3 and M-CSFR (CD115)114, but has lost monocyte potential. Downstream CDPs, two 
branches diverge to produce pDCs and cDCs115, 116.  Along the pDC pathway, CDPs produce pre-
pDCs, a progenitor that produces pDCs, retains Flt3 but lacks CD115116. Along the cDC 
pathway, CDPs differentiate into Siglec-H- pre-cDC1s and pre-cDC2s in the bone marrow 
through a Siglec-H+ stage52, 117. Both pre-cDCs leave the bone marrow, migrate through the 
blood, and enter peripheral tissues110, where they finish their differentiation into cDC1s and 
cDC2s52, 117. Hence, cDC commitment and final differentiation are anatomically separated. 
Therefore, mouse DC development goes through a sequence of progenitors with increasing 
commitment and loss of potential to granulocyte, monocyte and other DC subsets. 
Despite the transcriptional and functional conservation between humans and mice, the 
identification of restricted DC precursors in human is an arduous process with major conceptual 
and technical hurdles. 
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Human DCs were first proposed to derive from circulating blood monocytes. Sallusto and 
Lanzavecchia118 showed that blood monocytes cultured in GM-CSF and IL-4 readily adopted 
dendritic membrane processes, expressed MHC class II and I molecules (e.g. HLA-DR, CD1a, b, 
c) on the surface, upregulated T cell costimulatory molecules, CD40 and B7, and lacked the 
monocyte marker CD14, altogether resembling the cDC2s. These monocyte-derived DCs 
(MoDCs) also had high antigen presenting activity and could induce strong stimulation of mixed 
lymphocyte reactions (MLRs) with either allogeneic or autologous T cells. Hence, monocytes 
were first considered to be the main precursors for human cDC2s118, 119. 
However, it was not until recently that MoDCs have been proven to be a separate cell 
type not normally found in steady state conditions. Further phenotypic, functional and 
transcription profile characterization conclusively showed that these cells do not give rise to 
cDC2s. For instance, MoDCs express the C-type lectin molecule DC-SIGN and MMR, receptors 
that recognize mannose carbohydrates on bacteria and activate phagocytosis, while cDC2s do 
not24. Furthermore, MoDCs were far less prone to maturation upon CD40L or prostaglandin-E2 
(PGE2) exposure, and less migratory than blood cDC2s in response to CCL2194. Genome-wide 
expression comparison among monocytes, MoDCs and DC subsets, showed that MoDCs 
clustered together with monocytes and macrophages rather than with pDCs and cDCs. More 
importantly, MoDCs did not express FLT3, a DC-specific marker103, 120. In sum, this strongly 
suggested that blood monocytes are not the cDC precursors in humans. 
Another cDC precursor was proposed in parallel to monocytes: the plasmacytoid DC. 
Similar to monocytes, pDCs were considered to be the precursors for cDCs because they gained 
dendritic morphology and stimulated MLRs after culture with IL-3 and CD40L86. However, 
neither monocytes nor pDCs in the mouse produce any cDCs upon adoptive transfer in the 
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steady state121. Such confusion was clarified after the identification of murine pre-DC115, the 
cDC precursor that is distinct from monocytes and pDCs. Developmental studies showed that 
pDCs and cDCs are two separate DC subsets that bifurcate downstream of the CDPs, with pre-
cDC arising from the CDP and being the immediate precursor for cDCs.  
When I started my thesis work, there was no knowledge of the human counterparts to 
these sequential cDC progenitors. A major obstacle was that a system that allowed the 
simultaneous evaluation of all three authentic DC subsets was lacking. Therefore, to enable 
identification of human DC progenitors, a method to interrogate steady state DC development 

















Figure 1.4 Mouse DC development. Schema shows the sequence of DC-restricted progenitors 
and their anatomical compartmentalization in mouse. MP, myeloid progenitor; MDP, monocyte-





























ogy. Later, the progeny of pre-DCs become sessile and
develop dendritic morphology and join the lymph node DC
network, where they show exhibit their signature probing
motion (58, 64). In conclusion, the DC and monocyte lin-
eages split in the BM, where MDPs give rise to both mono-
cytes and CDP; the latter produces pre-DCs, which migrate
from BM through the blood to the periphery to give rise to
DCs (Fig. 1).
Origin of DCs in non-lymphoid tissues
Skin
The skin contains LCs in the epidermis and
CD103+ CD11bloLangerin+ and CD103)CD11bhiLangerin)
DCs in the dermis. LCs have many of the features of DCs,
including morphology, ability to re-distribute large amounts
of MHC II from the endocytic system to the cell surface, and
capacity to stimulate allogeneic T-cell proliferation in vitro after
activation (64–68). Importantly, LCs differ from DCs in that
they are resistant to irradiation, they are not replaced by BM
transfer in the steady state because they are self-renewing in
situ, and like monocytes and macrophages, their development
is dependent on macrophage colony-stimulating factor
(M-CSF) (69). LC precursors, which are CX3CR1
+CD45+,
colonize the dermis during late embryonic development
(70, 71). In mice, these precursors complete their differentia-
tion into LCs by postnatal day 2, whereupon they undergo a
burst of cell division between postnatal d2-d7, which
accounts for the dramatic increase in LCs during this develop-
mental window. The LC precursor in skin appears to resemble
the MDP, which is the bone marrow progenitor for mono-
cytes and cDCs with a CD45+CX3CR1
+ phenotype (70). We
speculate that the MDP or a closely related cell is the LC
progenitor, which seeds the skin directly prior to birth. This
hypothesis would place the LC in its own differentiation path-
way, which branches off from the classical DC in the same
place in development as the monocyte (Fig. 1).
The dermal layer of the skin contains two subsets of DCs,
CD103+CD11bloLangerin+ DCs and CD103)CD11bhiLanger-
in) DCs (CD103+ and CD103) dermal DCs, respectively)
(10, 72–74) (Table 1). Although both LCs and CD103+ der-
mal DCs express Langerin, CD103+ dermal DCs are more
closely related to spleen CD8+ DCs than to LCs (30, 33, 34).
While LC development is dependent on M-CSF and indepen-
dent of Flt3, CD103+ dermal DCs like spleen DCs are M-CSF
independent and Flt3 dependent (34). Unlike LCs that can
self-renew in situ, dermal CD103+ DCs are continually replen-
ished from the same blood-borne pre-DCs that give rise to
lymphoid organ DCs (74). Like CD8+ splenic DCs, develop-
ment of CD103+ dermal DCs requires expression of the
IRF8, Id2, and Batf3 transcription factors (see below). Finally,
both dermal CD103+ dermal DCs and CD8+ spleen DCs
specialize in antigen cross-presentation (11, 30). CD103)
dermal DCs differ from the CD103+ in expressing higher
levels of M-CSFR and lower levels of Flt3. Consistent with
this expression profile, either Flt3L or CD115 (MCSF-R)
deficiency results in a decrease in dermal CD103) DCs (34).
Finally, pre-DCs give rise to CD103) dermal DCs but less
efficiently than to CD103+ DCs. Thus, CD103) DCs may be a
heterogeneous collection of cells with distinct origins, or they
may come from a single Flt3+ precursor that remains M-CSF
responsive.
Skin-draining lymph nodes contain a subpopulation of
DCs that resemble CD103+ and CD103) dermal DCs (72, 74).
Their migration from the skin to the draining lymph nodes is




















Fig. 1. Dendritic cell and monocyte origin and development.
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5. Systems for analysis of human DC development 
The history of elucidating human DC development is also the history of an in vitro 
culture that supports DC development. In order to identify progenitors from which DCs develop, 
a system that allows the ex vivo detection of DC potential is necessary.  
Shortly after the GM-CSF and IL-4 culture to produce DCs from monocytes was 
established, Flt3L treatment was shown to increase the number of DCs in mice. Flt3L injection 
dramatically boosted the number of CD11c+MHCII+ DCs, more so than when mice were treated 
with GM-CSF or with GM-CSF and IL-4123. Following clinical investigations examining the 
effect of FLT3L injections in human subjects provided additional evidence on the effect of 
FLT3L as a strong DC-poietin. Volunteers administered with FLT3L showed significant 
expansion of CD11c+HLA-DR+ cDCs as well as CD11c-CD45RA+CD123hi cells, which 
correspond to pDCs94, 95, 124. These results together with advances in mouse genetic manipulation 
investigations have elucidated the indispensable role of FLT3L in DC development125. 
Since then, several liquid cultures using FLT3L alone or in combination with other 
cytokines have been used in an attempt to produce human DCs. The first culture to differentiate 
unknown precursors to DCs using FLT3L alone tested the capacity of cord blood derived 
CD34+CD45RA+CD123+ cells to produce pDCs126. CD34+CD45RA+CD123+ cells successfully 
generated high numbers of pDCs after 20 days and produced high levels of IFNα upon HSV 
infection. Although this culture seemed to support pDC development, it could not reliably 
facilitate the development of cDCs127. 
More recently, a two-step culture was reported to produce massive numbers of cDC1 
cells97. CD34+ cells were first expanded in the presence of SCF, FLT3L, IL-3 and IL-6, and then 
were differentiated in the presence of FLT3L, SCF, GM-CSF and IL-4. This culture supported 
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robust production of CLEC9a+ cDC1s, which were capable of engulfing apoptotic cells and 
expressing cDC1-specific genes (NECL2, BATF3, IRF8 and TLR3). Although a large number of 
cells bore the CD1a+HLA-DR+ phenotype in this culture, phenotypic characterization to 
determine whether they were MoDCs or cDC2 that acquired CD1a was not performed. 
Additionally, this culture failed to produce any pDCs. Therefore, a culture that supported the 
development of all three subsets had not yet been established. 
In parallel to liquid cultures, a different type of culture system was using immortalized 
mouse stromal cell lines. CD34+ progenitor cells on a layer of Sys-1 stromal cells with FLT3L 
developed into pDCs and cDC2s, but not cDC1s19. Interestingly, Sys-1 cells simultaneously 
supported the development of B cells together with pDCs and cDC2s. Although this culture was 
not able to produce all three DC subsets, it was a milestone in being able to interrogate two 
distinct lineages (the DC lineage and B cell lineage) simultaneously. This provided a tool to 
study the DC lineage in relation to the B cell lineage.  
More importantly, because this culture system supported the development of two distinct 
lineages, it could be used to assess the developmental potential for these two lineages at the 
single cell level. Previous assays determined the potential of separate lineages using separate 
cultures, and it was only assumed that a progenitor had multiple potentials. This approach could 
not resolve clonal heterogeneity within the progenitor population. In other words, whether a 
single progenitor cell is capable of producing two lineages, or whether two clones individually 
produce different lineages can only be resolved by single cell analysis. 
One of the latest culture systems used to investigate potential at the single cell level 
employs MS5 stromal cells together with SCF, TPO, IL-7, IL-2, G-CSF, GM-CSF and M-CSF20. 
This culture could detect the potential of CD14+CD1a- macrophages in addition to CD14-CD1a+ 
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DCs, B cells and NK cells (4 lineages). However, the markers used to detect DCs could not 
discriminate between MoDCs and cDC2s, and hence cannot be used to convincingly define 
authentic DC lineage. Thus, a culture that supports all three DCs together with lymphocytes was 
still needed. 
One culture that is crucial for determining whether DC-producing clones share myeloid 
potential is a culture that nurtures both granulocyte and DC development. The primary culture to 
support myeloid cell development is a semisolid culture with a cocktail of myeloproliferative 
cytokines11 (granulocyte-colony stimulating factor G-CSF, GM-CSF, erythropoietin, SCF) in 
methylcellulose. In this system, CD34+ progenitor cells produce megaerythrokaryocytes, 
granulocytes and macrophages, as determined by their colony morphology, but never DCs. 
Therefore, in order to determine whether a progenitor is able to produce both DCs and other 
myeloid cells, a culture that could evaluate the potential for granulocytes, macrophages and all 
three DC subsets needed to be developed. 
Another powerful system to studying human DC development is xenotransplantaion into 
immunodeficient mice. Human HSCs transferred into NOD.Cg-Prkdcscid-IL2rgtmlWjl/Sz 
(NOD/SCID/IL2rγnull or NSG) NSG bone marrow or intraveneously can recapitulate the 
development of all human blood cell types128, 129, 130. These mice are able to produce all three DC 
subsets, as well as robust B cell and monocyte reconstitution. However, NSG mice show poor 
granulocyte chimerism even after extended periods of time131. Furthermore, because of the need 
to transfer a large number of human cells (except for HSCs) in order to obtain readable counts, 
DC potential can only be determined at the population level and not at the single cell level. 
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Therefore, in order to conclusively determine whether a progenitor is restricted to DCs, 
or belongs to either the myeloid or lymphoid lineage, a culture supporting granulocytes, 























6. Summary and Goals 
 The classical model of hematopoiesis separates blood cells into two lineages (myeloid 
and lymphoid) each originating from their respective common progenitors. This model was 
established based on two premises: (1) the development of the myeloid and lymphoid branches 
does not overlap or converge, and (2) progenitors isolated on a common phenotype also have 
homogeneous potential. However, these premises have been heavily contested by studies 
showing that both myeloid and lymphoid progenitors produce DCs, and by showing that 
progenitors with homogeneous phenotype have great degree of heterogeneity in their clonal 
potential both in vitro and in vivo. These studies also proposed that DCs, in mice at least, might 
be a lineage on their own with intermediate DC restricted progenitors, challenging the standard 
model of hematopoiesis. 
 Despite the extensive work on mouse DC development, very little is known regarding 
human DCs. In humans, DCs have only been thoroughly characterized in the past two decades 
and a system to interrogate the potential of all three DC subsets is still lacking, delaying the 
progress in identifying human DC restricted progenitors. Furthermore, many oligopotent 
progenitors have been reported, yet a coherent cross comparison in phenotype, 
interdevelopmental relationship and clonal potential has not been performed. 
 In order to clarify the conflict in DC origin, I first established a culture system that allows 
the simultaneous interrogation of myeloid and lymphoid lineages: granulocytes, monocytes, 
cDC1s, cDC2s, pDCs and B cells. Using a combination of human cytokines and mouse stromal 
cell lines, I tested and optimize an in vitro system that can support the development of single 
progenitor cells into the different cell types. 
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 Furthermore, based on the evidence that mouse and human DCs have evolutionarily 
conserved gene expression signatures, I hypothesize that mouse MDPs, CDPs and pre-cDCs can 
also be found in humans. I searched for and found these precursors by tracing the expression of 
DC-poeitin receptor FLT3 and tested them using in vitro and in vivo assays. 
Finally, I established a staining panel that can exhaustively identify all currently known 
hematopoietic progenitors and determine their progenitor-progeny relationship as well as their 



















Chapter II. Materials and Methods 
 
1. Mononuclear cell isolation from human tissue samples 
Human umbilical cord blood and leukophoretic peripheral blood (buffy coat) were 
purchased from New York Blood Center.  Human bone marrow was obtained from total hip 
arthroplasty at Hospital for Special Surgery (New York). Tonsils were obtained from routine 
tonsillectomies performed at the Babies and Children's Hospital of Columbia-Presbyterian 
Medical Center. Informed consent was obtained from the patients and/or exempt from informed 
consent being residual material after diagnosis and fully de-identified. All samples were 
collected according to protocols approved by the Institutional Review Board at Columbia 
University Medical Center and The Rockefeller University. The specimens were kept on ice 
immediately after surgical removal. Tonsil samples were minced, treated with 5ml of HBSS 
(Invitrogen) with 2,000U of collagenase (Roche) at 37oC for 20 minutes. Digestion was stopped 
by adding 100ul of 0.5M EDTA (Gibco) and incubated for an additional 5 min. Cells were 
collected, filtered through a 100nm nylon mesh and washed with complete alpha MEM media 
(Invitrogen, see below). Cell suspension were then overlaid on Ficoll-Hypaque (Amersham 
Pharmacia Biotech, Piscataway, NJ) and spun for 15 min at room temperature. Buffy coat was 
then washed and collected for cell analysis. Bone marrow samples were preserved in solution 
containing 1000 Units/ml heparin (NDC #63323-540-11), and digested in RPMI containing 20 
mg/ml collagenase IV (Sigma #C-5138) for 15 min at 37oC. After density centrifugation using 
Ficoll-Hypaque (Amersham Pharmacia Biotech, Piscataway, NJ), aliquots of mononuclear bone 




2. Stromal cell culture 
S17, OP9 and MS5 murine bone marrow stromal cells were maintained and passed in 
complete alpha MEM medium supplemented with L-glutamine, ribonucleosides and 
deoxyribonucleosides (Invitrogen) with 10% FCS and penicillin/streptomycin (Invitrogen). 24 
hours before coculture with human cells, stromal cells were seeded at 3.75 x 104 cells per well in 
a 96-well plate or 1.5 x 105 cells per well in a 24-well plate, in 50ul or 500ul, respectively of 
complete alpha MEM medium. For MS5 and OP9 mix cultures, a fixed number of MS5 cells 
(1.5 x105) was mixed with the increasing numbers of OP9 (Fig 3.6) and then plated on 24-well 
plates. Human cells and cytokines were added the following day reaching a total final volume of 
100ul or 1ml for 96-well plates or 24-well plates. Half media was changed every 7 days of 
culture. 
For mitomycin C treatment, stromal cells were treated with 10ug/ml mytomicin C 
(Sigma) for three hours, washed with PBS, dislodged from the plate with Trypsin 0.05% (Gibco) 
and re-seeded as mentioned above. 
Human cell culture was performed with medium supplemented with recombinant 
cytokines: 100ng of FLT3L/ml (Celldex), 20ng/ml SCF (Peprotech) or 10ng/ml GM-CSF 
(Peprotech). Cells were harvested between day1-21 for flow cytometry analysis. 
  
3. Flow cytometry and cell sorting 
Samples from cord blood, peripheral blood, bone marrow and tonsil were incubated with 
fluorescent-labeled antibodies for direct analysis on the BDLSR II flow cytometers (Becton 
Dickinson Immunocytometry Systems [BDIS], San Jose, CA) or further purification by 
fluorescence-activated cell sorting on the Influx, both using HeNe and argon lasers. 
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For hematopoietic progenitor analysis, single cell lineage potential, developmental 
hierarchy relationship experiments, and characterization of progenitor cells from cord blood and 
bone marrow, CD34+ cells were first enriched using CD34 MicroBead Kit and LS MACS 
magnetic columns (Miltenyi Biotec, Auburn, CA). Enriched CD34+ cells (70%-95% purity) were 
incubated with appropriate antibody cocktails to each experiment. 
For the isolation of CD34+ cells or the identification of human GMDPs, MDPs and CDPs 
(Fig 3.1 through 4.7), enriched CD34+ cells were incubated with CD3 (OKT3, Brilliant Violet 
(BV) 650, Biolegend), CD19 (HIB19, BV650, Biolegend), CD56 (HCD56, BV650, Biolegend), 
CD14 (TuK4, Qdot-655, Invitrogen), CD66b (G10F5, PerCP-Cy5.5, Biolegend), CD303 (201A, 
PerCP-Cy5.5, Biolegend), CD141 (M80, PerCP-Cy5.5, Biolegend), CD1c (L161, APC-Cy7, 
Biolegend), CD34 (581, Alexa Fluor (AF) 700, Biolegend), CD38 (HIT2, BV421, Biolegend), 
CD45RA (HI100, BV510, Biolegend), CD10 (HI10a, PE-Cy7, Biolegend), CD115 (9-4D2-1E4, 
APC, Biolegend), CD123 (9F5, PE, BD), CD116 (4H1, FITC, Biolegend). Alternatively, CD135 
(4G8, PE, BD) was used instead of CD123. 
For purification of differentiated DCs and monocytes from peripheral blood and culture 
(Fig 3.2), single cell cultures or NSG bone marrow, cells were stained with LIVE/DEAD® (Life 
technologies), CD45 (AF700), CD66b (PerCP-Cy5.5), CD56 (B159, Pacific Blue (PB), BD), 
CD19 (HIB19, PB, Biolegend), CD14 (Qdot-655), CLEC9a (8F9, PE, Biolegend), CD1c (L161, 
PE-Cy7, Biolegend), CD303 (201A, FITC, Biolegend), CD123 (6H6, Brilliant Violet (BV) 510, 
Biolegend), CD141 (AD5-14H12, APC, Miltenyi) for 40 minutes on ice. 4 or 10ul of antibody 
mix was used to stain cells harvested from 96- or 24-well plates, respectively. 
For surface marker analysis (Fig 3.4), CD11c (3.9, Biolegend), HLA-DR (G46-6, BD), 
CD80 (2D10, Biotin, Biolegend), CD83 (HB15e, Biolegend), CD86 (IT2.2, Biolegend), DC-
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SIGN/CD209 (DCN46, BD) were used in PerCP-Cy5.5 and CD123 (9F5, BD), CX3CR1 (2A9-
1, Biolegend), SIRP α/CD172 (SE5A5, Biolegend) or CD1a (HI149, BD) were used in PE. 
For isolation of rare pre-cDCs from cord blood and peripheral blood (Fig 4.3), an 
enrichment step was performed prior to sorting. In brief, mononuclear cells were incubated with 
antibodies against CD135 (4G8, PE, BD) and CD117 (A3C6E2, Biotin, Biolegend) for 40 
minutes at 4°C. After washing, antibody against PE (PE001, Biotin, Biolegend) was added and 
incubated for another 10 minutes at 4°C. Following wash, CD117+CD135+ cells were positively 
selected using anti-biotin MicroBeads and LS MACS magnetic columns (Miltenyi). For sorting 
pre-cDCs, enriched CD117+CD135+ cells (from CB or PB) or total mononuclear cells (from BM 
or Tonsils) were stained for CD14 (TuK4, Qdot-655, Invitrogen), CD3 (OKT3, Brilliant Violet 
(BV) 650, Biolegend), CD19 (HIB19, BV650, Biolegend), CD20 (2H7, BV650, Biolegend), 
CD56 (HCD56, BV650, Biolegend), CD66b (G10F5, PerCP-Cy5.5, Biolegend), CD303 (201A, 
PerCP-Cy5.5, Biolegend), CD1c  (L161, PE-Cy7, Biolegend), CD141 (M80, PE-Cy7, 
Biolegend), CD34 (581, AlexaFluor700, Biolegend), CD117 (104D2, BV421, Biolegend), 
CD135 (4G8, PE, BD), CD45RA (HI100, BV510, Biolegend), CD116 (4H1, FITC, Biolegend) 
and CD115 (9-4D2-1E4, APC, Biolegend) for 40 minutes on ice. pre-cDCs were isolated as 
Lin(CD3/19/20/56/14)-Granulocyte(CD66b)-pDC(CD303)-cDC(CD1c/CD141)-CD34-CD117+ 
CD135+SSCloCD116+CD115-CD45RA+. 
For progenitor-progeny relationship between GMDPs, MDPs and CDPs (Fig 4.7), 
cultured progenitor cells were harvested at specific time points and stained with LIVE/DEAD® 
(Invitrogen), CD45 (HI30, AF700, Biolegend), CD14, CD3, CD19, CD56, CD66b, CD303, 
CD1c, CD141, CD34 (581, APC-Cy7, Biolegend), CD117 (104D2, BV421, Biolegend), CD123 
(9F5, PE, BD), CD45RA (BV510) and CD116 (FITC) for 40 minutes on ice. 
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For progenitor-progeny relationship experiments of CDPs and pre-cDCs (Fig 4.7), 
cultured CDPs were harvested at specific time points and stained with LIVE/DEAD®, CD45, 
CD14, CD3, CD19, CD20, CD56, CD66b, CD303, CD1c, CD141, CD34 (581, APC-Cy7, 
Biolegend), CD117, CD123 (9F5, PE, BD), CD45RA and CD116 for 40 minutes on ice. 
For hematopoietic progenitor cell analysis, single cell lineage potential, developmental 
hierarchy relationship experiments, and characterization of progenitor cells from cord blood and 
adult bone marrow (Fig 5.1 through 5.5), enriched CD34+ cells were stained with CD3 (OKT3, 
Brilliant Violet (BV) 650, Biolegend), CD19 (HIB19, BV650, Biolegend), CD56 (HCD56, 
BV650, Biolegend), CD14 (TuK4, Qdot-655, Invitrogen), CD66b (G10F5, PerCP-Cy5.5, 
Biolegend), CD303 (201A, PerCP-Cy5.5, Biolegend), CD141 (M80, PerCP-Cy5.5, Biolegend), 
CD1c (L161, APC-Cy7, Biolegend), CD34 (581, Alexa Fluor (AF) 700, Biolegend), CD38 
(HIT2, BV421, Biolegend), CD90 (5E10, PE, Biolegend), CD45RA (HI100, AF488, Biolegend), 
CD123 (6H6, BV510, BD), CD10 (HI10a, PE-Cy7, Biolegend), CD115 (9-4D2-1E4, APC, 
Biolegend). For culture experiments, progenitors were sorted from Lin(CD3/19/56/14/66b/303/ 
141/1c)-cells and following Table 5.1 surface phenotypes. 
For inter-developmental relationship experiments (Fig 5.3), cells from either culture or 
NSG bone marrow were stained for LIVE/DEAD® (Life technologies), CD45 (HI30, AF700, 
Biolegend), CD14 (Qdot-655), CD3 (OKT3, BV650, Biolegend), CD19 (HIB19, BV650, 
Biolegend), CD56 (HCD56, BV650, Biolegend), CD16 (3G8, BV650, Biolegend), CD11c (3.9, 
PerCP-Cy5.5, Biolegend), CD66b (PerCP-Cy5.5), CD303 (PerCP-Cy5.5), CD141 (PerCP-
Cy5.5), CD34 (581, APC-Cy7, Biolegend), CD38 (BV421), CD90 (PE), CD7 (CD7-6B7, PE-
Cy7, Biolegend), CD45RA (AF488), CD123 (BV510) and CD115 (APC). Also, CD45RA 
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(HI100, BV510, Biolegend) and CD123 (9F5, PE, BD) were used alternatively for experiments 
measuring CFSE halving. 
 
4. RT-PCR 
mRNA was isolated using RNAqueous®-Micro kit (Life technologies) and cDNA was 
produced by SuperScript® III First Strand kit (Invitrogen). cDNA concentration was measured 
by Nanodrop 2000c spectrophotometer (Thermo Fisher Scientific) and quantitative PCR was 
performed using predesigned primers (Table 2.1) and LightCycler® 480 SYBR Green I Master 
mix (Roche). CT values for each gene transcript of interest was measured by LightCycler® 480 
II (Roche). Briefly, samples were heated to 95°C for 5 min and amplified for 40 cycles (melt at 
95°C for 10 sec, anneal at 60°C for 20 sec, elongate at 72°C for 20 sec). Relative gene 
expression was measured as the difference in CT values between the housekeeping gene and the 
gene of interest (i.e. ΔCT). 
 
Gene Forward Reverse 
GAPDH 5'- TGGTCACCAGGGCTGCTTTT-3' 5'- ATCTCGCTCCTGGAAGATGGTG-3' 
IRF8 5'- CTTCGACACCAGCCAGTTCTTC-3' 5'- ACAGCTCTTCCCAGCCTCTTCT-3' 
E2-2 5'- CTCTTCCTGTACGCCTCCTG-3' 5'- TAGGAGACGATGAGGCCTGT-3' 
XCR1 5'- TCAAGACGCATGTAAAGAGGTGTAG-3' 5'- GGCAGGGACGTTTAGAGCAT-3' 
FLT3 5'- GCGTTCCAGAGCCGATCGTGG-3' 5'- GCACAGCACCTTATGTCCGTCCC-3' 
TLR2 5'- TACCTGTGGGGCTCATTGTG-3' 5'- TGCAGATACCATTGCGGTCA-3' 
TLR3 5'- AGTGCCGTCTATTTGCCACA-3' 5'- GCATCCCAAAGGGCAAAAGG-3' 
TLR7 5'- CTCCTTGGGGCTAGATGGTTTC-3' 5'- TGGTGAGGGTGAGGTTCGT-3' 
TLR9 5'- GAGTGCTGGACCTGAGTGAG-3' 5'- ATCGAGTGAGCGGAAGAAGATG-3' 
 




5. Cytokine secretion assay 
DC subsets were sorted from culture and 40,000 cells/100ul were plated in complete 
RPMI medium (Invitrogen) containing 10% FCS and penicillin/streptomycin (Invitrogen). Cells 
were stimulated with 1uM of CpG ODN2216 (Invivogen), 50ug/ml Poly(I:C) (Invivogen) or 
10ug/ml LPS (Sigma). 48hrs hours later, supernantant was collected and IFNα (Mabtech), IL-
12p70 and IL-6 were analyzed using ELISA (eBioscience). 
 
6. Colony forming unit 
For colony forming unit cultures, 1 x 103 cells or 5 x102 cells were sorted and plated in 
non-adherent 35mm dish (Stemcell). Colony forming unit assay was performed using 
MethoCultTM (Stemcell, H4434), containing SCF, GM-CSF, IL-3 and EPO. Colony-forming 
unit–cells (CFU-C) were counted after 14 days of culture. 
 
7. CFSE staining 
To determine cellular divisions in culture, input populations were labeled for 15min with 
5µM carboxyfluorescein diacetate succinimidyl ester (CFSE; Molecular Probes) at 37°C in PBS. 
Cells were washed with complete alpha MEM media and plated on stromal cell cultures. 
 
8. Clonal analysis 
Single progenitor cells were directly sorted into pre-plated stromal cells on 96-well 
plates. Immediately after, media containing cytokine mix was added. Each well was harvested 
after 7-21 days of culture and stained with LIVE/DEAD®, CD45, CD66b, CLEC9a, CD14, 
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CD1c, CD303, CD141, CD19 and CD56. Positive clones were determined by the detection of at 
least 2 (for CDPs) or 7 (for all other progenitors) events in any of the lineage specific gates. 
To determine the setting and efficiency for single cell sorting, human PBMCs were 
stained for 15min with 5µM of carboxyfluoresceindiacetatesuccinimidyl ester (CFSE; Molecular 
Probes) at 37°C and CFSE+ single cells were sorted into each well of a 96-well plate. 90.5% of 
wells contained 1 cell, 9.5% of wells had 0 cells and none had more than 1 cell as verified by 
microscopy. 
 
9. In vivo transfers 
NOD.Cg-Prkdcscid-IL2rgtmlWjl/Sz (NOD/SCID/IL2rγnull) (NSG) and NOD.Cg-Prkdcscid-
IL2rgtmlWjl Tg(CMV-IL3,CSF2,KITLG)1Eav/MloySzJ (NSG-SGM3) mice were developed at the 
Jackson Laboratory (Bar Harbor, ME). All experiments were performed according to the 
guidelines of IACUC at CUMC. Mice were injected intraperitoneally with busulfan (Sigma, 
30ug/g of body weight) to ablate endogenous hematopoietic system 2 days prior to human cell 
transfer. 
Briefly, 45mg of busulfan was diluted into 3ml of N,N-Dimethylacetamide (Sigma). 2ml 
of such solution was then added to 8ml of solution containing 1:1 ratio of molecular grade water 
(Invitrogen) and Polyethylene glycol 400 (Fluka). Final cocktail was filtered through 0.2um PES 
filter (Corning) and chilled in ice prior to injection. 
Human progenitors purified from cord blood were resuspended in 10µl PBS and injected 
into the tibia bone cavity of anesthetized mice. For fig 4.7A, mice were injected intraperitoneally 
for 5 consecutive days with 10ug Flt3L, starting at 1 day after transfer. 7 or 14 days after 
transplantation, bone marrow was harvested from recipient mice and analyzed for human CD45+ 
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cells. Briefly, tibia bone marrow cells were flushed with cold PBS into individual tubes and spun 
down. Red blood cells were lysed with 250ul of ACK lysis buffer (Invitrogen) for 1 min and 
washed with complete alpha MEM media. Cells were filtered through 100um nylon mesh and 











































Results in this chapter have been published and can be found in: 
Lee J, Breton G, Aljoufi A, Zhou YJ, Puhr S, Nussenzweig MC, Liu K. Clonal analysis of 
human dendritic cell progenitor using a stromal cell culture. J Immunol Methods. 2015 




 In humans, there are three subsets of DCs: pDCs, CD1c cDCs and CD141 cDCs. 
Together, they orchestrate the innate and adaptive immune response against foreign pathogens 
and tolerance to self. DCs in the periphery are short-lived and need constant replenishment from 
bone marrow progenitors cells through hematopoiesis122. 
 Different lineages depend on distinct cytokines for lineage development, proliferation 
and survival.  FMS-tyrosine kinase 3 ligand (FLT3L) is essential cytokine for all DC lineages in 
mouse and humans125. Correspondingly, an Flt3L-based in vitro culture system has been 
established to differentiate and grow murine DCs from bone marrow stem and progenitor 
cells132. This culture nurtures the differentiation of all three DC subsets from bone marrow cells 
and allowed the characterization of DC-restricted progenitors in mouse. Another culture 
important for tracing mouse DC lineage is the stromal cell coculture. Murine S17 and OP9 
stromal cells have been widely utilized to investigate DC potential in the context of other cell 
lineages. S17 cells were used to promote both myeloid (macrophages) and B lymphoid cell 
development111, 133, while OP9 cells were used to produce primarily lymphoid cells. It is 
suggested that this difference is due to the expression of IL-15 and lack of M-CSF in OP9 
stromal cells134, 135. 
 Despite the extensive work on mouse DCs, little is known about human DCs 
development. This is primarily because of a lack of culture that supports the development of all 
three DC subsets or together with other myeloid or lymphoid cells. Contrasting the murine 
example, liquid cultures supplemented with human recombinant FLT3L alone only produced 
pDCs and failed to nurture cDC subsets from human hematopoietic progenitors126, 127, 136. 
Recently, a two-step liquid culture system was proposed which attempted to produce DCs using 
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FLT3L, GM-CSF, IL-4 and SCF. However, this culture only generated CD141 cDCs but failed 
to produce pDCs. Murine stromal cells have also been tried for producing human DCs97. Co-
culture of human hematopoietic progenitor cells with Sys-1 stromal cells in the presence of 
FLT3L, only produced pDCs and CD1c cDCs, but not CD141 cDCs12. Most studies of human 
DC development performed in S17 and MS5 stromal cell culture used only CD11c, HLA-DR 
and CD1a, as markers for DC detection, could not discriminate different DC subsets or between 
DCs and monocyte-derived DCs20, 137. 
 Another issue from these previous attempts is that because of limited lineage output of 
these cultures, DC development could not be evaluated simultaneously with and in relation to 
other cell lineages. Therefore, in order to identify DC-restricted progenitors that lack the 
potential to other lineages, a culture system that can simultaneously evaluate multiple lineages is 
required. 
In this chapter, we show that a mix of MS5 and OP9 is able to simultaneously support not 
only three DC subsets, but also monocytes, granulocytes and B lymphocytes from human 
hematopoietic progenitors in the presence of FLT3L. We also optimized this culture for 
maximum output of all six lineages by treating stromal cells with mitomycin C and adding GM-










Stromal cells support human DC development 
 None of the previous in vitro cultures attempting human DC differentiation have 
successfully shown to support the development of all three DC subsets together. In order to 
establish a culture that supports differentiation of all DC subsets, we have tested the effect of 
FLT3L, an essential DC-poietin, in combination with different murine stromal cell lines that had 
been previously shown to support the development of separate DC subsets. Therefore, we tested 
three different murine stromal cells (MS5138, S17 and OP9) in the presence of 100ng of 
FLT3L/ml for their capacity to support human DC development from CD34+ hematopoietic 
progenitors isolated from cord blood (Fig 3.1).  
After two weeks of culture, cell output was analyzed for the presence of granulocytes, 
monocytes, CD1c cDCs, CD141 cDCs, pDCs and B cells among total CD45+ leukocytes (Fig 
3.2A). Compared to cultures with FLT3L alone, the presence of stromal cells significantly 
increased total CD45+ cell yield as well as for all identifiable cell subsets (Fig 3.2B). Among the 
stromal cells, only MS5 allowed the production of all six cell-types and the highest CD45+ cell 
output. All three stromal cell cultures generated robust granulocytes, but only MS5 and S17 
cultures generated high numbers of monocytes and CD1c cDCs. MS5 cultures also produced the 
highest numbers of pDCs and B cells. On the other hand, OP9 cultures produced the highest 
numbers of CD141 cDCs followed by MS5, suggesting that OP9 cultures have a greater bias 
toward CD141 cDC subset. When DC subset composition was analyzed from all three cultures 
(Fig 3.2C), we observed that cultures without stroma were biased toward pDCs, MS5 cultures 
produced similar ratios to the DC composition in peripheral blood, while S17 and OP9 cultures 
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were drastically biased toward CD1c cDCs and CD141 cDCs, respectively. We conclude that 
MS5 are capable to support development of multiple lineages including all three DC subsets. 
 In order to improve the yield of human leukocytes, we have treated MS5 stromal cells 
with mitomycin C prior to culturing them with CD34+ cells. We reason this will stop stromal 
cells from expanding and competing for nutrients against progenitors. After 14 days, we 
compared cultures with treated MS5 stromal cells to untreated ones and observed an increase of 
CD45+ leukocytes by 1.5 fold in post-mitomycin C treatment cultures (Fig 3.3A). Furthermore, 
all six cell-subsets increased in numbers. In particular, pDCs increased by 1.5-fold, CD1c cDCs 
by 2-fold, CD141 cDCs by 4-fold, and B cells by 3-fold. There was a less than 10% increase of 
granulocytes and monocytes (Fig 3.3A). Mitomycin C treatment did not affect the overall cell 
composition (Fig 3.3B). Therefore, because mitomycin C treatment increases the overall cellular 
yield without drastically affecting the relative cell composition, stromal cells have been 













Figure 3.1 Isolation of human CD34+ Hematopoietic stem and progenitor cells. Flow 






















































































Figure 3.2 Stromal cell culture and human DC development.  (A) Plots show representative 
flow cytometry analysis of human CD45+ composition from each culture at day 14. 
Granulocytes, brown; monocytes, orange; pDCs, green; CD1c cDCs, blue; CD141 cDCs, red; B 
cells and NK cells, purple.  (B) Bar plots show the absolute number of specified cell types at day 
14 from cultures without stroma (white), with MS5 (light gray), S17 (gray) or OP9 (black) 
stromal cells. Results are from three independent experiments and error bars are SEM. (C) Pie 


































































































































































































Figure 3.3 Stromal cell treatment with Mitomycin C enhances cellular output. (A) Bar plots 
show absolute counts of human CD45+ cells from 1 × 103 CD34+ HSPC cocultures with 
mitomycin C untreated (gray) or treated (black) MS5 stromal cells. (B) Bars show the relative 
frequencies of (from the bottom) granulocytes (brown), monocytes (orange), pDCs (green), 
CD1c cDCs (blue), CD141 cDCs (red) and B cells (purple). Results show the mean averages 
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In vitro DCs are phenotypically and functionally equivalent to in vivo DCs 
In order to confirm that these cultured-derived DCs are physiologically equivalent to that 
of the in vivo, we compared the expression levels of DC signature genes. Both in vitro and in 
vivo cDCs and monocytes expressed CD11c, HLA-DR and CD86, with much lower expression 
on pDCs (Fig 3.4A). The lack of CD80 and CD83 on all DCs reflects their immature state. 
pDC’s specific expression of CD123 is also markedly high on culture-derived pDCs as their in 
vivo counterparts. In vitro CD1c cDCs and monocytes were also high in CX3CR1 and SIRPa 
expression but not on CD141 cDCs or pDCs either in vitro or in vivo. CLEC9a, a receptor that 
captures necrotic cells, is specifically expressed on both in vitro and in vivo CD141 cDCs but not 
on other cells. Of note, culture-derived cDCs did not express CD1a or DC-SIGN (Fig 3.4A), 
which are markers that identify monocyte-derived DCs in vitro, suggesting that MS5 culture 
supports steady state DC lineage development. 
In addition to their surface markers, we also analyzed the expression of DC subset 
specific signature genes, which include transcription factors and genes associated with DC 
functions (Fig 3.4B). Transcription factor IRF8 was expressed on pDCs and CD141 cDCs alone, 
and E2-2, an essential transcription factor for pDC development, was also specifically detected 
in in vitro derived pDCs. Chemokine receptor XCR1 was uniquely expressed on both in vivo and 
in vitro CD141 cDCs and DC specific cytokine receptor FLT3 was also expressed on all DCs but 
not on monocytes (Fig 3.4B), further confirming that cultured DCs have not trans-differentiated 
from monocytes. Another distinction between monocytes and different DC subsets is their 
capacity to initiate discrete immune responses in response to different stimuli. This has been 
shown to depend on their differential expression of specific toll-like receptors (TLR). The 
relative expression pattern of TLR2, 3, 7 and 9 in cultured cells were identical to that of their in 
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vivo counterparts. TLR2, a lipoteichoic acid, LPS and peptidoglycan receptor, was highly 
expressed on monocytes followed by CD1c cDCs. TLR3, a double stranded RNA receptor, was 
highly expressed by CD141 cDCs followed by CD1c cDCs. TLR7 and 9, an intracellular 
bacterial DNA receptor, was detected in pDCs alone. 
In order to show that their unique TLR expression pattern also reflects their functional 
specialization, we measured the cytokine secretion levels upon TLR stimulation with their 
cognate ligands (Fig 3.5). After LPS stimulation (a TLR2 agonist), monocytes produced the 
highest amount of IL-6. After poly I:C stimulation (a TLR3 agonist), CD141 cDCs produced the 
highest level of IFNa and IL-12, and none of the cells secreted IL-6. The TLR7/9 agonist CpG 
induced massive production of IFNa by pDCs alone, and very little to none of IL-12 or IL-6 by 
any of the other cell types. In conclusion, culture-derived monocytes and DCs are equivalent to 













Figure 3.4 In vitro DCs are phenotypically and transcriptionally identical to in vivo DCs. 
(A) Histograms show cell surface markers of human monocytes and DCs isolated from blood 
(top rows) and MS5+FLT3L cultures (bottom rows). (B) Bar plots show the relative mRNA 
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Figure 3.5 In vitro generated DCs are functionally active. Cord blood CD34+ derived DC 
subsets were cultured for 14 d, purified by FACs, and exposed to the indicated TLR stimuli. 
Graphs indicate concentration of IFNa, IL-12p70 and IL-6 in the supernatant measured by 
ELISA after 48h. n (number of donors) = 3. Error bars indicate SEM. Orange, Monocytes; green, 













































































































MS5 and OP9 together with FLT3L, SCF and GM-CSF provide optimal condition for DC 
development 
Although MS5 stromal cells supported the development of all DC subsets, as well as 
three other cell types, we observed a slight bias toward CD1c cDCs (Fig 3.2C), with 
comparatively fewer pDCs and CD141 cDCs. In order to correct this bias, we added titrating 
numbers of OP9 cells into MS5 culture. We did this because OP9 has shown a preference for 
supporting CD141 cDCs development (Fig 3.2C). We then cultured CD34+ progenitor cells in 
these new culture conditions and measured the cell output for multiple lineages as well as for 
each specific DC subset. After 14 days, we observed that adding OP9 cells specifically increased 
the number of CD141 cDCs cells by 10-fold without drastically changing the cell output for 
other cell types (Fig 3.6A). Additionally, we found that a ratio of 1 OP9 -to- 6 MS5 generated 
relative composition of three DC subsets that most resembles their in vivo counterparts (Fig 
3.6B). 
Finally, we optimized the output of multiple lineages by adding stem cell factor (SCF) 
and granulocyte-macrophage colony stimulating factor (GM-CSF) to the MS5+OP9 stromal cell 
culture (Fig 3.7). Compared to FLT3L alone, adding these two cytokines induced a significant 
increase in the total output of CD45+ leukocytes by 6-fold. In particular, SCF and GM-CSF 
increased the yield of granulocytes by 23-fold, monocytes by 7-fold, CD1c cDCs by 6-fold, 
CD141 cDCs by 11-fold, pDCs by 1.5-fold and B cells by 5-fold. Considering the robust output 
of both myeloid and lymphoid cells, including all three DC subsets, we conclude that mitomycin 
C treated MS5+OP9 at a 6:1 ratio in combination with FLT3L, SCF and GM-CSF (MP+FSG 
herein) is optimal for simultaneous multilineage differentiation from CD34+ progenitors. 
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Therefore, we conclude that MS5 stromal cells, together with OP9 (1 OP9 : 6 MS5) and 
cytokines (100ng FLT3L/ml, 20ng SCF/ml and 10ng GM-CSF/ml), support the differentiation of 
all three human DC subsets as well as granulocytes, monocytes and B lymphocytes. Clonal 
cultures described in Chapter V were performed using MP+FSG, however, for Chapter IV we 





















Figure 3.6 OP9 stromal cells specifically increase CD141 cDC numbers. (A) Dots indicate 
the cell number output for the specified population (y-axis) from each culture combination (y-
axis) from 1x103 CD34+ cells. (B) Bar graphs show the relative composition of each DC subset 























































































Figure 3.7 FLT3L, SCF and GM-CSF increase cellular yield. Bars show the absolute number 
of cells from 2 × 103 HSPCs and mitomycin C pretreated MS5 cocultures in FLT3L alone (gray) 
or FLT3L, SCF and GM-CSF (gray). Bars are mean averages are from three independent 






































































































 This culture system allows us to determine the DC potential of candidate progenitors in 
the context of both myeloid (i.e. granulocytes and monocytes) and lymphoid (i.e. B cells) 
lineages. Based on the phenotypic, transcriptional and functional characterization of in vitro 
DCs, we have proved that cultured DCs are equivalent to that of their in vivo counterparts and 
not a result of trans-differentiation from monocytes. The development of steady-state DCs allows 
us to investigate the DC potential in relation to the monocyte lineage. Finally, optimizing the 
culture by treating stromal cells with mitomycin C and adding SCF and GM-CSF provides an 
environment that promotes maximal cell output from early progenitors, a promotion that could 
be due to increasing proliferation and/or maintaining survival. This culture (MP+FSG) promotes 
maximal cell output from candidate progenitors with limited proliferation capacity, thereby 
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 In mouse, DCs develop from hematopoietic stem cells in the bone marrow through a 
sequence of progenitors that have increasing restriction to terminal DCs. Identification of these 
progenitors was made possible by understanding the role of several cytokines and their 
corresponding receptors in DC development. 
 Flt3 ligand and its receptor (CD135) are essential for DC development125. In the 
periphery, CD135 is strictly expressed on DCs and administering Flt3L in vivo dramatically 
expands DC numbers in lymphoid and non-lymphoid organs123. In mice with genetically ablated 
Flt3L, peripheral DCs are significantly decreased and genetic deletion of CD135 also showed 
similar deficiencies in DC development139. Based on the dependence on Flt3 signaling for DC 
development, DC progenitors have been searched on the criterion that they should also express 
CD135 on their surface. 
However, when bone marrow CD135+ cells have been tested for their potential, not only 
did they produce DCs, but also lymphocytes, monocytes and polymorphonuclear cells140, 141. 
Thus, additional cytokine receptors were needed to further fractionate the CD135+ population 
and identify specific cells with restricted DCs potential. 
Two receptors that have been essential in the search for DC progenitors are SCF receptor 
or CD117, and M-CSF receptor or CD115. SCF receptor is mainly expressed by early bone 
marrow progenitors and is lost as cells differentiate13, 142. CD117 is essential for maintaining 
hematopoietic progenitors, and homozygous knockout mice are embryonic lethal due to anemic 
conditions. This shows that the expression of CD117 and the capacity to respond to SCF is 
critical for early progenitor cell survival. M-CSF, on the other hand, is a cytokine essential for 
monocyte development and dispensable for DCs. Mice that lack its receptor, CD115, show 
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symptoms of osteoporosis due to the absence of osteoclasts, as well as a deficiency in monocytes, 
macrophages and skin Langerhans cells, but not DCs143. 
The analysis of CD135, CD115 and CD117 expression in non-terminal (i.e. Lin-), non-
HSC (i.e. sca-1-) bone marrow cells led to the identification of two DC progenitors with different 
degrees of developmental restriction. One population with CD135+CD115+CD117hi phenotype 
produced only macrophages and DCs, and was termed macrophage-DC progenitor (MDP). The 
second cell population with CD135+CD115+CD117lo phenotype only produced all three DC 
subsets, and was named the common DC progenitor (CDP). In vivo experiments also showed that 
CDPs arise downstream from MDPs, therefore identifying for the first time intermediate DC 
progenitors in mouse.  
In a separate investigation, spleen and bone marrow cells with Lin-
CD135+CD11c+MHCII- phenotype have been identified and when tested for their developmental 
potential in vitro and in vivo, they could only produce cDCs but not pDCs, suggesting an 
additional step of lineage restriction prior to cDC differentiation110. Furthermore, CDPs in vitro 
or in vivo showed that they were able to give rise to the newly identified cDC precursors, or pre-
cDCs. In sum, the identification of MDPs, CDPs and pre-cDCs by tracing the expression of 
CD135 revealed the sequential process of DC differentiation in the mouse. 
In humans, DC-restricted progenitors have not yet been identified. However, human DCs 
share many similarities with mouse DCs. Transcriptional profile analysis of human DC subsets 
and comparison to their murine counterparts reveals high degree of similarity between the two 
species. For example, CD135 expression is also specific on terminal DCs but not on other cell 
types103. FLT3L injection of human subjects dramatically increased the number of DCs in 
circulation124. Furthermore, functional properties (e.g. T cell activation, TLR expression 
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signature, cytokine secretion) of each DC subset are also highly conserved between humans and 
mice92. This suggests that human DC development may also follow similar developmental stages. 
Hence, we hypothesize that restricted DC progenitors can be identified by analyzing and 
evaluating the potential of CD135+ cells. 
In this chapter, we report four consecutive DC progenitors in human cord blood and bone 
marrow with increasing degree of commitment toward DCs. Using our culture system and 
analysis of cytokine receptor expression on CD34+ progenitor and CD34- non-progenitor cells, 
we have been able to identify the sequential human DC progenitors, from a granulocyte-
monocyte-DC progenitor (GMDP), which develops into a more restricted human monocyte-DC 
progenitor (MDP), which then produces monocytes and human CDPs, which generate pDCs and 
pre-cDCs, which finally give rise to cDCs. We also determined the anatomical location where 
each of these progenitors can be found in humans. Lastly, we discussed the possibility to resolve 
the myeloid or lymphoid origin of DCs by evaluating how myeloid and lymphoid progenitors 













Single cell culture reveals developmental heterogeneity within GMPs 
DCs have been traditionally considered to be myeloid cells and closely related to 
monocytes. There are currently two identified myeloid progenitors in the human hematopoietic 
tree: the CD34+CD38+CD10-CD135+CD45RA- common myeloid progenitor (CMP) and the 
CD34+CD38+CD10-CD135+CD45RA+ granulocyte-macrophage progenitor (GMP). Both of 
these have granulocyte, monocyte and DC activity in vitro and in vivo. However, CMP can have 
megaerythrokaryocyte potential, while GMPs are downstream of CMPs and lack 
megaerythrokaryocyte potential. Additionally, transcriptional profile of GMP population also 
shows that it expresses transcription factors essential for DC development144, suggesting that 
GMPs may contain cells with DC potential. 
Therefore, in order to determine the clonal DC activity in GMPs, we have isolated 
individual cells from cord blood and cultured them together with MS5+FSG (Fig 4.1A). After 
two weeks of culture we determined their clonal developmental potential based on the cell type 
generated. Results show that the clonal efficiency is high (65%), indicating that this culture is 
appropriate for single cells to proliferate and differentiate. Out of 144 GMP clones, 93 have 
generated identifiable CD45+ leukocytes.  
Surprisingly, there is a remarkable heterogeneity within GMPs as determined by their 
lineage output (Fig 4.1B). The majority of the 93 clones (84/93) produced myeloid and/or DCs 
alone and lacked lymphoid potential. Only a small fraction (6/93) produced lymphoid and 
myeloid cells together, and even fewer clones (3/93) remained undifferentiated. Among the 84 
myeloid clones, however, only 6 (6.5%) simultaneously produced granulocytes, monocytes and 
DCs. Twenty five clones (26.9%) were bipotent. Of these, 11 clones (11.8%) produced 
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monocytes and DCs, 13 clones (14.0%) generated granulocytes and monocytes, and very rare 
clones (1.1%) produced granulocytes and DCs. A high percentage of clones (53/93, 57.0%) 
showed uni-lineage potential, i.e., commitment; these include 25 producing only granulocytes, 
11 only monocytes and 16 only DCs. Therefore, our culture system allows testing of the 
development of granulocytes, monocytes, DCs and lymphocytes from single progenitor cells. In 
addition, this test reveals that phenotypically homogeneous GMPs are heterogeneous in their 
clonal potential, especially in DC producing clones. 
We found 17.2% of the clones within GMPs were committed to DCs alone (Fig 4.1B), 
resembling the mouse CDPs. We also found that 11.8% of clones with monocyte and DC 
potential, resembling the mouse MDPs, as well as multipotent clones (6.5%) with granulocyte, 
monocyte and DC potential. This indicates that GMPs is comprised of a mix of progenitor cells 
that differ in their developmental capacity and lineage commitment, and can thus be further 
identified and isolated. Therefore, further dissection of GMPs using additional surface receptors 
that can distinguish pure populations with homogeneous potential may allow further purification 











Figure 4.1 GMPs are clonally and phenotypically heterogeneous. (A) Flow cytometry plots 
show gating strategy for sorting cord blood derived human GMPs. (B) Single GMP cells were 
directly sorted into 96 well plates and culture in MS5+FSG. Bar graphs show the cumulative 
number of wells giving rise to the specified potential out of the total number of positive clones. 
G, granulocyte; M, monocyte; DC, pDCs and/or cDCs; L, lymphoid (B and/or NK cells); Undiff, 
undifferentiated; +, “and”; /, “or”.  (C) low cytometry plots show exhaustive sepa- ration of 
CD34+ cord blood cells into six populations, HSCs/MPPs, MLPs, B and NK progenitors 
(B/NK), CMPs, megakaryocytic and erythroid progenitors (MEP), and GMPs (a), and expression 






























































































Differential expression of cytokine receptors allows fractionation of GMPs into three 
developmentally restricted progenitors 
 In order to identify lineage-restricted progenitors we analyzed the differential expression 
of DC-, monocyte- and granulocyte-associated cytokine receptors within GMPs. Since GM-CSF, 
M-CSF and IL-386 have been shown to affect granulocyte, monocyte and DC development, we 
used their respective receptors (i.e. CD116, CD115 and CD123) to fractionate CD45RA+ GMPs. 
Flow cytometry analysis revealed five distinct populations (Fig 4.1C, 4.2A). One population 
expresses high CD123 (i.e. CD123hi) and the rest CD123int cells can be divided into four 
additional populations based on the differential expression of CD116 and CD115: 
CD116+CD115- (i.e. CD116+), CD116+CD115+ (i.e. DP), CD116-CD115+ (i.e. CD115+) and 
CD116-CD115- (i.e. DN). In order to determine their developmental capacity, we have isolated 
200 cells from each fraction and put them on our MS5+FSG culture (Fig 4.2B). After 7 days of 
culture we have analyzed the generation of granulocytes, monocytes, CD1c cDCs, CD141 cDCs, 
pDCs and lymphocytes (i.e. B and NK cells, data not shown).  
 In order to identify DC progenitor candidates, one criterion must be met: DC progenitors 
should be able to produce all three DC subsets. Out of the five populations tested, two failed this 
criterion and were excluded as potential DC progenitors. CD116+ and DP cells, although they 
produced CD1c cDCs, did not produce other DC cell types and were disregarded as potential 
precursors. 
 On the other hand, CD123hi cells produced all three DC subsets and no other cell-types, 
resembling mouse CDPs (Fig 4.2B). They constitute 0.20 + 0.13% of CD34+ cells and we named 
them human CDPs (CDPs herein). CD115+ cells generated all three DC types as well, together 
with monocytes and very few, if any, granulocytes, resembling murine MDPs. CD115+ cells 
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represent 0.31 + 0.18% of CD34+ cells and can be identified as CD45RA+CD123intCD115+ due 
to the negligible frequency of DP cells (~0.04% of CD34+ cells). Consequently, we named them 
MDPs. Finally, the DN fraction, which represents 4.16 + 0.98% of CD34+, generates 
granulocytes, monocytes and all three DCs and hence, we named these Granulocyte, Monocyte 
and DC progenitor (GMDP).  
When we analyzed their proliferative capacity, GMDPs and MDPs produced higher yield 
of cells than CDPs, which reflects their less differentiated status and more proliferative activity 
(Fig 4.2C). In addition, upon culture of 4 days, MDP and GMDP expanded and resulted in 
increased number of CD34+ cells (Fig 4.2D). In contrast, CDPs rapidly lost the expression of 
CD34, a marker for early progenitors (Fig 4.2D and data not shown).  
We also determined their megaerythrokaryocyte and granulocyte potential by culturing 
500 cells of each population in methylcellulose culture assays for 14 days (Fig 4.2E). As 
expected, CDPs did not produce any detectable colonies since this assay does not support DC 
development. This indicates that CDPs lack megaerythrokaryocyte, granulocyte and macrophage 
potential. MDPs, on the other hand, were able to generate monocyte-producing colonies and very 
few granulocyte colonies. GMDPs generated both monocyte- and granulocyte-producing 
colonies as well as colonies with mixed cell types, suggesting the presence of oligopotent clones. 
MDPs and GMDPs produced comparable colony counts, similar to their comparable clonal 
efficiency in MS5+FSG cultures (Fig 4.2E). Of note, none of the three populations tested had 
megaerythrokaryocyte potential when compared to the CMPs. 
Therefore, we conclude that human GMPs contain phenotypically and functionally 
distinct sub-populations that show increasing commitment to DC lineage. Cells with 
CD34+CD38+CD10-CD45RA+CD123hi phenotype generated only the three types of DCs, and 
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therefore we called these CDPs. Cells with CD34+CD38+CD10-CD45RA+CD123int CD115+ 
phenotype generated monocytes and DCs, and thus we called these MDPs. Finally, cells with 
CD34+CD38+CD10-CD45RA+CD123intCD115- phenotype produced granulocytes, monocytes 






















Figure 4.2 Identification of progressively restricted DC progenitors in GMPs. (A) Flow 
cytometry plots show gating of cord blood GMP cells and further separation into five separate 
populations based on CD123, CD115, and CD116 expression: CD123hiCD115 (CD123hi), 
CD123intCD115+CD116-  (CD115+), CD123intCD115+CD116+ (DP), CD123intCD115-CD116+ 
(CD116+), and CD123intCD115-CD116- (DN). (B) Differentiation potential of 200 purified cells 
from each of the five populations indicated in (A) in MP+FSG culture harvested after 7 d. Flow 
cytometry plots show CD45+CD56-CD19- cells. (C) Graph indicates output/input ratio of total 
number of CD45+ cells obtained from each of the five populations sorted in (A).  Bars and error 
bars are means and SEM, respectively, from three independent experiments. (D) Graph shows 
the fold-increase of CD34+ cells after 4 days of culture. Bars are means and error bars are SEM 
from three independent experiments. (E) Graph indicates the differentiation potential of CDPs, 
MDPs, GMDPs, and CMPs in methylcellulose colony formation assays   in vitro. Colonies were 
enumerated at 14 d after culture. BFU-E, burst-forming unit erythroid; GEMM, granulocyte, 
erythrocyte, macrophage, megakaryocyte; GM, granulocyte and macrophage; G, granulocyte; M, 
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Cytokine receptor expressions analysis in CD34- cells allows the identification of pre-cDCs 
The identification of GMDPs, MDPs and CDPs in cord blood shows that human DC 
development resembles that of the mouse. Consequently, we speculate that humans also have a 
downstream precursor between CDPs and cDCs. 
Seeing that CDPs lose CD34 expression to produce cDCs, we reasoned that the human 
equivalent of pre-cDCs should be present within the CD34- portion. Thus, in order to search for 
the precursor, we decided to look into the non-terminally differentiated (i.e. Lin(B/T/NK/ 
granulocytes/monocytes/DCs)-) and non-progenitor (i.e. CD34-) cells (Fig 4.3A). We subdivided 
the Lin-CD34- fraction using differential expression of cytokine receptors CD117 and CD135, 
which are expressed on terminally differentiated cDCs. We isolated CD117-, CD117+CD135- 
(CD135-) and CD117+CD135+ (CD135+) and tested their DC potential on MS5+FSG cultures 
(Fig 4.3B). After 7 days of culture, we compared their output with CD34+ multipotent progenitor 
cells. As expected, CD34+ progenitors were able to generate mature cells of multiple lineages 
(monocytes, DCs and lymphocytes). Among CD34- cells, both CD117- and CD117+CD135- cells 
failed to produce any identifiable cells, and only CD117+CD135+ cells produced monocytes and 
cDCs but not pDCs. This suggests that CD117+CD135+ cells contain pre-cDCs and can further 
be isolated. For this purpose, we subdivided CD117+CD135+ cells according to the differential 
expression of CD116 and CD115, as well as CD45RA (Fig 4.3C). We isolated CD116-, 
CD116+CD45RA- (CD45RA-), CD116+CD45RA+CD115+ (CD115+) and CD116+ 
CD45RA+CD115- (CD115-) cells and cultured them in MS5+FSG for 7 days. Cell output 
analysis shows that CD116- and CD45RA- fractions lacked both monocyte and DC activity (Fig 
4.3D). Interestingly, CD115+ cells produced a high number of monocytes and a few CD1c cDCs, 
which resemble the mouse monocyte precursor cMOP. CD115- cells produced only cDCs but 
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failed to produce monocytes or pDCs (Fig 4.3E), and resemble the mouse pre-cDC. These cells 
were present in cord blood and in the peripheral blood (Fig 4.6A). 
Further phenotypic characterization of human pre-cDCs in cord blood shows that they 
have low expression of CD11c and CD123 but are positive for HLA-DR (Fig 4.3F) at 
comparable levels with fully differentiated DCs. In conclusion, we have identified the human 
pre-cDCs and they are characterized by Lin-CD34-CD117+CD135+CD116+CD45RA+CD115-. 
We next sought to determine pre-cDC’s proliferative capacity. We isolated pre-cDCs 
from cord blood and peripheral blood and incubated them in MS5+FSG culture. After 7 days, we 
compared their cell output with CD34+ hematopoietic stem and progenitor cells (HSPCs) as well 
as with terminally differentiated CD1c cDCs and CD141 cDCs isolated from peripheral blood 
(Fig 4.4A). As expected, CD34+ cells were highly proliferative and expanded approximately 156 
fold. In contrast, pre-cDCs, either from cord blood or peripheral blood, had significantly lower 
proliferative capacity (approximately 8- and 6-fold, respectively). Pre-cDCs were, however, still 
able to significantly expand more than fully differentiated DCs. We next determined whether the 
increase in cell number was due to pre-cDCs dividing before differentiating or fully 
differentiated cDCs dividing after differentiation. For this purpose, we stained cord blood 
derived pre-cDCs with CFSE and followed their differentiation and division for 2 and 7 days. 
Pre-cDCs had generated CD141 cDCs and CD1c cDCs as early as 2 days of culture and 
increased in numbers by 7 days (Fig 4.4B), while CD34+ HSPCs produced cDCs and monocytes 
only by day 7. When tracing CFSE dilution at day 2, pre-cDCs produced terminal cDCs 
expressing equal levels of CFSE, suggesting that division and differentiation happens 
simultaneously (Fig 4.4C). However, at day 7, precursor-derived cDCs had lower levels of 
CFSE than remaining pre-cDCs, which indicates that differentiated cDCs can undergo further 
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divisions. Confirming this notion, CD141 cDCs and CD1c cDCs purified from blood, were able 
to undergo several divisions in MS5+FSG after 7 days of culture, indicated by the dilution of 
CFSE (Fig 4.4C). Therefore, this shows that human pre-cDCs, either in cord blood or in 
peripheral blood, differentiate into cDCs as they divide and that terminally differentiated cDCs 





















Figure 4.3 Identification and developmental potential of cDC precursors. (A) Flow 
cytometry plots show gating of CD45+CD3-CD19-CD56-CD14-CD66b-CD1c-CD141-CD303- 
cells in human cord blood can be divided into four populations based on CD117, CD34, and 
CD135: CD34+CD117+ (CD34+), CD34-CD117- (CD117-), CD34-CD117+CD135- (CD135-), and 
CD34-CD117+CD135+ (CD135+). Numbers indicate the frequency of respective gates. (B) 
Differentiation potential of 1,000 purified cells from each of the 4 populations indicated in (A) in 
MP+FSG cultures for 7 d. Flow cytometry plots show gated live human CD45+ cells. (C) Flow 
cytometry plots show CD135+ cells indicated as in (A) can be further separated into 4 
populations based on CD116, CD115, and CD45RA: CD135+CD116- (CD116-), 
CD135+CD116+CD45RA- (CD45RA-), CD135+CD116+CD45RA+CD115+ (CD115+), and 
CD135+CD116+CD45RA+CD115- (CD115-). (D and E) Differentiation potential of 100 purified 
cells from each of 4 populations indicated in (C) in MP+FSG cultures for 7 d. (D) Flow 
cytometry plots of CD45+ cells gated as in (C). (E) Graphs show mean output of pDC, CD1c 
cDC, CD141 cDC and monocytes from each population from three independent experiments. (F) 
Histograms show expression of CD11c, HLA-DR, CD123, CD135, CD117, CD45RA, CD116, 
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Figure 4.4 Proliferative capacity of pre-cDCs. (A) Expansion of purified pre-cDCs or CD34+ 
HSPCs from peripheral blood (PB) or cord blood (CB) in MP+FSG cultures for 7 d. Graph 
shows the mean fold change of live human CD45+ cells from 100 input cells from three 
independent experiments. *, P < 0.005, unpaired two-tailed Student’s t test. (B and C) CD34+ 
HSPCs and pre-cDCs were purified from CB, labeled with CFSE, and cultured in MP+FSG for 2 
or 7 d; proliferation was assessed by flow cytometry. FACs plots show (B) gated CD45+ culture-
derived cells, including CD34+ cells (purple), CD34-CD1c-CD141- cells (orange), CD141 cDCs 
(red), and CD1c cDCs (blue) and (C) their CFSE dilution. Dotted lines mark last division by pre-
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Physiological localization of early DC progenitors and precursors 
DC development in mice is anatomically compartmentalized. All early progenitors prior 
to pre-cDCs are localized in the bone marrow and do not effectively migrate to the periphery110. 
DC progenitors restrictively develop in the bone marrow cavity from hematopoietic stem cells 
until reaching pre-cDC stage. Only when they become pre-cDCs can they migrate through blood 
to the periphery, where they finish their differentiation into cDCs. 
Therefore, we determined whether human progenitors and precursors also followed 
similar anatomical distribution. We first determined the presence of CD34+ DC progenitors in 
the adult human bone marrow as well as in the peripheral blood and tonsils. In bone marrow, 
GMDPs comprised approximately 5.2% of total CD34+ cells (range of 1.8-7.4%), MDPs 
approximately 0.6% of total CD34+ cells (range of 0.1 – 1.9%) and CDPs represented 
approximately 1.9% of total CD34+ cells (range of 0.1 – 7.3%) as determined by flow cytometry 
analysis (Fig 4.5A). Furthermore, GMDP, MDP and CDP in the bone marrow demonstrated 
identical developmental potential as those identified in cord blood when cultured on MS5+FSG 
(Fig 4.5B). Minor differences between adult bone marrow and cord blood DC progenitors were 
in GMDPs and CDPs. Bone marrow MDPs were significantly (P <0.05) biased toward producing 
more monocytes and toward producing less CD1c cDCs (P <0.001) than cord blood GMDP 
counterparts (Fig 4.5C). Bone marrow CDPs also showed a significant bias toward producing 
less pDCs than from cord blood derived CDPs. 
On the other hand, very little CD34+ cells were detectable in peripheral blood or in tonsils 
(Fig 4.5A) (approximately <1% of CD45+ cells), and human CDPs, MDPs and GMDPs were 
unidentifiable among CD34+ cells in the periphery. Therefore, early DC progenitors are 




We next determined the migratory capacity of human pre-cDCs by looking for their 
presence in the bone marrow and peripheral lymphoid organs (i.e. peripheral blood and tonsils). 
Similar to cord blood, human bone marrow contained both pre-cDCs as well as CD115+ 
monocyte precursors (Fig 4.6A). However, peripheral blood or tonsils lacked monocyte 
precursors and only contained pre-cDCs, suggesting that human DC precursors develop in the 
bone marrow and migrate to the periphery, while monocytes finish their development in the bone 
marrow and do not enter circulation. In order to verify their DC developmental potential, we 
isolated both pre-cDCs (Fig 4.6B) and CD115+ monocyte precursors (Fig 4.6C) from each 
tissue, and culture them in MS5+FSG. After 7 days of culture, pre-cDCs were able to strictly 
produce cDCs but not pDCs, and very few, if any, monocytes. Similarly, CD115+ monocyte 
precursors from cord blood and bone marrow generated primarily monocytes and a few CD1c 
cDCs. Pre-cDCs constitute 0.008% (range, 0.001-0.016%) of CD45+ cells in cord blood, 0.117% 
(range, 0.056-0.188%) in BM, 0.001% (range, 0.001-0.002%) in peripheral blood and 0.001% 
(range, 0.001-0.002%) in tonsil. Thus, this shows that, like in the mouse, human pre-cDCs 
develop in the bone marrow, enter circulation and reach peripheral lymphoid tissue where they 









Figure 4.5 Presence of early DC progenitors in bone marrow and peripheral tissues. (A) 
Representative flow cytometry plots of gated CD45+Lin(CD3/19/56/14)-CD34+ cells show 
GMDPs, MDPs, and CDPs in human BM (n=4), peripheral blood (PBMC; n=4), and tonsils 
(n=4). (B) GMDPs, MDPs, and CDPs were purified from human BM, and 2,500 progenitors 
were cultured in MP+FSG for 7 d. Flow cytometry plots of gated live CD45+ cells show 
phenotype of output cells, including granulocytes (brown), CD141 cDCs (red), CD1c cDCs 
(blue), monocytes (orange), and pDCs (green). Data represent three independent experiments. (c) 
Graph shows output/input cell ratio in percentage of the indicated cells derived from BM (n=3) 
or cord blood (CB; n=3) cultures of GMDPs, MDPs, and CDPs in MP+FSG for 7 d. Statistical 
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Figure 4.6 Presence of pre-cDCs in bone marrow and peripheral tissues. (A) Representative 
flow cytometry plots of gated Lin(CD3/19/56/14/66b)-DC(CD1c/141/303)-CD34- cells show 
gating strategy and composition of pre-cDCs (SSCloCD117+CD116+CD135+ CD45RA+CD115-, 
red) and pre-monocytes (SSCloCD117+ CD116+CD135+CD45RA+ CD115+, green) in human cord 
blood (CB), BM, peripheral blood (PB), and tonsil. Numbers indicate frequency of cells of 
parent gate (CB, n=5; BM, n=4, PB, n=5; Tonsil, n=3; n, number of donors). (B) Differentiation 
potential of purified pre-cDCs indicated in (A) in MP+FSG cultures for 5 d. Flow cytometry 
plots of gated live human CD45+ cells show culture output of CD141 cDC (red) and CD1c cDC 
(blue). Representative results of four (CB), three (BM), three (PB), and two (tonsil) independent 
experiments are shown. (C) Differentiation potential of purified pre-monocytes from cord blood 
(CB) and BM in MP+FSG cultures for 5 d. FACS plots show phenotype of gated live human 
CD45+ culture-derived cells including monocytes (orange) and CD1c cDCs (blue). 






















































































































Interdevelopmental relationship among early DC progenitors and precursors 
 The progressively increasing degree of commitment and loss of lineage potential suggests 
an inter-developmental relationship between GMDPs, MDPs, CDPs and pre-cDCs. In order to 
determine their progenitor-progeny relationship we first elucidated the relationship among 
CD34+ progenitors. For this purpose, we isolated GMDPs from cord blood and transferred them 
into the bone cavity of conditioned NSG mice. After 7 days of transfer, we analyzed the 
phenotype of GMDP-derived progeny cells and found that MDPs and CDPs were generated in 
vivo (Fig 4.7A). This suggests that GMDPs are upstream of MDPs and CDPs. 
We have further refined the inter-developmental relationship using MS5+FSG cultures by 
incubating each GMDP, MDP and CDP population for 1, 4 and 8 days. Flow cytometry analysis 
reveals that GMDPs remained as GMDPs in day 1 but soon produced MDPs on day 4 (Fig 
4.7B), and later CDPs at day 8 of culture. Initial MDP cells quickly produced CDPs as early as in 
day 1, increased in numbers by day 4, and failed to generate GMDPs on any day throughout the 
experiment. By day 8 most MDPs have differentiated, which is marked by the loss of CD34 on 
the surface. Next, CDPs in culture retained their phenotype only on day 1 but quickly 
differentiated into CD34- cells by day 4 without prior production of either MDPs or GMDPs. We 
therefore conclude that GMDPs are upstream of MDPs, and that MDPs are upstream of CDPs. 
CDPs are also the last progenitor stage within CD34+ cells able to produce DCs and, therefore, 
the most likely precursor for pre-cDCs. 
In order to determine the developmental relationship of pre-cDCs with CDPs, we have 
isolated CDPs from cord blood and cultured them in MS5+FSG (Fig 4.7C). Consistent with 
previous experiments (Fig 4.2D), the majority of CDPs readily lost CD34 expression and very 
few pDCs and cDCs were detectable in culture on day 1. However, we observed an increase in 
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numbers of CD34- cells expressing CD45RA, CD117 and CD116, which resemble pre-cDCs 
phenotype. At day 2, all of CDPs have downregulated CD34 expression, pDCs and cDC 
numbers increased, while pre-cDC numbers remained unchanged. By day 4, CD34+ cells and 
pre-cDCs were not detectable, and only pDCs and cDCs were produced. In other words, CDPs 
differentiate first into pre-cDCs prior to becoming cDCs. Thus, we conclude that pre-cDCs are 
immediately downstream of CDPs and upstream of fully differentiated cDCs. 
In sum, we have identified four different progenitors with (1) increasing commitment 


















Figure 4.7 Interdevelopmental relationship among DC progenitors. (A) Differentiation of 
GMDP in vivo. 10,000 GMDPs were purified from cord blood and adoptively transferred into the 
bone cavity of the preconditioned NSG mice. Seven days later, bone marrow cells were 
analyzed. Flow cytometry plots show phenotype of bone marrow cells from NSG mice receiving 
PBS or GMDP (n=2, each). (B) Differentiation of GMDP, MDP and CDP in vitro. 200-400 
GMDP, MDP and CDP cells were purified and cultured in MP+FSG. Cultures were analyzed on 
days 1, 4 and 8. Flow cytometry plots gated on live CD45+Lin(CD3/19/20/56/14)-CD66b-
DC(CD1c/141/303)-CD45RA+ cells show cell surface markers and frequency of CDP (red), 
MDP (blue) and GMDP (grey). Results are representative of three independent experiments. (C) 
Differentiation kinetics of CDPs purified from CB in MP+FSG cultures for 1, 2, or 4 d. FACS 
plots show culture output of live human CD45+ cells, including CD34+ cells (purple), pDC 
(green), CD1c cDC (blue), CD141 cDCs (red), and pre-cDCs (orange). Representative of four 
independent experiments are shown. Graphs summarize composition of indicated populations 
among total CD45+ cells. Bars are mean values from four independent experiments, and error 










































































































































































 In this chapter, we have identified four new sequential myeloid progenitors with 
increasing commitment toward DCs. By using single cell cultures and cytokine receptor 
expression analysis, we identified three of these in the GMP fraction. These are the GMDPs 
(granulocyte, monocyte and DC progenitor), MDPs (monocyte and DC progenitor) and CDPs 
(common DC progenitor), and they can be distinguished by their differential expression of 
CD123 and CD115. Similarly, by fractionating non-progenitor and non-terminally differentiated 
cells based on DC-associated cytokine receptor markers, we identified a committed precursor for 
cDCs that descend immediately downstream from CDPs. We have also anatomically located 
each step of DC development in adults. All four progenitors and precursors develop in the bone 
marrow, but only pre-cDCs migrate through blood to the periphery where they finish 
differentiation into cDCs. 
Furthermore, identification of three progenitors within a myeloid progenitor (i.e. GMP) 
seems to support that DCs pertain to the myeloid lineage. GMPs have been extensively shown to 
develop from common myeloid progenitors (CMPs), which are capable of producing 
megaerythrokaryocytes and myeloid cells (including DCs) but not lymphocytes. Thus, our 
results suggest that DCs follow the myeloid track of development. This is very similar to what 
has been observed in mice (reference). 
However, despite these data in mouse and humans, some conflict on DC origin and 
lineage remain unresolved. The main issue regarding DC development is that these cells can also 
derive from lymphoid progenitors, both in humans and in mice. Previous findings identifying 
and characterizing lymphoid progenitors in human cord blood and bone marrow have shown that 
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DCs can be generated from progenitors that produce B/NK and T cells but not granulocytes or 
megaerythrokaryocytes, which led to speculate a lymphoid DC ancestry. 
One recent work has shown that single cells with CD34+CD38-CD45RA+CD10+ 
phenotype were able to generate only B cells and DCs, but not granulocytes, formally proving a 
common lymphoid ontogeny20. In fact, patients with B/NK/Monocyte/DC deficiency109, 145 who 
lack all three DC subsets, yet have relatively normal levels of granulocytes, also lack this 
progenitor population but with reduced GMP numbers in their bone marrow, further suggesting 
DC association with the lymphoid lineage instead of the myeloid. Nevertheless, how lymphoid 
progenitors produce DCs and through which developmental stages it progresses to DCs remains 
to be elucidated.  
In order to resolve the classification of monocyte and DC lineage, all identified 
progenitors, both myeloid and lymphoid, need to be identified and exhaustively tested for their 
developmental potential as well as their progenitor-progeny relationship. By analyzing which 
progenitor is capable of producing GMDPs, MDPs and CDPs, we will be able to trace and 
determine which progenitor contributes toward the DC pathway the most. Furthermore, single 
cell cultures also need to be done in order to determine the clonal composition of DC producing 
clones, as we suspect that lymphoid progenitors are heterogeneous in their clonal potential 


































The origin of human DCs has been contentious. This is primarily because data generated 
from DC development studies often conflict with the standard model of hematopoiesis. The 
standard model of hematopoiesis proposes that the myeloid-erythroid lineage and lymphoid 
lineage split into two separate non-overlapping trajectories downstream the long term 
hematopoietic stem cells (HSCs) and short term multipotent progenitors (MPPs)146. This map 
was established after the identification of two progenitors supporting this process: (1) the 
common lymphoid progenitor (CLP)9 and (2) the common myeloid progenitor (CMP)10, 12. 
Following identification of CMPs and CLPs in mouse, CLPs in human were identified as 
CD34+CD45RA+CD10+ cells in the bone marrow14. Extensive clonal analysis testing their 
developmental potential showed that these cells failed to produce myeloerythroid cells but 
successfully produced B, NK and T cells both in vitro and in vivo. This provided evidence that 
the lymphoid lineage, indeed arises from a progenitor that lacks myeloerythroid potential. 
Interestingly, when single CLPs were tested for DC potential in vitro, they showed significant 
DC activity, which suggested a lymphoid origin for human DCs. 
Then CMPs11, 13 were identified by the expression of CD34+CD348+CD45RA-CD123+. 
CMPs, on the other hand, had megaerythrokaryocytic potential, as well as granulocyte and 
macrophage potential, but failed to produce any lymphocytes. This same study also showed that 
CMPs produce megaerythrokaryocytes and granulocytes-macrophages through two progenitors 
with mutually exclusive phenotype. CD34+CD348+CD45RA+CD123+ were called 
megaerythrokaryocyte progenitor (MEK) and the CD34+CD348+CD45RA-CD123- cells were 
called granulocyte-macrophage progenitor (GMP). These results showed, for the first time, that 
the myeloid lineage in humans is clearly a separate lineage from the lymphoid. 
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CMPs and GMPs were later examined for their DC potential both in vitro and in vivo15, 19. 
Not surprisingly, CMP and GMPs both produced DCs. However, when DCs derived from 
CMP/GMPs were compared to DCs derived from CLPs, results showed that they were 
transcriptionally indistinguishable, which suggested that DCs could derive from both myeloid 
and lymphoid progenitors15. Since then, the central origin of DCs became debated. 
With more antibodies available to differentiate surface markers on human cells, 
additional progenitors have been identified thereafter and placed on the hematopoietic map, 
adding more layers of complexity. A new progenitor was identified in AML leukemia patients 
with a CD34+CD38-CD45RA+ phenotype that could produce GMPs, bypassing CMP stage21. We 
showed in our last chapter that GMPs are, indeed, heterogeneous and identified three consecutive 
DC progenitors based on the differential expression of CD123 and CD115. Additionally, CLPs 
could be further subdivided into CD38+ BNK progenitors and CD38- multilymphoid progenitors 
(MLPs), with DC potential residing in MLPs20. However, how these different progenitors 
developmentally relate with each other has not been thoroughly addressed. 
Therefore, to resolve the DC origin conflict, we need to exhaustively separate the 100% 
of CD34+ human hematopoietic progenitors into phenotypically non-overlapping populations in 
order to determine their terminal differentiation potential as well as their inter-progenitor 
relationship at the population and single cell level. 
In this chapter, we present first a multi-channel staining panel to characterize ten 
mutually exclusive populations based on their phenotype. Then, by combining in vitro and in 
vivo assays we describe the developmental potential of each population as well as their inter-
progenitor relationship. Finally, we show single cell culture analysis in order to increase the 




Exhaustive phenotypic characterization of 10 non-overlapping progenitors 
 In order to determine the developmental relationship of different myeloid and lymphoid 
progenitors to DCs, we first established a staining panel able to identify all previously 
characterized CD34+ hematopoietic precursors in cord blood (Table 5.1). This analysis allows us 
to exhaustively fractionate and phenotypically compare previously found progenitors, including 
the recently described GMDPs, MDPs and CDPs (Fig 5.1A and B). 
 By using only seven surface markers (CD34, CD38, CD45RA, CD90, CD10, CD123, 
CD115), we are able to divide CD34+ cells into 10 non-overlapping marker pure progenitors (Fig 
5.1A and B). All hematopoietic progenitors and stem cells are uniformly CD34+. Among these, 
two main groups can be subdivided according to their CD38 expression: CD38- early 
progenitors, and CD38+ late progenitors. Within the early CD38- cells we can identify the 
hematopoietic stem cells (HSCs) by their expression of CD90 and lack of CD45RA 
(CD34+CD38-CD45RA-CD90+). HSCs have been shown to produce all hematopoietic lineages in 
culture and in vivo in xenogeneic NSG mice. HSCs can also repopulate secondary recipient mice 
after serial transplantation, resembling the long-term hematopoietic stem cells in mouse (LT-
HSC). 
Within the CD90- cells, we can further identify three populations. The short-term 
hematopoietic stem cells, also called multipotent progenitor (MPP), and two lymphoid 
progenitors. The MPPs are characterized by their CD34+CD38-CD45RA-CD90- phenotype and, 
although they can produce all blood lineages, they can do so only transiently. The two lymphoid 
precursors are the lymphoid-primed multipotent progenitors (LMPPs, CD34+CD38-CD90-
CD45RA+CD10-) and the multilymphoid progenitors (MLPs, CD34+CD38-CD90-
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CD45RA+CD10+). These two express CD45RA but differentially express CD10 on their surface. 
They both have the potential to produce B, NK cells, monocytes and DCs, but not 
megaerythrokaryocytes. One difference between these two is that LMPPs have very limited 
granulocyte potential while MLPs completely lack granulocyte potential. 
Among the late progenitors, we can also identify a committed B/NK progenitor (BNKP, 
CD34+CD38+CD45RA+CD10+). These, like their parent MLPs, express CD10 and CD45RA on 
their surface but strictly produce lymphocytes and not myeloid cells of any type, including DCs. 
Within the CD10- late progenitors, we can find five myeloid progenitors. The earliest among 
these five is the common myeloid progenitor (CMP, CD34+CD38+CD45RA-CD123+), which has 
the potential to produce all myeloid lineages both in vivo and in vitro: megaerythrokaryocytes, 
granulocytes, monocytes and DCs. CMPs then produce two separate progenitors with distinct 
developmental potential. One is the megaerythrokaryocyte progenitor (MEK, 
CD34+CD38+CD45RA-CD123-), which is restricted to producing red blood cells and 
megakaryocytes, and the other is the aforementioned GMDPs (CD34+CD38+CD45RA+CD123+), 
which can produce granulocyte, monocytes and DCs, but not megaerythrokaryocytes or 
lymphocytes. As previously shown, downstream GMDPs are the MDPs, which produce only 
monocytes and DCs, and finally the CDPs, which are restricted to DCs alone. 
Therefore, this panel allows us to exhaustively fractionate progenitor cells from cord 
blood and bone marrow into 10 non-overlapping marker-pure populations. This in time will also 
allow us to determine their separate developmental potential toward DCs and other lineages, as 





Table 5.1 Phenotype, potential and inter-developmental relationship of human CD34+ 
hematopoietic progenitor populations. (A) Name, surface marker phenotype, differentiation 
potential of 10 non-overlapping CD34+ hematopoietic progenitor populations: HSC, MPP, 
LMPP, MLP, CMP, MEP, GMDP, MDP and CDP in human cord blood and bone marrow. CFU, 





























Population Phenotype CB (% of CD34+) 
BM (% of 
CD34+) 
Lineage output 
Hematopoietic stem cell (HSC) CD34+CD38-CD45RA-CD90+ 3.79 1.70 
Multipotent progenitor (MPP) CD34+CD38-CD45RA-CD90- 18.97 11.30 
Lymphoid-primed multipotent progenitor (LMPP) CD34+CD38-CD45RA+CD10- 1.36 16.50 
Multilymphoid progenitor (MLP) CD34+CD38-CD45RA+CD10+ 4.88 0.80 
B and NK cell progenitor (BNKP) CD34+CD38+CD45RA+CD123int/-CD115-CD10+ 3.12 2.20 
Common myeloid progenitor (CMP) CD34+CD38+CD45RA-CD10-CD123int 39.84 33.80 
Granulocyte/Monocyte/DC progenitor (GMDP) CD34+CD38+CD45RA+CD10-CD123int 11.38 11.20 
Monocyte/DC progenitor (MDP) CD34+CD38+CD45RA+CD123intCD115+ 0.81 5.60 
Common DC progenitor (CDP) CD34+CD38+CD45RA+CD123hiCD115- 0.54 3.00 
Megaerythrokaryocyte progenitor (MEP) CD34+CD38+CD45RA-CD10-CD123- 15.34 11.40 
ME, erythrocyte and megakaryocyte; G, granulocyte; M, monocyte; DC, dendritic cell; L, B/NK lymphocytes. Colony forming 
unit assay, CFU; MS5 stromal cell culture assay, MS5. 
ME G M DC L 
ME G M DC L 
G M DC L 
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Figure 5.1 Phenotypic characterization of 10 non-overlapping populations. The gating 
scheme of defining populations as in Table 5.1 from a representative human (A) cord blood and 

















































































































Determining the developmental potential of CD34+ progenitors 
 After phenotypic separation of CD34+ progenitors into 10 non-overlapping progenitors, 
we determined the developmental potential of each population by using three separate assays: 
methylcellulose culture, MP+FSG culture and cell transfers into NSG-SGM3 
immunocompromised mice (Fig 5.2). 
 In order to determine their myeloerythrocytic potential, we have isolated 500 cells from 
each progenitor population and cultured them on methylcellulose supplemented with human 
recombinant cytokines (SCF, GM-CSF, IL-3, EPO) (Fig 5.2A). Colony formation analysis 
shows that, consistent with previous experiments (Fig 4.2E), CDPs failed to produce any 
identifiable colonies, MDPs produced only macrophage colonies at high numbers, GMDPs 
produced both macrophage and granulocyte colonies, and none of the progenitors produced 
erythrocyte colonies. In contrast, CMPs, HSCs and MPPs had the capacity to produce 
erythrocyte, macrophage and granulocyte colonies (Fig 5.2A). This confirms that CMP possess 
megaerythrokaryocyte potential and that GMDPs do not. 
As expected, lymphoid progenitors (LMPPs, MLPs and BNKPs) lack 
megaerythrokaryocytic potential. Furthermore, although LMPPs produced myeloid colonies, the 
numbers are low compared to GMDPs or MDPs (3-fold) (Fig 5.2A). Of those positive clones, 
the majority were macrophages (approximately 70%) and the remaining colonies were mixed 
with both macrophages and granulocytes, which indicates that LMPPs have limited macrophage 
and granulocyte potential (Fig 5.2A). MLPs produced very few macrophage colonies in 
methylcellulose (i.e. 2+2 per 500 plated cells) (Fig 5.2A). Finally, BNKPs failed to produce any 
positive megaerythrokaryocyte and myeloid colonies. We conclude that the lymphoid 
progenitors do not possess megakaryocyte and erythrocyte potential and have limited, if any, 
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myeloid potential. This follows the traditional model of hematopoiesis whereby lymphoid and 
myeloid lineages follow mutually exclusive and non-overlapping pathways, with CMPs and 
LMPPs bifurcating downstream HSC/MPPs.  
We then determined their monocyte, DC and lymphoid potential using the MP+FSG 
culture (Fig 5.2B). Based on lineage output results, HSCs and MPPs are multipotent, as seen by 
their robust production of granulocytes, monocytes, lymphocytes and all three DC subsets. 
Consistent with previous results (Fig 4.2B), CMPs and GMDPs produced all myeloid cell types 
except for lymphocytes. MDPs produced robust monocyte and DC output, but very few 
granulocytes and no lymphocytes. CDPs, on the other hand, were restricted to DCs alone. 
LMPPs, on the other hand, had robust lymphoid, monocyte and DC potential, but much 
fewer granulocyte potential than GMDPs or CMPs (Fig 5.2B). MLPs, produced high number of 
B/NK cells, fewer monocytes and no granulocytes. Interestingly, MLPs produced more pDCs 
than cDCs. Finally, BNKPs only produced lymphocytes and failed to generate any type of 
myeloid cell. 
Therefore, consistent with previous investigations, multipotent progenitors (HSCs, 
MPPs) and myeloid progenitors (CMP, GMDP, MDP, CDP) have the potential to produce 
myeloid cells, including monocytes and DCs. What was surprising was that, lymphoid 
progenitors, which can produce B/NK cells in culture, also overlap in their potential to produce 
monocytes and DCs. 
In vivo transfers into NSG-SGM3 mice also confirm these results (Fig 5.2C). Multipotent 
progenitors (HSC/MPPs) were capable of producing all cell types after 14 days of transfer, 
including B/NK cells. Myeloid progenitors (CMPs and GMDPs) produced granulocytes 
monocytes and DCs, but very little lymphocytes compared to LMPPs and MLPs. The latter two 
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populations produced robust number of B/NK cells but fewer granulocytes and monocytes. 
Especially, MLPs almost lacked any granulocyte and monocyte activity but retained strong DC 
activity. Although LMPPs produced granulocytes, it was at a lower frequency than those from 
CMPs and GMDPs. However, they were still able to produce DCs at higher frequencies than 
CMPs and GMDPs. These results further support that lymphoid and myeloid progenitors show 
persistent developmental overlap on the monocyte and DC lineage. 
Thus, we conclude that DC and monocyte potential are present in multipotent progenitors 
(HSCs, MPPs), as well as in myeloid (CMPs, GMDPs, MDPs or CDPs) and in lymphoid 
progenitors (LMPPs, MLPs). Our culture and in vivo experiments show that the developmental 
potential is not as pure and non-overlapping as the surface phenotype is. The “convergence” of 
myeloid and lymphoid progenitors on the monocyte and DC lineage suggests the presence of an 














Figure 5.2 Megaerythrokaryocyte, myeloid and lymphoid potential. (A) Stacked columns 
show colony forming units (CFU) produced by HSC, MPP, CMP, GMDP, MDP, CDP, LMPP, 
MLP and BNKP in methylcellulose after 14 days of culture. M, macrophage; G, granulocyte; 
GM, granulocyte and macrophage; GEMM, granulocyte, erythrocyte, megakaryocyte and 
macrophage; E, erythrocyte. Bars are mean averages and error bars are SEM from four 
independent experiments. (B) Flow cytometry plots show output from 100 cells from each of 
HSC, MPP, CMP, GMDP, MDP, CDP, LMPP, MLP and BNKP populations in MP+FSG culture 
after 14 days. Cells gated initially are live CD45+ and plots are representative of five independent 
experiments. (C) Plots show in vivo progeny of HSC/MPPs, CMPs, LMPPs and MLPs. 1x104 
cells of indicated progenitors were sorted from cord blood and injected into the bone cavity of 
conditioned NSG-SGM mice. 2 weeks post-transfer, tibias have been harvested and analyzed for 
the presence of fully differentiated cells. Cells gated initially are live/CD45+ and plots are 
















































































































































Interdevelopmental relationship among CD34+ progenitors 
Based on the overlapping myeloid and lymphoid potential of different progenitors, we 
decided to further investigate whether there was a progenitor-progeny relationship among 
different populations. In order to do this, we first stained CD34+CD38-CD45RA- HSC/MPP cells 
with CFSE and cultured them on MP+FSG. After seven days, we determined the developmental 
hierarchy of different populations by analyzing the proliferation cycle at which different 
downstream progenitors arise (Fig 5.3A): LMPPs appeared at division 1-2, CMPs at division 3, 
GMDPs at division 3-4, MLP/BNKPs and MDPs at division 5, and CDPs at division 7, 
indicating a hierarchy among the marker-pure progenitor populations. 
We then investigated whether there was a direct progenitor-progeny relationship between 
myeloid and lymphoid progenitors. For this, we analyzed by flow cytometry downstream 
progeny cells derived from HSC/MPPs, CMPs, LMPPs, MLPs and BNKPs separately after 
MP+FSG cultures (Fig 5.3B). After 7 days, HSC/MPPs produced CMPs, LMPPs, GMDPs and 
very few MDPs and MLP/BNKPs. CMPs generated GMDPs, MDPs and very few CDPs, but 
failed to produce lymphoid progenitors, such as LMPPs or MLP/BNKPs. LMPPs, on the other 
hand, produced downstream MLP/BNKPs, but more strikingly, GMDPs, MDPs and CDPs. 
Similarly, MLPs also produced MLP/BNKPs, as well as GMDPs, MDPs and CDPs. However, 
neither LMPPs or MLPs produced CMPs. Finally, BNKPs produced negligible CD34+ cells, 
indicating rapid differentiation. In sum, lymphoid progenitor LMPPs and MLPs can generate 
GMDPs, MDPs and CDPs but not CMPs. The latter, which cannot give rise to lymphoid 
progenitors, also produce GMDPs, MDPs and CDPs. This reveals that lymphoid and myeloid 
progenitors developmentally “converge” at the GMDP stage without giving rise to each other, 
which we also corroborated through in vivo transfers into NSG-SGM3 mice (Fig 5.3C). 
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Thus, we show by phenotypic analysis three distinct developmental pathways for 
lymphoid and myeloid cell differentiation: (1) HSC/MPP è LMPP è MLP/BNKP; (2) 
HSC/MPP è LMPP è MLP è GMDP è MDP è CDP; (3) HSC/MPP è CMP è GMDP 
è MDP è CDP (Fig 5.3D). Although this model supports the classical hematopoiesis model, 
whereby myeloid (i.e. CMP) and lymphoid progenitors (i.e. LMPPs and MLPs) follow separate 
pathways immediately downstream MPPs, it presents a new conflict: LMPPs and MLPs, which 
have limited granulocyte potential, are upstream of GMDPs, a population with robust 
granulocyte potential. This is incompatible with the dogma of hematopoiesis, i.e., lineage 

















Figure 5.3 Interdevelopmental relationships among CD34+ progenitors. (A) Concatenated 
FACS plots show division of indicated populations descending from HSCs. 1 x 103 HSCs 
defined as Fig. 5.1 were sorted, labeled with CFSE and cultured for 6 days. Populations were 
gated as in (B), and CFSE dilution was shown in dot plots. Numbers indicate divisions that cells 
have undergone. Plot is representative of four independent experiments. (B) Representative flow 
cytometry plots show output populations from 1x103 HSCs/MPPs, CMPs, LMPPs, MLPs and 
BNKPs after 7-day culture of 3 independent experiments. Cells were initially gated as live 
CD45+Lin(CD3/19/56/14/16/1c/303/141)-CD34+. (C) Plots show the in vivo production of 
downstream progenitors from HSC/MPPs, CMPs, and LMPPs. 1x104 cells from indicated 
progenitors were sorted and injected into the tibia of preconditioned NSG-SGM3 mice. Tibias 
were analyzed after 7 days for the presence of hematopoietic progenitors. Cells were initially 
gated as live/CD45+Lin(CD3/19/56/14/16/1c/303/141)-CD34+. Plots are representative from 
three independent experiments. (D) Schematic picture summarizes the inter-progenitor 






























































































































Phenotypically uniform progenitors are clonally heterogeneous 
 The above results show that there are three populations that can potentially contribute to 
GMDPs, MDPs and CDPs. This suggests that phenotypically homogeneous GMDPs are actually 
heterogeneous, with input from both lymphoid and myeloid progenitor cells. In order to resolve 
this question, we decided to increase the resolution by performing single cell cultures from each 
progenitor. 
 Using our MP+FSG culture and CD34+ staining panel, we isolated a total of >5,000 
individual clones from HSCs, MPPs, LMPPs, MLPs, BNKPs, CMPs, GMDPs, MDPs and CDPs 
from cord blood. Through flow cytometry analysis (Fig 5.4A), we determined their granulocyte 
(G), monocyte (M), CD1c cDC (C), CD141 cDC (A), pDC (P) and lymphocyte (B or NK, L) 
potential at the clonal level. 
 The high clonal efficiency, as determined by clones that generated identifiable human 
CD45+ cells, of HSCs (>40%), MPPs (50%), GMDPs (60%) and MDPs (60%) indicates that 
MP+FSG cultures are optimal for survival, proliferation or differentiation of single CD34+ 
progenitor cells (Fig 5.4B). We obtained a cumulative total of 2,247 positive clones from all nine 
progenitors. 
 Analysis of global composition of positive clones from each progenitor does follow the 
developmental hierarchy observed in Fig 5.3A. HSCs and MPPs have the highest ratio of 
multipotent clones (6-lineage clones, Fig 5.4C) with the highest average yield (Fig 5.4D) than 
other progenitor populations. As downstream progenitors differentiate from HSC/MPPs, they 
contain more committed clones with more limited mean proliferative capacity (Fig 5.4C and D), 





 On the other hand, our analysis also reveals that each population is extremely clonally 
heterogeneous. The standard model presumes that phenotypically homogeneous populations are 
also functionally homogeneous. However, our findings demonstrate that each population defined 
by phenotype is indeed comprised of a mix of clones with distinct differentiation and 
proliferation capacity (Fig 5.4C and D). For example, LMPP progenitors contain clones with 
different lineage combinations (Fig 5.4E, horizontal red box), which suggest that different clones 
with distinct clonal potential may acquire identical phenotype. Furthermore, we observe that the 
same type of clone can also be present in different progenitors that have different phenotype (Fig 
5.4E, vertical red box). This proves that a specific lineage potential does not directly correlate 
with a specific phenotype. 
 In fact, we can also observe that lineage commitment, as defined by the presence of 
unilineage clones, occurs at different stages of hematopoiesis (Fig 5.4C and F) rather than at a 
single population. Granulocyte-committed clones are concentrated in both CMP and GMDP 
populations, but can also be found as early as in HSC and MPPs (Fig 5.4F). Monocyte-
committed clones are concentrated in MDPs, but can also be found in GMDPs, CMPs and 
HSC/MPPs. DC-committed clones are concentrated in CDPs and MDPs, as well as in GMDPs, 
MLPs and LMPPs. Finally, B/NK cell-committed clones gradually increase in numbers from 
HSC/MPPs, to LMPPs, to MLPs and to BNKPs. 
Therefore, we conclude that progenitor populations defined by their homogeneous 
expression of specific surface markers do not clearly represent their true developmental potential 




Figure 5.4 Phenotypically uniform progenitors are clonally heterogeneous. (A) 
Representative flow cytometry plot shows phenotype of live, human CD45+ cells produced from 
a single multipotent positive clone. All clones were classified by their output cells including 
granulocytes (G, brown), monocytes (M, orange), B/NK cells (L, purple), CD141 cDCs (A, red); 
CD1c cDCs, (C, blue) and pDCs (P, green).  (B) Single cells with progenitor population markers 
presented in Table 5.1 were sorted by FACS and cultured for 2-3 weeks. Emerging clones were 
analyzed by flow cytometry for production of G, M, C, A, P or L. Results are from cumulative 
clones isolated from 17 cord blood donors. Bar graphs show clonal efficiency. n, number of total 
seeded clones. (C) Stacked bar graphs summarize global lineage outcome of clones in each 
population. (D) Scatter plots show CD45+ cell yield of all clones in each population. (E) Scatter 
plots show lineage outcome (X-axis) and CD45+ cells yield (Y-axis) of all clones for each 
population (rows). (F) Dot plots show clonal yield of granulocytes, monocytes, CD1c cDC, pDC, 
CD141 cDC and lymphocytes from uni-potent (colored) and multi- or oligo-potent (grey) clones 
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Correlation between clonal output and lineage potential 
 In order to trace each lineage, including that of the DCs and monocytes, with high 
resolution, we propose to use two clonal parameters: (1) number of lineages a cell produced (G, 
M, C, A, P or L) and (2) yield of cells generated per lineage. When we clustered all positive 
clones according to the number of lineages each cell produced, we see a strong correlation 
between cell number output and lineage combinations (Fig 5.5A). This shows that the more 
multipotent a clone is, the more cells a clone can generate. In other words, it suggests that there 
is a relationship between the proliferative capacity and lineage commitment. 
In order to prove this relationship, we have stained HSC/MPPs with CFSE and performed 
clonal cultures from cells that have undergone 0, 3 or 6 divisions as in Fig 5.3A. After two 
weeks of culture, we measured their clonal yield as well as the lineage composition. Compared 
to cells that have not divided (division 0), cells that had divided 3 times showed approximately 
ten-fold decrease in CD45+ cell number output (Fig 5.5B) as well as a decrease in multipotent 
clones. Inversely, the relative number of oligopotent (2-5 lineage combinations) and unipotent 
clones increased (Fig 5.5C). Cells that had divided 6 times showed additional decrease of 
cellular output and a significant increase of unipotent clones. Thus, this shows that cellular yield 
and clonal lineage potential can be indicative of the developmental stage and distance from 
HSC/MPPs, independent of surface marker phenotype. 
Therefore, we propose that by using the cellular output for each lineage generated by a 
single clone as a metric for lineage direction, we will be able to determine its developmental 





Figure 5.5 Correlation between clonal output and lineage potential. (A) Scatter plot shows 
correlation between lineage potential and CD45+ cell yield of all clones. r, Spearman correlation 
coefficient. (B and C) 1 x 103 CFSE-labeled HSCs were cultured for 6 days on MP+FSG. Cells 
were sorted from division 0, 3 and 6 for clonal analysis. (B) Graph shows the yield of clones 
isolated from dividing HSCs that had undergone 0, 3 or 6 divisions (Div). (C) Stacked bars show 
global view of lineage outcome for clones in (B). Results are from cumulative clones of 3 
independent experiments. Asterisks indicate significance based on Fisher’s exact test on uni-
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 Using a staining panel that allows the identification of 10 non-overlapping marker pure 
progenitors in cord blood and bone marrow, we have extensively characterized the 
developmental potential of each separate population in vitro and in vivo. This revealed consistent 
with previous findings that both myeloid and lymphoid progenitors retained DC and monocyte 
potential. We have also elucidated that both myeloid and lymphoid progenitors are capable of 
doing so by giving rise to DC associated progenitors, namely GMDPs, MDPs and CDPs. 
 However, these results opened a new question: how can lymphoid progenitors that lack 
granulocyte activity produce GMDPs, which have granulocyte potential? This suggested a mix 
contribution to GMDPs by both myeloid and lymphoid potential. Interestingly, clonal analysis of 
each progenitor revealed with high resolution the heterogeneity in clonal potential within 
phenotypically homogeneous progenitors, not only within GMDPs, but in all others as well, 
therefore making phenotypic analysis to trace lineage development inadequate. 
 In order to accurately trace each lineage irrespective of its phenotype of origin, we 
proposed to use the cellular output information obtained from clonal cultures. Since the cellular 
yield and lineage combination produced by each clone reflect the developmental distance and 
direction from HSC/MPPs, we hypothesize that these values can be used as metrics for 








Chapter VI. Discussion 
 
1. Result summary 
 Our studies have endeavored to overcome three major hurdles deterring our 
understanding of human DC development: (1) lack of culture that allows the development of the 
three authentic DC subsets together with multilineage cells, (2) unclear identity of DC restricted 
progenitors in human bone marrow and in the periphery, and (3) conflict in overlapping DC 
activity in both myeloid and lymphoid progenitors. 
First, we have established a novel culture system (MP+FSG) able to support the 
development of three subsets of human DCs, together with monocytes, granulocytes and 
lymphocytes, such as B and NK cells. This allowed us to determine the DC potential of new and 
previously identified progenitors within the context of other myeloid and lymphoid lineages. 
Especially, we have shown that the DCs produced in vitro are phenotypically, transcriptionally 
and functionally equivalent to those in peripheral blood, and are not derived from monocytes. 
Furthermore, this culture also supported robust proliferation from single hematopoietic 
progenitor cells, allowing us to investigate the developmental potential of individual clones. 
Using this culture we have identified the granulocyte, monocyte and DC progenitor 
(GMDP), the monocyte and DC progenitor (MDP) and common DC progenitor (CDP), all within 
the previously described CD34+CD38+CD10-CD45RA+ GMPs. Single cell culture of GMPs 
revealed clonal heterogeneity within this population, prompting us to fractionate them using DC-
associated cytokine receptor expression. Phenotypic characterization and separation of GMPs 
based on the differential expression of CD116, CD115 and CD123 allowed the identification of 
three novel DC developmental stages with restricted DC activity. We showed that GMDPs 
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(CD123+CD115-) produce granulocytes and MDPs (CD123+CD115+), which produce monocytes 
and CDPs (CD123hiCD115-), which finally produce all three DC subsets. We also identified one 
more step of specification between CDPs and cDCs, which we called the pre-cDCs. By 
fractionating cord blood CD34- cells according to the differential expression of cytokine 
receptors, we have identified a committed cDC precursor that lacks pDC potential with 
CD45+Lin-CD34-CD117+CD135+CD116+ CD45RA+CD115- phenotype downstream CDPs. 
Finally, in order to determine the main contribution by either myeloid or lymphoid 
progenitors to the DC pathway, we have established a staining panel for CD34+ cells that allows 
the identification of 10 non-overlapping marker-pure progenitors. Using this characterization 
method for identifying distinct progenitors, we have thoroughly tested the developmental 
relationship of these 10 progenitor populations for their potential to produce DCs, granulocytes, 
monocytes and lymphocytes.  Our results show that (1) myeloid and lymphoid progenitors have 
overlapping DC and monocyte potential, (2) myeloid and lymphoid progenitors “converge” at 
the GMDP stage, and (3) marker pure populations are remarkably heterogeneous in 
developmental. Such results challenge the reliability of markers as parameters for identifying 
developmentally pure progenitors, for determining progenitor-progeny relationship, and 
eventually, for tracing the DC developmental pathway. Toward this end, we propose that 
quantitative clonal output number for any lineage can be used as a parameter to measure the 
developmental distance of each lineage from HSCs and from other cell lineages, independent of 
their cell surface markers. We hypothesize that quantitative clonal output could indicate potential 





2. Establishing culture method and its importance in elucidating DC ontogeny 
Despite the importance of human DC hematopoiesis, there has not been a good method to 
analyze simultaneously the differentiation potential of a single progenitor cell to all three DC 
subsets as well as other myeloid and lymphoid lineages. This is of high relevance in the field of 
human DC differentiation for two main reasons. First, DCs have been shown to descend from 
lymphoid progenitors as well as conventional myeloid progenitors; and although a restricted DC 
progenitor has been identified in mouse, its equivalent in humans was unknown. Therefore, to 
identify DC- restricted progenitors, candidate precursors must be tested for their DC 
differentiation potential in the context of other cell types. This can only be achieved in a culture 
that simultaneously nurtures myeloid and lymphoid lineages as well as DCs. 
Furthermore, the DC lineage has been difficult to distinguish from the monocytic lineage. 
Although GM-CSF and IL-4 culture has been widely used to generate human DCs from CD34+ 
cells or blood monocytes118, these GM-CSF-driven DCs have been shown to descend from 
monocytes and differ significantly from the authentic DCs in the steady state that depend on 
FLT3L103. Therefore, a culture that simultaneously supports the development of both monocytes 
and authentic DCs was necessary to discern monocyte and authentic DC lineages. 
We show that MS5 and OP9 stromal cells together with FLT3L, or with FLT3L, SCF and 
GM-CSF, can simultaneously support the development of all three subsets of DCs, monocytes, 
granulocytes and lymphoid cells from CD34+ hematopoietic progenitors. The MP+FSG culture 
drives sufficient proliferation and differentiation for clonal assay. This indicates that signals from 
MS5 and OP9 stromal cells enable differentiation of human DCs, suggesting that the molecules 
mediating such effects must be highly conserved between mouse and human. 
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Importantly, different stromal cells selectively support the preferential expansion of 
specific DC populations. OP9 cells show significant bias toward CD141 cDCs and S17 cells 
toward CD1c cDCs. This suggests that each stromal cell expresses a different molecule or groups 
of molecules that collectively influence and regulate DC subset development. It is not known 
whether these are soluble or membrane bound surface proteins, but their identification would 
shed light in the process of DC subset specification, the developmental stages at which signaling 
is necessary for subset instruction and potential therapeutic approaches to selectively expand 
individual DC subsets. 
Furthermore, MP+FSG may also support the development of other cell types not 
analyzed in this work. HSC/MPP cultures consistently showed the presence of a big portion of 
cells that did not express any of the markers we utilized to categorize fully differentiated cells 
(Fig 5.2C). Thorough phenotypic characterization of these “undifferentiated” cells could reveal 
additional lineages that this culture can support. Additionally, MP+FSG cultures can also be used 
to elucidate the origin of lymphoid organ resident DCs. Recent studies have identified additional 
DC subsets in lymph nodes (CD1c+CD1a+EpCam- DCs, CD1c+CD1a-CD206- DCs and 
CD1c+CD1a-CD206+ DCs)88, 147 and in spleen (CD1c+CD14+ DCs)148. By using our stromal cell 
culture, we can determine the progenitor source and elucidate the molecular mechanism for their 
differentiation. 
Lastly, although the administration of FLT3L, SCF and GM-CSF has provided a highly 
permissive environment for six lineages to develop, it still has some limitations. MP+FSG 
cultures do not support megaerythrokaryocytes or T cells, which are the great majority of the 
blood composition. We hypothesize that adding EPO for erythrocyte development and TPO for 
thrombocyte development, as well as using OP9-DL instead of OP9 cells135, will rescue this 
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deficit. Therefore, we believe our culture is not exhaustive as is, and there is room for 
optimization in order to support more lineages than those we described. 
 
3. DC development in health and disease 
 The number of human diseases involving abnormal numbers of DCs is increasing. 
However, our understanding of their developmental aberrations is still very limited. Two main 
reasons that hindered us from studying anomalous DC development are (1) the lack of 
knowledge in healthy DC development and (2) the lack of a system to interrogate the DC 
potential of hematopoietic progenitor cells from patients. Therefore, the identification of 
restricted monocyte and DC progenitors in human bone marrow, as well as establishing a culture 
system that supports multilineage cell development, will facilitate our understanding of aberrant 
DC hematopoiesis. 
 For example, patients with genetic mutations in the IRF8 transcription factor gene 
completely lack DCs in the periphery149. In addition to DCs, these patients have significantly 
reduced numbers of monocytes while the granulocyte counts are normal. Irf8 has been shown to 
be necessary for murine DC and monocyte development, and human DCs and monocytes also 
express IRF8. This suggests that IRF8 is required for the transition from GMDPs to MDPs, but is 
dispensable for granulocyte development. 
 Another genetically defined syndrome of DC deficiency is the GATA2 associated 
DC/monocyte/B and NK lymphoid (DCML) deficiency145, 150, 151. Patients harboring GATA2 
mutations have a combined mononuclear cell deficiency in leukocytes and their interstitial tissue 
DCs are lacking. Increased in serum FLT3L concentration and disseminated nontuberculous 
mycobacterial, viral and fungal infections are characteristic susceptibilities in these patients. 
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Analysis of their CD34+ cell compartment revealed a dramatic reduction of CD45RA+ 
progenitors, which include the GMDPs, MDPs and CDPs, as well as the lymphoid MLP 
progenitor138. The normal number of granulocytes in these patients suggests that acquiring 
CD45RA marks a crucial developmental step in monocyte and DC, but not for granulocytes. 
 DC deficiency is also common in chronic myelogenous leukemia (CML). CML is caused 
by a chromosomal translocation between chromosomes 9 and 22, forming the fusion oncogene 
BCR-ABL152. cDCs and pDCs are consistently low in all stages of CML progression, while 
monocytes and granulocytes are present at either normal or higher levels153. CD34+ cell analysis 
revealed a complete absence of CD34+CD45RA+CD123hi cells154, 155, which correspond to the 
human CDPs, and a significant decrease of CD34+CD45RA+CD123+ cells, which include 
GMDPs and MDPs. We can infer, therefore, that the MDP to CDP transition is blocked in CML 
patients. 
 DC deficiency is not restricted to CML, but is also regularly observed in acute myeloid 
leukemia (AML). Similar to CML, AML is mainly driven by chromosomal translocations 
leading to the formation of the oncogenes FLT3-ITD and AML1-ETO156. AML patients also 
showed drastic reduction in pDC and cDC numbers in their periphery, suggesting a decrease in 
DC progenitors in the bone marrow157, 158. However, which developmental stage has been 
terminated still remains unknown. We suggest that by CD34+ cell compartment analysis, we will 
be able to elucidate the aberrant steps along DC differentiation. 
 There are also other diseases where DCs are specifically expanded. One such syndrome is 
the blastic plasmacytoid dendritic cell neoplasm (BPDCN)159. This disease is characteristic of 
their selective increase of a CD303+CD45RA+CD123hiCD4+CD56+ cell population160, which 
resembles the human pDCs. These cells have the capacity to produce IFNa and respond to IL-3 
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in vitro by increasing their survival and upregulating costimulatory molecules. Clinical 
manifestations are cutaneous “bruise-like” lesions and leukemic dissemination161. The genetic 
cause of BPDCN has been partially attributed to a dysregulated and activated NF-kB pathway162. 
Interestingly, BPDCN-derived pDCs express the myeloid markers CD13 and CD33163, 164 on 
their surface and transcriptional analysis revealed higher resemblance to cDCs than pDCs160, 
which is indicative of a problem in pDC vs. cDC commitment. Although progenitor analysis in 
bone marrow has not been done, we believe that phenotypic characterization and isolation of 
CD34+ cells will reveal the cellular stages of abnormal development as well as the molecular 
programs, including NF-kB signaling dysregulation, that induce BPDCN syndrome. 
 In conclusion, we propose that exhaustive phenotypic characterization of CD34+ cells in 
DC-associated diseases together with a culture system that allows the investigation of DC 
potential, will enable us to investigate the transcriptional programs regulating specific DC 
developmental stages and will also provide a platform for interrogating potential therapeutic 
approaches in order to rescue DC-deficiency or expansion. 
 
4. Clonal heterogeneity in marker-defined progenitors 
 The standard model of hematopoiesis explains that blood cell production begins from 
hematopoietic stem cells (HSCs), which then proceed through a series of developmental stages 
hierarchically organized according to their restricted developmental potential, to finally 
terminally differentiated cells. 
 Much of our understanding of this progressive process has been built on two main 
factors: (1) the identification of separate progenitors by the differential expression of surface 
markers, and (2) in vivo and in vitro culture systems that can measure their developmental 
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potential and their interdevelopmental relationship. For example, HSCs have been 
phenotypically characterized as CD34+CD38-CD90+ cells and placed at the apex of the 
hematopoietic tree based on their multipotency measured by in vitro and in vivo experiments146. 
Multipotent progenitors (MPPs, CD34+CD38-CD90-), which are also able to produce all blood 
lineages, are placed downstream HSCs because of their lower self-renewal capacity and because 
CD90+ HSCs can produce cells with CD34+CD38-CD90- phenotype, which resemble MPPs, but 
not in the opposite direction. Using this approach, old and new candidate progenitors have been 
placed on specific lineage pathways along the hematopoietic map, either upstream or 
downstream of each other, depending on their developmental potential difference and their 
progenitor-progeny relationship. 
However, this approach fails to explain and place DC-restricted progenitors on the 
hematopoietic map. We have shown that myeloid progenitor CMP, and lymphoid progenitors 
LMPPs and MLPs have the capacity to produce DCs in vitro and in vivo, as well as their 
intermediate progenitors, without giving rise to each other. This suggested to us that the marker-
pure GMDPs, MDPs and CDPs were comprised of a mix of progenitors derived from both 
myeloid and lymphoid cells. In fact, when we cultured single cells from these progenitors, we 
were surprised to see the prevalent clonal heterogeneity within each population. Contrary to the 
traditional model, we also observed that the process of lineage commitment to a single cell type 
is not restricted to one single progenitor stage, but rather occurs gradually starting as soon as in 
the HSC/MPP stage. Furthermore, our clonal analysis showed that even clones with identical 
potential could have drastically different surface phenotype, which could explain why two 
phenotypically different progenitors had shared or overlapping potential. 
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Previous cultures determining the lineage potential of candidate progenitors have been 
evaluated primarily by bulk cultures. Although this method provided important information 
regarding the average power for a progenitor to produce certain lineages, it had failed, until 
today, to prove whether the resulting lineages were shared by one common cell or whether it was 
the combined product of two separate cells. Limiting dilution cultures have statistically 
approximated the shared clonality of separate lineages, but this too could not definitively 
demonstrate the shared origin. 
Therefore, our clonal analyses show that the direct correlation of progenitor phenotype to 
developmental potential is unreliable, and that the previous developmental assays are only 
indicative of the overall developmental capacity of a population, and do not accurately trace the 
lineages for each of blood cell type. 
So what parameters can be used to indicate and measure developmental status of 
progenitors? In order to draw the path for each lineage on the hematopoietic map, we propose to 
use the quantitative clonal output instead of marker-defined phenotype as an indicator of 
developmental status. We have shown that cell output, as well as the number of lineages it 
produces, can be used as a measure of their developmental distance from HSCs. The fewer cells 
a clone produces, the farther it is in the hematopoietic tree, and the fewer the number of lineages 
a clone produces the more committed it is. Therefore, we propose that by placing each clone in a 
multidimensional space using the number of cells each clone generated for each of the six 
lineages our culture supports, we will be able to delineate the developmental path not only for 
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INTRODUCTION
DCs are a heterogeneous population of immune cells that 
are essential mediators of immunity and tolerance1–3. Although 
DCs share a common ability to process and present antigen 
to naive T cells for the initiation of an immune response, they 
are not all identical, and their unique abilities and phenotypes 
are current areas of investigation. DCs from humans, which are 
best defined in the blood, are identified with BDCA markers. 
BDCA-2(CD303)+ plasmacytoid DCs (pDCs) have the unique 
ability to rapidly produce abundant type I interferon (IFN) in 
response to viral infection4. BDCA-1(CD1c)+ conventional DCs 
(cDCs) have been proposed to excel in CD4+ T-cell priming5,6. 
Finally, BDCA-3(CD141)hi cDCs have the ability to capture dead 
cells and to cross-present exogenous antigen, offering a mecha-
nism for priming CD8+ T cells specific for pathogens that do not 
directly infect DCs7–12.
Whereas DC development has been studied extensively in 
mice13, the origin of human DCs and their relation to mono-
cytes have been long debated. Our group has recently clarified the 
pathway for human DC hematopoiesis and shown its sequential 
origin from increasingly restricted but well-defined BM progeni-
tors14,15 (Fig. 1). Human granulocyte, monocyte and DC lineages 
originate from a common progenitor, the GMDP. GMDPs develop 
into a more restricted human MDP. MDPs give rise to monocytes 
and a CDP, which loses the potential to produce monocytes and 
is restricted to produce the three major subsets of DCs. These 
committed DC progenitors reside in BM, as well as in cord blood 
(CB), but not in blood or lymphoid tissues14. Finally, CDPs 
give rise to pDCs, as well as to a circulating cDC precursor cell 
(pre-cDC). Indeed, pre-cDCs develop in the BM, travel through 
the blood and differentiate into the two subsets of cDCs in periph-
eral lymphoid organs. In studies of human volunteers injected 
with Fms-related tyrosine kinase 3 ligand (FLT3L), we showed 
that human pre-cDCs are mobilized into the blood similarly 
to the more differentiated DC subsets15. Now that the lineage-
committed progenitors and immediate precursors for human 
DCs have been identified, studies to further define human DC 
hematopoiesis in health, disease and vaccine settings are possi-
ble, as well as the exploration of their potential utility in cellular 
immunotherapies. This can be facilitated by the use of this 
protocol, in which we describe flow cytometry assays to isolate 
and characterize DC progenitors.
Development of the protocol
The study of human DC hematopoiesis has been hampered by the 
absence of validated markers to identify and track progenitors. 
Human hematopoietic stem and progenitor cells (HSPCs) are 
commonly defined by the expression of the cell surface protein 
CD34, as well as the non-expression of lineage antigens that 
are present on mature leukocytes. These Lin− (lineage) CD34+ 
HSPCs comprise only a small and variable fraction of human BM 
cells (2–4%), CB cells (~1%) and peripheral blood (PB; <0.2%). 
Human HSPCs have been further fractionated using common 
markers such as CD38, CD90, CD45RA, CD117 (stem cell 
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Human dendritic cells (DCs) develop from progressively restricted bone marrow (BM) progenitors: these progenitor  
cells include granulocyte, monocyte and DC progenitor (GMDP) cells; monocyte and DC progenitor (MDP) cells; and  
common DC progenitor (CDP) and DC precursor (pre-DC) cells. These four DC progenitors can be defined on the basis of the 
expression of surface markers such as CD34 and hematopoietin receptors. In this protocol, we describe five multiparametric  
flow cytometry panels that can be used as a tool (i) to simultaneously detect or phenotype the four DC progenitors,  
(ii) to isolate DC progenitors to enable in vitro differentiation or (iii) to assess the in vitro differentiation and proliferation  
of DC progenitors. The entire procedure from isolation of cells to flow cytometry can be completed in 3–7 h. This protocol 
provides optimized antibody panels, as well as gating strategies, for immunostaining of BM and cord blood specimens to  















Figure 1 | Schematic view of human dendritic cell (DC) hematopoiesis. 
DC hematopoiesis is initiated in the bone marrow (BM). A granulocyte, 
monocyte and DC progenitor (GMDP) develops into a monocyte and  
DC progenitor (MDP). MDPs give rise to monocytes and a common  
DC progenitor (CDP), which loses the potential to produce monocytes.  
CDPs give rise to plasmacytoid DCs (pDCs), as well as a circulating cDC 
precursor (pre-cDC). Pre-cDCs migrate from the BM through the blood  
to the periphery to produce the two major subsets of conventional  
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TABLE 1 | List of monoclonal antibodies used in this study.
Marker Fluorochrome Clone Host species and isotype Manufacturer Cat. no.
BDCA-2 (CD303) FITC AC144 Mouse IgG1 Miltenyi 130-090-510
CD116 FITC 4H1 Mouse IgG1 BioLegend 305906
BDCA-3 (CD141) PE AD5-14H12 Mouse IgG1 Miltenyi 130-090-514
CD135 PE 4G8 Mouse IgG1 BD Biosciences 558996
CD45 PE Texas Red HI30 Mouse IgG1 Life Technologies MHCD4517
HLA-DR PE Texas Red TÜ36 Mouse IgG2b Life Technologies MHLDR17
CD45RA PE Texas Red MEM-56 Mouse IgG2b Life Technologies MHCD45RA17
CD3 PE Texas Red S4.1 Mouse IgG2a Life Technologies MHCD0317
CD19 PE Texas Red SJ25-C1 Mouse IgG1 Life Technologies MHCD1917
CD14 PE Texas Red TüK4 Mouse IgG2a Life Technologies MHCD1417
BDCA-2 (CD303) PerCP-Cy5.5 201A Mouse IgG2a BioLegend 354210
CD66b PerCP-Cy5.5 G10F5 Mouse IgM BioLegend 305108
CD335 PerCP-Cy5.5 9E2 Mouse IgG1 BioLegend 331920
CD10 PerCP-Cy5.5 HI10a Mouse IgG1 BioLegend 312216
CD335 PE-Cy7 9E2 Mouse IgG1 BD Biosciences 562101
BDCA-3 PE-Cy7 M80 Mouse IgG1 BioLegend 344110
HLA-DR PE-Cy7 L243 Mouse IgG2a BioLegend 307616
CD11c PE-Cy7 3.9 Mouse IgG1 BioLegend 301608
CD33 PE-Cy7 WM53 Mouse IgG1 eBioscience 25-0338-42
CD38 PE-Cy7 HIT2 Mouse IgG1 BioLegend 303516
CD117 Brilliant Violet 421 104D2 Mouse IgG1 BioLegend 313216
BDCA-3 (CD141) Brilliant Violet 421 M80 Mouse IgG1 BioLegend 344114
CD117 Brilliant Violet 510 104D2 Mouse IgG1 BioLegend 313220
CD123 Brilliant Violet 510 6H6 Mouse IgG1 BioLegend 306022
CD45 V500 HI30 Mouse IgG1 BD Biosciences 560777
CD10 Brilliant Violet 605 HI10a Mouse IgG1 BioLegend 312222
CD20 Brilliant Violet 605 2H7 Mouse IgG2b BioLegend 302333
CD123 Brilliant Violet 650 6H6 Mouse IgG1 BioLegend 306019
CD45RA Qdot 655 MEM-56 Mouse IgG2b Invitrogen Q10069
CD14 Qdot 800 TüK4 Mouse IgG2a Invitrogen Q10064
BDCA-2 APC AC144 Mouse IgG1 Miltenyi 130-090-905
CD115 APC 9-4D2-1E4 Rat IgG1 BioLegend 347306
Clec9A Alexa Fluor 700 683409 Mouse IgG1 R&D Systems FAB6049N
CD34 Alexa Fluor 700 581 Mouse IgG1 BioLegend 343526
BDCA-1 (CD1c) APC-Cy7 L161 Mouse IgG1 BioLegend 331520
CD3 BUV395 UCHT1 Mouse IgG1 BD Biosciences 563546
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TABLE 2 | Antibody panels for human dendritic cell progenitors.
Panel
Panel #1, 15 color 
(identification)
Panel #2, 15 color 
(characterization)
Panel #3, 11 color  
(isolation)
Panel #4, 13 
color  
(culture output)
Panel #5,  
14 color (culture 
proliferation)
FITC CD116 CD116 CD116 BDCA-2 CFSE
PerCP Cy5.5 CD66b/CD335/BDCA-2 CD66b/CD335/BDCA-2 CD66b/CD335/BDCA-2/CD10 CD66b CD66b
PE CD135 CD135 CD135 BDCA-3 BDCA-3
PE Texas Red CD45 CD45RA CD3/CD19/CD14 HLA-DR HLA-DR
PE-Cy7 BDCA-3 (antibody of choice) BDCA-3 CD335 CD335
APC CD115 CD115 CD115 — BDCA-2
Alexa Fluor 700 CD34 CD34 CD34 Clec9A Clec9A
APC-Cy7 BDCA-1 BDCA-1 BDCA-1 BDCA-1 BDCA-1
BV421 CD117 BDCA-3 CD117 — —
V500, BV510 CD123 CD117 CD123 CD45 CD45
BV605 CD10 CD10 — CD20 CD20
Qdot 655, BV650 CD45RA CD123 CD45RA CD123 CD123
Qdot 800 CD14 CD14 — CD14 CD14
Live/Dead Live/Dead blue Live/Dead blue — Live/Dead blue Live/Dead blue
BUV395 CD3/CD19 CD3/CD19 — CD3 CD3
factor (SCF) receptor) and CD135 (FLT3 receptor)16–19. However, 
the combination of these markers does not separate DC 
lineage–committed progenitors from multipotential progeni-
tors. Moreover, it has been reported that a small fraction of cells 
that lack the expression of CD34 have progenitor potential20. 
These Lin− CD34− cells probably represent precursor cells that 
have lost CD34 expression but that are still too immature to 
express lineage markers. Therefore, CD34, as well as the afore-
mentioned markers, are not enough to further separate HSPCs, 
and additional markers are required to identify and isolate DC 
lineage–committed progenitors.
As hematopoiesis relies on instructive cues from the BM niche 
such as hematopoietins, we hypothesized that the lineage potential 
of a progenitor might be determined by the set of growth factor 
receptors that it expresses. We showed that multipotential pro-
genitors such as myeloid and lymphoid progenitors were hetero-
geneous, and they could be further fractionated using antibodies 
against receptors for granulocyte–macrophage colony-stimulating 
factor (GM-CSFR; CD116), macrophage colony-stimulating 
factor (M-CSFR; CD115) and interleukin-3 (IL-3R; CD123) 
(refs. 14,15). By using two slightly different antibody panels, we 
identified the following: (i) the human DC lineage–committed 
GMDP, MDP and CDP in the Lin− CD34+ fraction by combin-
ing antibodies against CD45RA, CD116, CD115 and CD123, as 
well as CD38 (ref. 14), and (ii) the human pre-cDC, which was 
found in the Lin− CD34− fraction and identified on the basis of 
the expression or lack of CD45RA, CD116, CD115 and CD123, 
as well as CD135 and CD117 (ref. 15). These progenitors are 
rare, which presents a challenge for the isolation of these cells. 
When working with scarce cells, the simultaneous analysis of all 
four DC progenitors seems to be essential in order to provide a 
comprehensive view of DC hematopoiesis.
The proven multicolor panels presented in this protocol are 
based on our original studies14,15 with modifications enabling 
simultaneous assessment of all DC lineage–committed progeni-
tors. As the common feature of progenitors that are capable of 
developing into DCs is surface expression of CD117 and CD135, 
the panel to define them includes the following: (i) antibodies 
specific to CD117 and CD135, as well as CD34, CD123, CD115, 
CD116 and CD45RA; (ii) antibodies specific to CD3 (T cell), CD19 
(B cell), CD14 (monocytes), CD335 (natural killer (NK) cell), 
CD66b (granulocytes) and CD10 (lymphoid progenitors) to 
exclude specific lineages (Lin−); (iii) antibodies specific to BDCA-1, 
BDCA-2 and BDCA-3 to exclude differentiated DCs (BDCA−); 
(iv) a viability dye to exclude dead cells; and (v) an optional 
antibody specific to CD45 to visualize hematopoietic cells in 
nonhematopoietic tissues or in vitro cultures. All antibodies 
(Table 1) and fluorochrome combinations (Table 2) are com-
mercially available, and experiments can be run on commonly 
available flow cytometers and flow sorters that are capable of 
multicolor analysis (see configurations in Tables 3 and 4).
Defining human DC progenitors also required that we develop 
an efficient culture assay to study the ability of the progenitors to 
proliferate and differentiate in response to hematopoietic growth 
factors. Through systematic testing of different combinations of 
cytokines, as well as the use of mouse stromal cell lines, we showed 
that the in vitro differentiation of CD34+ HSPCs on MS-5 stromal 
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to as MS5+FSG herein) support the development of multiple 
lineages, including all three major human DC subsets. The resulting 
DC subsets resemble their blood counterparts both in gene 
expression and function14.
Experimental design
In this protocol, we give a flow cytometry–based workflow for 
(i) simultaneous detection of DC progenitors (Table 2, panel #1 
and Fig. 2), as well as their characterization (Table 2, panel #2 
and Fig. 3); (ii) isolation of DC progenitors to enable in vitro 
differentiation (Table 2, panel #3 and Fig. 4); and (iii) evaluation 
of DC progenitor in vitro differentiation (Table 2, panel #4 and 
Fig. 5) and proliferation (Table 2, panel #5 and Fig. 6). The pro-
cedure also covers various preparatory steps—isolation, freezing 
and thawing of mononuclear cells (MNCs) and hematopoietic 
differentiation on stromal cells.
Source tissue. The procedure can be performed on BM or CB 
samples. BM samples are typically obtained from elderly human 
donors; however, as age-related developmental changes may 
affect the composition of the progenitor compartment, CB cells 
can also be examined. As CB can be collected quite easily and 
cryopreserved, it is a good source of human progenitors. When 
these populations are purified and cultured in MS5+FSG, CB 
progenitors showed a differentiation potential similar to that 
exhibited by their BM counterparts14,15.
Identification and characterization of DC progenitors. As 
described, human DC progenitors can be identified by the lack 
of lineage and BDCA markers and by combining CD123, CD34, 
CD115, CD116, CD45RA, CD117 and CD135 markers (Table 2; 
panel #1). As shown in Figure 2b for BM and Figure 2c for CB, 
the following cells can be distinguished:
Cells with the phenotype Lin−BDCA−CD123−/loCD34+CD117+ 
CD135+CD116−CD115−CD45RA+ correspond to the GMDPs 
with the ability to generate granulocytes, monocytes and DCs.
Cells with the phenotype Lin−BDCA−CD123−/loCD34+CD117+ 
CD135+CD116− CD115+CD45RA+ represent the MDPs, which 
have the potential to give rise to monocytes and DCs but not to 
granulocytes.
Cells with the phenotype Lin−BDCA−CD123hiCD34+CD117+C
D135+CD116+CD115−CD45RA+ correspond to the CDPs with 
the capacity to give rise to all DCs but not to monocytes and 
granulocytes.
Pre-cDCs have the phenotype Lin−BDCA−CD123−/loCD34−  
CD117+CD135+CD116+CD115−CD45RA+ and are restricted to 





TABLE 3 | Configuration of LSR II.
Detector Long-pass filter Band-pass filter Fluorochrome
Blue laser (488 nm)
A 685LP 695/40 PerCP-Cy5.5
B 505LP 530/30 FITC, CFSE
C 488/10 SSC
Yellow/green laser (561 nm)
A 750LP 780/60 PE-Cy7
D 600LP 610/20 PE Texas Red
E — 582/15 PE
Red laser (633 nm)
A 735LP 780/60 APC-Cy7
B 690LP 710/50 Alexa Fluor 
700
C — 660/20 APC
Violet laser (405 nm)
A 635LP 655/20 Qdot 655, 
BV650
B 595LP 605/20 BV605
C 505LP 525/50 V500, BV510
D — 450/50 BV421
UV laser (355 nm)
A 735LP 780/60 Qdot 800
B 410LP 450/50 Live/Dead blue
C — 379/28 BUV395
TABLE 4 | Configuration of ARIA III.
Detector Long-pass filter Band-pass filter Fluorochrome
Blue laser (488 nm)
A 655LP 695/40 PerCP-Cy5.5
B 502LP 530/30 FITC
C — 488/10 SSC
Yellow/green laser (561 nm)
A 735LP 780/60 PE-Cy7
D 600LP 610/20 PE Texas Red
E — 582/15 PE
Red laser (640 nm)
A 735LP 780/60 APC-Cy7
B 690LP 730/45 Alexa Fluor 
700
C — 660/20 APC
Violet laser (407 nm)
A 600LP 660/20 Qdot 655
B 502LP 510/50 BV510





































































Preparation of BM or CB sample Stain with identificationantibody panel (panel #1)
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Figure 2 | Gating strategy for the identification of human DC progenitors. (a) Workflow for the identification of DC progenitors. (b,c) Human BM (b) and  
CB (c) MNCs were stained as indicated in Table 2 (panel #1). Progenitors are identified by first gating on live cells (FSC-A versus SSC-A), and then on 
singlets (SSC-A versus SSC-W) and live cells (Live/Dead blue versus SSC-A). Lin− BDCA− cells are obtained by successively gating out CD3+, CD19+ cells  
(CD3, CD19 versus SSC-A), CD14+, CD10+ cells (CD14 versus CD10), BDCA-1+, BDCA-3hi cells (BDCA-1 versus BDCA-3) and CD66b+, CD335+, BDCA-2+ cells 
(CD66b, CD335, BDCA-2 versus CD123). Lin−BDCA−CD123−/lo and Lin−BDCA−CD123hi populations are further subgated on the basis of the expression of CD34 
versus CD117, CD135 versus CD116 and CD45RA versus CD115. In these gated populations, GMDPs are CD123−/loCD34+CD117+CD135+CD116−CD115−CD45RA+; 
MDPs are CD123−/loCD34+CD117+CD135+CD116−CD115+CD45RA+; CDPs are CD123hiCD34+CD117+CD135+CD116+CD115−CD45RA+; and pre-cDCs are CD123−/lo 
CD34−CD117+CD135+CD116+CD115−CD45RA+SSC-Alo. FSC, forward scatter; SSC, side scatter. (d) Expression of CD45 by GMDPs, MDPs, CDPs and pre-cDCs  
from human BM. Histograms show the expression of stained (black line) and unstained (gray line) cells. (e) FMO control for CD115 staining used to 
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phycoerythrin (PE) channel for this purpose, as PE is bright, and 
most if not all antibodies are available in this color. Because CD135 
staining is crucial in order to identify DC progenitors and because 
only CD135 PE works well in our hands, we decided to open the 
PE-Cy7 channel. PE-Cy7 is a tandem dye that can degrade in the 
presence of light and heat, and it will then emit in the parent dye 
channel (PE). However, by avoiding the exposure of samples to 
light and heat, this problem can be largely avoided. The gating 
procedure is the same as that previously described (Fig. 2b,c), 
and the expression of CD11c, HLA-DR, CD38 and CD33 on 
DC progenitors is shown (Fig. 3b). HLA-DR, whose expression 
is neither specific nor identical within the DC subsets, is also 
expressed by DC progenitors. CD11c, which is weakly expressed 
on cDCs and completely lacking on pDCs, is upregulated dur-
ing DC development. CD38, which was initially used to identify 
multipotential progenitors16, as well as DC lineage–committed 
progenitors14, is also expressed by pre-cDCs. Because CD38 is 
expressed by all hematopoietic progenitors, we decided not to 
use it in our antibody panels and focus more on hematopoietin 
receptors that allow further separation of these cells. CD33, which 
is highly specific to the hematopoietic compartment, is expressed 
by all DC progenitors.
Isolation of progenitors. We developed our flow cytometry 
strategy to identify DC progenitors on a 16-color flow cytometer 
(BD LSR II with blue, yellow/green, red, violet and UV lasers; see 
configuration in Table 3). To isolate DC progenitors, we adapted 
our panel to maximize the capacities of an 11-color cell sorter 
(BD Aria III with blue, yellow/green, red and violet lasers; see 
configuration in Table 4). This was done in part by restricting 
the number of channels used for lineage markers and by omitting 
the Live/Dead blue stain to exclude dead cells, relying only on 
Of note, we do not include isotype controls in our immunostain-
ing, as the use of fluorescent isotype controls is not completely 
accurate, and because we have ascertained that the monoclonal 
antibodies are specific by carefully titrating them and using 
fluorescence minus one (FMO) controls for gating.
In nonhematopoietic tissues, we recommend using CD45 to 
visualize hematopoietic progenitors, as it may be challenging to 
identify these rare cells among other cells such as autofluorescent 
macrophages. As shown in Figure 2d, most, if not all, DC progeni-
tors express CD45. Therefore, one channel in antibody panel #1 
remains open to the potential use of CD45.
As DC progenitors are rare cells in both BM and CB, their iden-
tification is a matter of carefully defining the gates separating pos-
itive and negative cells. As shown in Figure 2b,c, the first step in 
the identification of human DC progenitors consists of excluding 
dead cells and debris by scatter gating. Live cells are then gated for 
singlets (side scatter(SSC)-W versus SSC-A; W = width, A = area), 
and dying cells are excluded on the basis of the uptake of the 
Live/Dead blue stain. The next step consists in the sequential 
exclusion of all lineage (CD3, CD19, CD14, CD66b, CD335 and 
CD10)- and BDCA (BDCA-1, BDCA-2 and BDCA-3)-expressing 
cells. To have a better resolution in our gates, we avoid as much 
as possible the use of a ‘dump’ channel containing all antibod-
ies marking all excluded populations. Nonetheless, if the use of 
a ‘dump’ channel is considered to accommodate an additional 
antibody of interest (as done in Table 2, panel #3), one should 
carefully titrate each antibody separately before combining 
them to avoid any compensation issues and difficulties in discrim-
inating between negative cells and cells with low expression. The 
use of CD123 allows clear separation of cells that express a high 
level of CD123 (CD123hi) from cells that express no or a low level 
of CD123 (CD123lo cells). CDPs are found within the CD123hi 
cells by sequentially gating on CD135+, CD116+, CD45RA+ and 
CD115− cells. The CD123lo gate is further analyzed by gating on 
CD34+ CD117+ (CD34+) cells or CD34− CD117+ (CD34−) cells. 
Pre-cDCs are found in the CD34− gate. Indeed, we first gate on 
cells that express CD135, CD116 and CD45RA but do not express 
CD115, and then exclude SSC-A-high cells, as these cells contain 
some monocyte precursors15. In contrast, the CD34+ population 
contains both GMDPs and MDPs. These progenitors are all 
CD135+, CD116− and CD45RA+; expression of CD115 allows the 
separation of GMDPs (CD115− cells) from MDPs (CD115+ cells). 
Even though the CD115 staining is very faint and it is not possible 
to get a clear-cut separation of positive and negative cells, the use 
of FMO control allows for proper gating on CD115+ cells (Fig. 2e). 
Moreover, if we consider that lineage commitment occurs when 
the capacity to give rise to one cell type, e.g., monocyte and DC, 
is increased and the capacity to produce another cell type, e.g., 
granulocyte, is lost, dim CD115 expression is sufficient to separate 
cells with GMDP potential from cells with MDP potential.
To characterize DC progenitors, we use a related combination 
of antibodies (Table 2, panel #2). Panel #2 leaves a channel open 
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Figure 3 | Characterization of human DC progenitors. (a) Workflow  
for the characterization of DC progenitors. (b) Expression of CD11c,  
HLA-DR, CD38 and CD33 by GMDPs, MDPs, CDPs and pre-cDCs from  
human BM. DC progenitors are defined as in Figure 2b. Histograms show 
expression (x axis) and number of cells (y axis) of stained (black line)  
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exclusion by scatter gating (Table 2, panel #3). Moreover, the gating 
hierarchy while sorting is limited to a maximum of an eight-gate 
sort depth. This limit is intrinsic to the current generation of BD 
Aria III sorter hardware and firmware. To limit our gating strategy 
to eight steps (Fig. 4b), we also removed the step to gate out the sin-
glets (SSC-W versus SSC-A). The gating strategy to identify and sort 
all DC-defined progenitors simultaneously is shown in Figure 4c. 
The sorted cells are suitable for various downstream applications 
such as cell culture or gene expression profiling.
Composition and proliferative capacity of in vitro– 
differentiated cells.  Hematopoietic differentiation can be 
induced in vitro by coculture of hematopoietic progenitors on 
mouse BM stromal cells plus cytokines. To assess the differentia-
tion potential of different hematopoietic progenitors and their 
multilineage or restricted potential, we developed an additional 
antibody panel (Table 2, panel #4). BM CD34+ HSPCs cultured 
in MS5+FSG for 7 d can produce T cells (CD3+), B cells (CD20+), 
NK cells (CD335+), granulocytes (CD66b+), monocytes (CD14+) 
and all three major subsets of DCs, that is, pDCs and both subsets 
of cDCs (Fig. 5b). Human CD45 antibody must be included in 
this panel, as it discriminates between human cells and mouse 
stromal cells, which are not entirely gated out by scatter analysis. 
Of note, BDCA markers are often used to classify human DCs. 
However, they are not strictly restricted to DCs; we therefore used 
them in combination with Clec9A for BDCA-3hi cDCs, CD14 for 
BDCA-1+ cDCs and CD123 for BDCA-2+ pDCs.
To examine the proliferative potential of DC progenitors, 
we purified them from CB and stained them with carboxy- 
fluorescein diacetate succinimidyl ester (CFSE) before culturing in 
MS5+FSG. By using a 14-color antibody panel (Table 2, panel #5) 
that includes CFSE, we were able to track the cells that were 
expanding in culture by CFSE dilution. As shown in Figure 6b,c, 
all progenitors are expanding in culture, even though DC lineage– 
committed progenitors—GMDP, MDP and CDP cells—have a 
greater proliferative capacity than DC immediate precursors, i.e., 
pre-cDCs. Moreover, BDCA-1+ and BDCA-3hi cDCs differentiate 
as early as 12 h from CDP and pre-cDC progenitors.
Applications of the protocol
We believe that the protocol described here has multiple applica-
tions and a wide interdisciplinary scope including (i) further defi-
nition of human DC hematopoiesis in health, disease and vaccine 
settings, as well as (ii) evaluating DC progenitors’ applications in 
therapeutic approaches.
Our protocol can be used as an initial tool to analyze normal or 
abnormal immunophenotypic changes during DC development in 
humans. For instance, it can facilitate the study of diseases involv-
ing aberrant DC hematopoiesis such as chronic myelogenous 
leukemia (CML)21 or a newly identified form of primary immu-
nodeficiency characterized by recurrent infections and dissemi-
nated bacille Calmette-Guérin (BCG) infection after vaccination 
in patients lacking GATA2 (ref. 22) and interferon regulatory factor 
8 (IRF8)23. Because of their capacity to elicit and regulate immune 
responses, DCs are essential to any effort for vaccine development. 
Therefore, our protocol provides important tools to design and 
monitor and potentially improve vaccines that rely on DCs.
Finally, the methods described above can support the 
exploration of new cellular therapeutic approaches based on 
Figure 4 | Gating strategy for the isolation  
of human DC progenitors. (a) Workflow for the 
isolation of DC progenitors. (b) Gate hierarchy 
for sorting. (c) Human BM MNCs were stained as 
indicated in Table 2 (panel #3). Progenitors are 
identified by first gating on live cells  
(FSC-A versus SSC-A). Lin− BDCA− cells are 
obtained by successively gating out CD3+,  
CD19+, CD14+ cells (CD3, CD19 and CD14 versus  
SSC-A), BDCA-1+, BDCA-3hi cells (BDCA-1 versus 
BDCA-3) and CD66b+, CD335+, CD10+, BDCA-2+ 
cells (CD66b, CD335, CD10, BDCA-2  
versus CD123). Lin−BDCA−CD123−/lo and 
Lin−BDCA−CD123hi populations are further 
subgated on the basis of the expression  
of CD34 versus CD117, CD135 versus  
CD116 and CD45RA versus CD115. In these  
gated populations, GMDPs are CD123−/lo 
CD34+CD117+CD135+CD116−CD115−CD45RA+;  
MDPs are CD123−/loCD34+CD117+CD135+ 
CD116−CD115+CD45RA+; CDPs are CD123hiCD34+ 
CD117+CD135+CD116+CD115−CD45RA+; and  
pre-cDCs are CD123−/loCD34−CD117+ 
CD135+CD116+CD115−CD45RA+SSC-Alo.  

































Human samples can be obtained from national blood centers for CB  
and from local hospitals for BM ! CAUTION Universal precautions must  
be taken while manipulating human specimens, and all experiments  
must be carried out in at least class II biological safety cabinets and  
using appropriate protection equipment. ! CAUTION Parental informed 
consent (CB) or patient informed consent (BM) must be obtained before 
collection, and protocols must conform to your Institutional Review  
Board (IRB)’s guidelines. IRB-approved protocols usually require that the 
samples be anonymous and fully deidentified at the site of collection  
by hospital personnel.
Cell culture
Dulbecco’s PBS 1× (DPBS; Life Technologies, cat. no. 14190)
RPMI-1640 (Life Technologies, cat. no. 21870-076)
-MEM 1× (Life Technologies, cat. no. 12561-056)
FBS, heat inactivated (Life Technologies, cat. no. 16140-071)  
 CRITICAL We recommend testing several lots of serum for culture  
optimization and then using the same lot for an entire series of experiments. 
In our case, we always test three or four lots for hematopoietic differentiation  
on MS-5 stromal cells and select the one that supports the development  
of CD34+ HSPCs with an overall better yield for DCs.
Antibiotic-antimycotic solution (Cellgro, cat. no. 30-004-CI)
Collagenase type IV (Sigma-Aldrich, cat. no. C-5138)
Ficoll-Paque plus (GE Healthcare, cat. no. 17-1440-03)










EDTA, 0.5 M (Life Technologies, cat. no. 15575)
ACK lysing buffer (Life Technologies, cat. no. A10492)
Mitomycin C (Sigma-Aldrich, cat. no. M4287) ! CAUTION Avoid contact 
and inhalation. Wear gloves, safety glasses and a lab coat.
DMSO (Sigma-Aldrich, cat. no. 154938)
Trypan blue stain 0.4% (wt/vol) (Life Technologies, cat. no. 15250-061)
Carboxy-fluorescein diacetate succinimidyl ester (CFSE; Life Technologies, 
cat. no. C1165)
Recombinant human SCF ligand (SCF; R&D systems, cat. no. 255-SC-050/CF)
Human FLT3 ligand (FLT3L; Celldex Therapeutics, special order)
Leukine (sargramostim) as a human GM-CSF (Genzyme)  
 CRITICAL Leukine is a prescription drug that must to be ordered  
through a pharmacy.
Human serum albumin (HSA; Sigma-Aldrich, cat. no. A9511)
MS-5 mouse bone marrow stromal cell line (Creative Bioarray,  
cat. no. CSC-C2763) ! CAUTION The cell lines used in your research  
should be regularly checked to ensure that they are authentic and that  
they are not infected with mycoplasma.
Benzonase nuclease, 10 kU, 25 U/ l (Novagen, cat. no. 70664-3)
Heparin, cell culture grade (Sigma-Aldrich, cat. no. H3149)
Bleach ! CAUTION Bleach is an irritant. Avoid contact with eyes, skin  
and clothing.
Plasticware
50-ml conical tubes (BD Falcon, cat. no. 352098)
15-ml conical tubes (BD Falcon, cat. no. 352097)


















DC progenitors including stem cell therapies focused on 
embryonic stem cells and induced pluripotent stem cells. The 
composition and the properties of the cells that are produced 
after in vitro differentiation of progenitors will differ considerably 
depending on the culture condition, and therefore this system 
can be used to evaluate DC progenitors to identify novel 
regulators of DC hematopoiesis or to test the toxicity of new 
drug candidates. Of note, therapeutic approaches based on 
human DC progenitors may require the development of a 
nonxenogeneic culture system; therefore, it would be good 
to explore the feasibility of expanding DC progenitors in an 
entirely human coculture system using either umbilical vein 
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Figure 5 | Gating strategy for culture output after hematopoietic differentiation on MS-5 stromal cells of human DC progenitors. (a) Workflow for isolation of 
DC progenitors. (b) CD34+ HSPCs from BM were isolated as in Figure 3c, and then cultured in MS5+FSG for 7 d. Culture output was assessed by flow cytometry 
using antibody panel #4, as indicated in Table 2. Cells developing in culture are identified by first gating on live cells (FSC-A versus SSC-A), and then on 
singlets (SSC-A versus SSC-W) and live cells (Live/Dead blue versus SSC-A). CD45+Lin− cells are obtained by successively gating on CD45+ cells (CD45 versus 
SSC-A) and gating out CD3+ cells (CD3 versus SSC-A), CD19+ cells (CD19 versus SSC-A) and CD335+ cells (CD335 versus SSC-A). Flow cytometry plots show 





























NATURE PROTOCOLS | VOL.10 NO.9 | 2015 | 1415
5-ml polystyrene round-bottom tube (BD Falcon, cat. no. 352052)
5-ml polystyrene round-bottom tube with cell-strainer cap (BD Falcon,  
cat. no. 352235)
25-ml serological pipette (Costar, cat. no. 4489)
10-ml serological pipette (Costar, cat. no. 4488)
5-ml serological pipette (Costar, cat. no. 4487)
Transfer pipette (Sarstedt, cat. no. 86.1171.001)
Microcentrifuge tubes (1.5 ml; Eppendorf, cat. no. 022363204)
Cryogenic screw-cap micro tubes (2-ml; Sarstedt, cat. no. 72.694.006)
Micro tubes with screw caps, conical bottom (1.5-ml; RPI Corp,  
cat. no. 144500)
Titertube micro test tubes (Bio-Rad, cat. no. 223-9391)
96-well micro-well plates V-bottom without lid (Nunc, cat. no. 249570)
96-well micro-well plates lid (Nunc, cat. no. 263339)
96-well tissue culture plates flat-bottom (BD Falcon, cat. no. 357072)
10-cm tissue culture dishes (BD Falcon, cat. no. 353003)
15-cm tissue culture dishes (BD Falcon, cat. no. 353025)
150-cm2 tissue culture flasks straight neck with vented cap (BD Falcon,  
cat. no. 355001)
10-ml syringe (BD Falcon, cat. no. 309604)
Syringe filter with a 0.2- m membrane (Pall, cat. no. 4612)
Cell strainer, 100 m (BD Falcon, cat. no. 352360)
Cell strainer, 70 m (BD Falcon, cat. no. 352350)
Precision specimen container, 4 ounce, positive seal indicator (Covidien, 
cat. no. 2200SA)
Flow cytometry reagents
Antibodies (Table 1)  CRITICAL Each antibody must be titrated  
before use (see Reagent Setup) ! CAUTION All antibodies must be kept at  
4 °C and protected from exposure to direct light.
Live/Dead fixable blue dead cell stain kit for UV excitation (Life  
Technologies, cat. no. L23105) ! CAUTION Keep it at −20 °C and protect 
 it from exposure to direct light.
Formaldehyde solution 37% (wt/vol) H2O (Sigma-Aldrich, cat. no. 252549) 
! CAUTION Formaldehyde is toxic by inhalation or if swallowed; it is  
irritating to the skin, eyes and respiratory system, and it may be carcinogenic. 
Formaldehyde should be used with appropriate safety measures, such as 
protective gloves, glasses, clothing and sufficient ventilation. All waste 
should be handled according to hazardous waste regulations.
BD CompBeads set anti-mouse Ig  (BD Biosciences, cat. no. 552843)
BD CompBeads set anti-rat Ig  (BD Biosciences, cat. no. 552844)
Amine-reactive compensation bead kit (Life Technologies,  
cat. no. A10346)
EQUIPMENT
Biological safety level 2 (BSL-2) tissue culture facilities
BSL-2 sorting facilities
Class II biological safety cabinet (The Baker Company, cat. no. SG403)
Cell incubator (37 °C, 5% CO2; Nuaire, cat. no. NU-5500)
Tabletop centrifuge with rotors and adapters for 50- and 15-ml conical 
tubes and 96-well plates (Sorvall, cat. no. 75-004-367)
Microcentrifuge (Eppendorf, cat. no. 5424)
Inverted microscope (Nikon, cat. no. Eclipse TS100)




































Cryo 1 °C freezing container (Nalgene, cat. no. 5100-0001)
LN2 storage systems (Thermo Scientific, cat. no. 7404)
BD LSR II flow cytometer running DIVA 8.0, or equivalent (BD Biosciences, 
special order). Our LSR II is equipped with four lasers with a configuration 
allowing 16-color, 18-parameter flow cytometry (Table 3)
BD Aria III cell sorter running DIVA 8.0, or equivalent (BD Biosciences, 
special order). Our Aria III is equipped with three lasers with a configura-
tion allowing 11-color, 13-parameter flow cytometry (Table 4)
BD FACSDiva V8.0.1 software (BD Biosciences) for data acquisition
FlowJo software V9.8.2 (TreeStar) for data analysis
REAGENT SETUP
Heparin Dissolve heparin in PBS at a final concentration of 1,000 U/ml. 
Filter this solution with a 0.2- m syringe filter and divide the solution  
into aliquots in a 5-ml polypropylene round-bottom tube. Store the  
heparin at 4 °C for up to 2 years.
Collagenase solution Dissolve 100 mg of collagenase type IV in 50 ml  
of RPMI-1640 to obtain a 2 mg/ml collagenase stock solution. Filter this 
solution with a 0.2- m syringe filter. Store the solution in 10-ml aliquots  
at −20 °C for up to 1 year.
Freezing medium Prepare freezing medium by adding 10% (vol/vol)  
DMSO in FBS on the day of use.
Thawing medium Prepare thawing medium by adding 10% (vol/vol)  
FBS in RPMI-1640, and store it at 4 °C for up to 4 weeks.
CFSE stock CFSE is resuspended in DMSO at a concentration of 5 mM. 
Store the stocks in aliquots of 50 l in Eppendorf tubes at −80 °C for up to  
1 year. Each batch of CFSE should be titrated before use in the procedure 
(Box 1) on cells to determine the optimal concentration for labeling  
(0.5 M final was used in the example results shown here).
MS-5 growth medium Prepare the growth medium by adding 10%  
(vol/vol) FBS and 1% (vol/vol) penicillin-streptomycin in -MEM.  
 CRITICAL Prepare the medium in advance and store it at 4 °C for up  
to 2–3 weeks.
Mitomycin C solution Dissolve mitomycin C in sterile H2O to obtain a  
0.5 mg/ml stock solution. Store the solution in 500- l aliquots at −20 °C for 
up to 1 year.
Cytokine buffer Mix 0.1% (vol/vol) HSA in PBS. Sterilize the solution by 
filtration using a 0.2- m syringe filter, and store it for up to 6 months at 4 °C.
Reconstitution of cytokines Reconstitute human cytokines in cytokine 
buffer at a stock concentration of 20 g/ml for GM-CSF and SCF ligand and 
100 g/ml for FLT3L. Store the cytokines in 50- l aliquots at −80 °C for up  
to 2 years.  CRITICAL Vials of lyophilized cytokines should be centrifuged  
in a microcentrifuge at maximum speed for 1 min at room temperature 
(20–25 °C) before opening vials.
Formaldehyde working solution Mix 2% (vol/vol) formaldehyde in PBS. 
Store the solution at 4 °C for up to 1 month.
Staining buffer Mix 1% (vol/vol) FBS in PBS.  CRITICAL Staining buffer 
can be prepared in advance and stored at 4 °C for up to 1 month.
Sorting buffer Mix 1% (vol/vol) FBS and 0.5 M EDTA (2 mM final)  
in PBS.  CRITICAL Sorting buffer can be prepared in advance and stored  
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Figure 6 | Proliferative capacity of human DC 
progenitors after hematopoietic differentiation 
on MS-5 stromal cells. (a) Workflow for culture 
proliferation of DC progenitors. (b) GMDPs, 
MDPs, CDPs and pre-cDCs were purified from CB, 
as shown in Figure 3c, labeled with CFSE, and 
cultured in MS5+FSG for 0.5, 1.5, 3 and 5 d;  
proliferation was assessed by flow cytometry 
using antibody panel #5, as indicated in Table 2. 
Flow cytometry plots show gated culture-derived 
cells, as defined in Figure 5b: CD45+ cells (gray), 
BDCA-1+ cDCs (blue) and BDCA-3hi cDCs (red). 
(c) Graphs showing the output of BDCA-1+ cDCs 
(blue) and BDCA-3hi cDCs (red) for 103 GMDPs (5 d), 
MDPs (5 d), CDPs (3 d) and pre-cDCs (3 d) 
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Live/Dead blue viability dye Thaw Live/Dead blue powder by leaving it for 
10 min at room temperature. Add 50 l of DMSO and vortex it thoroughly. 
Store the solution in 1- l aliquots in Eppendorf tubes at −20 °C for up to 
1 year. Each batch of Live/Dead blue should be titrated before use in the 
procedure on dying cells, for example, cells kept in culture at a very dense 
concentration such as 20 × 106 cells per ml, to determine the optimal dilution 
for labeling (1/1,000 final in the example results shown here). When you  
are ready to use Live/Dead blue, thaw and keep on ice a 1- l aliquot into 
which you add 99 l of PBS (1/100 Live/Dead blue working solution).
Amine-reactive Live/Dead blue CompBeads Vortex the beads thoroughly 
before use. Resuspend one drop of positive beads and one drop of negative 
beads in 500 l of PBS. Add 20 l of Live/Dead blue working solution to  
180 l of beads solution in a 5-ml polypropylene round-bottom tube (final 
dilution of Live/Dead blue is 1/1,000). Incubate the mixture for 30 min at  
4 °C in the dark. Wash the beads twice with PBS. Resuspend the beads in 
150 l of formaldehyde working solution and transfer them to a titer tube. 
Prepare the beads on the day of use.  CRITICAL It is crucial to use PBS alone 
and not staining buffer that contains serum, as proteins from the serum 
would prevent the binding of Live/Dead blue to the compensation beads.
Antibody staining solution The amounts of antibody needed per staining  
are determined by titration experiments done before performing the procedure.  
The optimal concentration of an antibody is determined by a titration  
experiment in which typically 2 × 106 cells in a 20- l volume are stained  
with 1×, 2×, 4× and 8× the amount of antibody. The optimal concentration 
for a specific antibody is the amount giving the best fluorochrome signal  
and the least fluorochrome spreading. To prepare the antibody staining  
solution, mix the titrated amount of antibody for all antibodies and make it 
up to 20 l with staining buffer (Table 2). The staining volume is 40 l total 
(20 l of cell suspension + 20 l of antibody staining solution). The staining 
volume should be scaled up according to the number of cells. Prepare this 
solution on the day of use.  CRITICAL Spin the antibody staining solution in  
a microcentrifuge at maximum speed for 1 min at room temperature  
to remove antibody aggregates. Use the supernatant only to stain cells.  
 CRITICAL Always prepare the antibody staining solution in excess  
(10% more than needed for the experiment).
BD CompBeads Vortex the beads thoroughly before use. Prepare a  
positive bead solution and a negative bead solution (typically one drop  
of beads is added to 500 l of PBS for the positive solution). For the  
negative FACS control, add 100 l of negative bead solution in one well  
of a 96-well V-bottom plate. For the positive FACS controls, add 100 l of  
positive bead solution per well of a 96-well V-bottom plate for each control. 
Add the titrated amount of antibody. Incubate the 96-well plate for 30 min  
at 4 °C in the dark. Wash the beads twice with PBS. Resuspend each control 
in 150 l of formaldehyde working solution. Transfer the controls to  
titer tubes. Prepare the beads on the day of use.  CRITICAL Carefully  
check that the monoclonal antibody chosen can be recognized by the  
beads (for example, use anti-mouse Ig  CompBeads for mouse  
monoclonal antibodies).
Box 1 | CFSE staining  TIMING 30 min 
To assess the ability of cells to proliferate in culture (Steps 36–38), we use a cell proliferation assay. Cells are labeled with the  
fluorescent dye CFSE. Those cells that proliferate show a reduction in CFSE fluorescence intensity, which is measured directly by  
flow cytometry.
1. Wash the cells twice in PBS and resuspend them in PBS at a 2 × 107 cells per ml concentration.
2. Prepare a 1 M working solution of CFSE from the stock (5 mM) by diluting the stock in PBS. Label the cells by adding one  
volume of working solution of CFSE (1 M) to one volume of cells. The final concentration of CFSE is then 0.5 M.
3. Incubate the cells in the dark with gentle mixing at room temperature for 8 min.
4. Quench the reaction by adding an equal volume of FBS for 2 min.
5. Wash the cells twice with PBS and resuspend them in MS-5 growth medium.
6. To assess the proliferation of bulk CD34+ cells or purified progenitors (see Step 36B for isolation of progenitors using panel #3)  
during hematopoietic differentiation on MS-5 stromal cells, proceed directly to Step 33.
PROCEDURE
Donor CB and BM collection and initial processing  TIMING 10–45 min
! CAUTION All human blood, body fluids and tissues must be treated as if infectious and universal precautions must be  
taken by lab workers while manipulating these specimens.
! CAUTION All human biological waste to be discarded should be treated with bleach or it should be autoclaved, and then  
it can be discarded according to your institution disposal procedures.
 CRITICAL All steps should be carried out in a class II biological safety cabinet.
1| Obtain human samples from CB, as described in option A, or obtain and prepare a single-cell suspension of BM,  
as described in option B.
(A) CB sample  TIMING ~10 min
 (i)  Obtain a fresh cord blood unit (CBU; typically 80–140 ml) provided in citrate phosphate dextrose adenine (CPDA-1)  
preservative solution. 
 CRITICAL STEP The CBU should be kept at room temperature until processing. For optimum results, processing 
should take place in <12 h, and the samples that are older than 24 h should not be used.
(B) BM sample  TIMING ~45 min
 (i)  Obtain biopsies from surgical procedures such as routine hip arthroplasty. The biopsy should be kept on ice  
immediately after surgical removal in a container for specimen collection, and it should be preserved in 1–2 ml of 
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 (ii)  Weigh the specimen for reference. 
 CRITICAL STEP Samples can be stored at 4 °C for a few hours before starting the isolation procedure. 
 CRITICAL STEP This protocol has been optimized for solid biopsies and not aspirates—i.e., a sample of the liquid 
portion of BM. 
 CRITICAL STEP This protocol is optimized for the processing of specimen weighing 20–40 g. For smaller or larger 
specimens, adjust the volumes accordingly.
 (iii)  Wash the BM biopsy in PBS and transfer it into a 50-ml tube with 10–20 ml of collagenase solution. Incubate the 
mixture for 30 min at 37 °C under continuous agitation. 
! CAUTION Collagenase digestion of tissues to create single-cell suspensions may result in the destruction of certain 
cell surface markers. However, we did not observe the destruction of any of the surface markers that we tested. 
 CRITICAL STEP Add 10 ml of collagenase solution to every 20 g of tissue. Collagenase is thawed and kept on ice. 
 CRITICAL STEP This short digestion allows the disruption of the bony matrix, as well as the release of the fat  
constituting the marrow.
 (iv) Filter the BM cell suspension through a fine mesh nylon screen.
Isolation of CB and BM MNCs via density gradient  TIMING 1.5 h 
2| Prepare CB (option A) or BM (option B) density gradients.
(A) CB gradient
 (i) Dilute the entire CBU 1:1 with sterile PBS in an upright appropriately sized sterile tissue culture flask.
 (ii)  Carefully and slowly layer 35 ml of diluted CB onto 15 ml of Ficoll-Paque in a 50-ml conical tube. Repeat the  
process in additional tubes for the remaining diluted CBU. If the last amount does not total 35 ml, make up the  
volume to 35 ml with PBS.
(B) BM gradient
 (i)  Carefully and slowly layer 35 ml of BM cell suspension onto 15 ml of Ficoll-Paque in a 50-ml conical tube.  
If the amount does not total 35 ml, make up the volume to 35 ml with PBS. 
 CRITICAL STEP The more diluted the sample, the better the purity of the MNCs. 
 CRITICAL STEP To avoid mixing Ficoll-Paque and the cell suspension, tilt the 50-ml conical tube at a 45 °C  
angle and slowly let the blood run down on the side of the tube onto the Ficoll layer.
3| Centrifuge the mixture at 850g for 30 min at 20 °C in a swinging-bucket rotor with no brake.
4| Aspirate the upper layer (yellow layer corresponding to the plasma, in the case of CB) leaving the mononuclear cell  
layer (white layer at the interphase between the Ficoll and the plasma) undisturbed.
? TROUBLESHOOTING
5| Carefully transfer each mononuclear cell layer using a sterile transfer pipette to a new 50-ml conical tube.
6| Fill the 50-ml conical tubes with RPMI-1640, mix well, and centrifuge the tubes at 480g for 5 min at 20 °C with brake.
7| Carefully remove the supernatant completely. Pool the pellet of all 50-ml conical tubes. Fill the 50-ml conical tube with 
RPMI-1640, mix it well and centrifuge it at 480g for 5 min at 20 °C with brake.
 CRITICAL STEP CB samples sometimes show substantial contamination of the interphase layer with red blood cells. In that 
case, resuspend the cell pellet in 5 ml of ACK lysing buffer. Allow it to stand for 5 min at 4 °C. Fill the 50-ml conical tube 
with RPMI-1640, mix it well and centrifuge it at 480g for 5 min at 20 °C with brake. Remove the supernatant; resuspend the 
cells in 50 ml of RPMI-1640 and centrifuge them once more at 480g for 5 min at 20 °C with brake.
8| Carefully remove the supernatant completely. Resuspend the cells in 50 ml of staining buffer, count the cells using a 
hemocytometer or other cell counter, and determine the viability by trypan blue stain exclusion. If you are not pausing, 
proceed directly to Step 35 (staining panel #1, 2 or 3) or Step 33 (staining panel #4 or 5).
PAUSE POINT Keep the cells in staining buffer at 4 °C for 1–2 h until use, or freeze them for long-term storage, as 
described in Steps 9–12.
Freezing of CB and BM MNCs  TIMING 20 min
9| Centrifuge the cells at 480g for 5 min at 20 °C.
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11| Transfer 1 ml of cells in freezing medium per sterile cryogenic micro tube.
 CRITICAL STEP Label each tube clearly (date, sample name, cell concentration).
 CRITICAL STEP The optimal cell concentration for freezing is 10 × 106 cells per ml. However, you can go up to 50 × 106 
cells per ml in case of large specimens.
12| Put the cryogenic vial in a freezing container, and store it at −80 °C for 12–24 h before transferring it to the liquid 
nitrogen tank for long-term storage.
PAUSE POINT Cells can be stored in liquid nitrogen for years.
Thawing CB and BM MNCs  TIMING 30 min
13| Add 10 ml of cold thawing medium in a 15-ml conical tube to thaw one vial or add 40 ml of cold thawing medium in a 
50-ml conical tube to thaw up to ten vials.
 CRITICAL STEP To obtain the best possible survival, thawing of cells must be performed as quickly as possible, and the 
thawing medium should be cold to minimize heat shocks.
14| Remove the vial from the liquid nitrogen tank, and hold it at room temperature until the sides are thawed but the center 
remains frozen.
 CRITICAL STEP Do not place the vial into a 37 °C water bath, as it is important not to dramatically heat-shock the cells.
15| Transfer the contents of the vial (~1 ml) into a 15-ml conical tube containing cold thawing medium.
16| Centrifuge the cells at 480g for 5 min at 20 °C.
17| Resuspend the cells in staining buffer for extemporaneous use.
Culture of mouse MS-5 stromal cells  TIMING 8 d
 CRITICAL Mouse MS-5 stromal cells are only required for staining panel #4 or 5.
18| Culture MS-5 stromal cells in 10-cm tissue culture dishes with 10 ml of MS-5 growth medium. Place the cells in a CO2 
cell incubator.
 CRITICAL STEP MS-5 stromal cells grow in monolayers. Examine the tissue culture dish under the microscope; the cells are 
ready to be split when they are 95% confluent.
19| Aspirate the MS-5 growth medium and wash the cells twice with 10 ml of PBS.
20| Add 2 ml of trypsin-EDTA 0.05% (wt/vol) solution and incubate the cells for 2 min at 37 °C in a CO2 cell incubator.
 CRITICAL STEP Inadequate washing of cells with PBS or using an old trypsin solution may result in partial detachment of 
cells from the dish.
21| Add 10 ml of MS-5 growth medium and collect the cells by pipetting.
22| Transfer the cell suspension in a 15-ml conical tube and centrifuge it at 480g for 5 min at 20 °C.
23| Aspirate the supernatant and resuspend the cells in 10 ml of MS-5 growth medium.
24| Add 0.5 ml of cell suspension to 9.5 ml of MS-5 growth medium, and plate the cells onto a 10-cm tissue culture dish. 
Place the cells in a CO2 cell incubator.
25| When the culture is 95% confluent, if required, split the dish for maintenance (by repeating Steps 19–24). Confluence 
should be reached after 3–4 d of culture.
26| To expand the cells for coculture experiment, prepare an extra tissue culture dish by adding 1 ml of cell suspension to  
19 ml of MS-5 growth medium into a 15-cm Petri dish.
 CRITICAL STEP Do not use cells that have a high passage number or that are growing slowly. The doubling time for healthy 
MS-5 is ~24 h.
PAUSE POINT It is possible to pause the protocol at this stage by freezing and storing MS-5 stromal cells in liquid nitrogen 
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Hematopoietic differentiation on MS-5 stromal cells  TIMING 8 d
27| The day before the coculture experiment (day 0), take the extra tissue culture dish of MS-5 stromal cells that was  
prepared (Step 26), and proceed to mitomycin C treatment. Aspirate the medium without disturbing the MS-5 stromal  
cell layer. Add 20 ml of fresh MS-5 growth medium containing 10 g/ml mitomycin C. Incubate the dish for 3 h in a  
CO2 cell incubator.
28| Trypsinize the MS-5 stromal cell layer, as described in Steps 19–23.
29| Count the MS-5 cells using a hemocytometer or other cell counters and determine viability by trypan blue stain exclusion.
30| Centrifuge the cells at 480g for 5 min at 20 °C; aspirate the supernatant.
31| Resuspend the pellet at 2.5 × 105 per ml in MS-5 growth medium.
32| Seed 2.5 × 104 cells (100 l) per well of a 96-well flat-bottom tissue culture plate. Incubate the cells overnight in  
a CO2 cell incubator.
33| The following day (day 1), resuspend a maximum of 104 bulk CD34+ cells or purified progenitors (see Step 36B for  
isolation of progenitors using panel #3) in 100 l of MS-5 growth medium containing 40 ng/ml GM-CSF and SCF ligand and 
200 ng/ml FLT3L.
 CRITICAL STEP If progenitors need to be stained with CFSE (panel #4) before coculture with MS-5 stromal cells, proceed as 
described in Box 1.
34| Seed the progenitor cells on top of the MS-5 stromal cells prepared in Step 32. Incubate the cells for 7 d in a  
CO2 cell incubator.
Cell surface staining  TIMING 1–2 h
35| Take all or an aliquot of the cell suspension from Step 8. Use at least 2–4 × 106 cells for simple phenotyping  
(panel #1) and characterization (panel #2) staining. If you are sorting the cells (panel #3), start with a sufficient number  
of cells to obtain a reasonable number of progenitors after sorting. We usually sort 100–200 × 106 CB or BM MNCs to  
achieve sufficient progenitors. Use the whole MS-5 culture from Step 34 for culture output (panel #4) and culture  
proliferation (panel #5) staining.
 CRITICAL STEP We recommend working with fresh samples. If you are working with frozen samples, thawing and staining 
should preferably be performed on the same day. If you are using frozen cells, count the cells (from Step 17) after thawing 
using the hemocytometer or other cell counter and determine the viability by Trypan Blue Stain exclusion.
? TROUBLESHOOTING
36| If you are performing cell surface staining for panel #1 and 2, follow option A; for panel #3, follow option B; and for 
panel #4 and panel #5, follow option C.
! CAUTION This and all subsequent steps should avoid exposure to direct light to preserve fluorochromes.
 CRITICAL STEP Do not forget to prepare the compensation tubes as well (see Reagent Setup).
(A) Staining for panel #1 and #2  TIMING 1 h 30 min
 (i) Resuspend the cells (from Step 8) in PBS at a density of 100 × 106 cells per ml.
 (ii) Put 2 × 106 cells (20 l) in each well of a 96-well V-bottom plate.
 (iii) Add 2 l of 1/100 Live/Dead blue working solution to each well.
 (iv) Incubate the cells at 4 °C in the dark for 20 min.
 (v) Wash the cells by adding 150 l of staining buffer per well.
 (vi) Centrifuge the cells at 480g for 5 min at 20 °C; flick the plate to decant the supernatant.
 (vii) Add 20 l of the antibody staining solution per well.
 (viii) Incubate the cells at 4 °C in the dark for 30 min.
 (ix) Wash the cells by adding 150 l of staining buffer per well.
 (x) Centrifuge the cells at 480g for 5 min at 20 °C; flick the plate to decant the supernatant.
 (xi) Resuspend the cells in 150 l of formaldehyde working solution per well. Transfer the samples to titer tubes.
 (xii)  Keep the samples in the dark at 4 °C, and acquire samples on a flow cytometer. 
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(B) Staining for panel #3  TIMING 1 h
 (i) Resuspend the cells (from Step 8) in staining buffer at a density of 400 × 106 cells per ml in a 50-ml conical tube.
 (ii) Add 20 l per 8 × 106 cells of the antibody staining solution.
 (iii) Incubate the cells at 4 °C in the dark for 30 min.
 (iv) Wash the cells by adding 40 ml of sorting buffer.
 (v) Centrifuge the cells at 480g for 5 min at 20 °C. Aspirate the supernatant.
 (vi)  Resuspend the cells in sorting buffer at a density of 30 × 106 cells per ml, and transfer them to a 5-ml polypropylene 
round-bottom tube. 
 CRITICAL STEP We recommend filtering the cell sample before sorting using a 5-ml polystyrene round-bottom tube 
with a cell-strainer cap. Transfer the sample in a 5-ml polypropylene round-bottom tube for sorting.
 (vii)  Keep the sample in the dark on ice, and then sort the sample on a cell sorter in a timely manner (within 1 h).
(C) Staining for panel #4 and #5  TIMING 1 h 30 min
 (i)  Collect all cells from MS-5 stromal coculture (from Step 34) by vigorous pipetting, and transfer them to a 96-well  
V-bottom plate.
 (ii) Centrifuge the cells at 480g for 5 min at 20 °C; flick the plate to decant the supernatant.
 (iii)  Stain the cells by the standard surface staining method, as in Step 36A(iii–xii). 
 PAUSE POINT Fixed cells can be kept in the dark at 4 °C for up to 48 h before analyzing by flow cytometry.
Acquisition and cell sorting  TIMING ~1–4 h
37| Run the compensation controls (see Reagent Setup). Create the compensation matrix and apply it to tubes for both 
acquisition and sorting.
 CRITICAL STEP Compensation controls must consist of a negative and a positive population for each single fluorochrome. 
The negative and positive populations should have the same autofluorescence, which means that each positive bead should 
be compared with its matching negative bead.
 CRITICAL STEP When you first set up a panel, you must include a nonstained tube, as well as FMO control (FMOC) tubes. 
FMOCs sequentially contain all fluorochrome or tandem dyes minus one; they are used to define proper gates and to control 
the compensation process.
? TROUBLESHOOTING
38| Run the samples (from Step 36A(xii) and Step 36C(iii)) for acquisition on the flow cytometer. Analyze data using 
FlowJo, as depicted in Figure 2 (panel #1), Figure 3 (panel #2), Figure 5 (panel #4) and Figure 6 (panel #5).
 CRITICAL STEP If you do not have FlowJo software, use FACSDiva software or an equivalent.
? TROUBLESHOOTING
39| Proceed to simultaneous sorting of the four populations of interest—i.e., GMDPs, MDPs, CDPs and pre-cDCs—from  
MNCs obtained in Step 8 and stained in Step 36B(i–vi) using an 85- m nozzle cell sorter. Collect the sorted cells in 1.5-ml 
conical-bottom tubes with screw caps, in which you add 300 l of MS-5 growth medium and vortex the collection tubes to 
coat the surface. You can collect up to 2.5 × 105 cells per tube.
 CRITICAL STEP If you are sorting cells to analyze mRNA expression by gene array, cells should be recovered without  




If the upper layer is contaminated with RBCs, the samples—that is, upper layer and interphase—should be mixed and  
layered over a second batch of Ficoll in a new 50-ml conical tube. Repeat this step if necessary.
Step 35
Post-thaw samples may clot. The cells are probably aggregating because of the release of DNA by cells dying during  
the freezing-thawing process. Include DNase such as benzonase (final concentration 25 U/ml) in thawing medium  
(Steps 13–17), as well as in staining buffer in Steps 36A(iii,iv), 36A(vii,viii) and 36B(ii,iii).
Step 37
If you have no staining of compensation beads, it may be because not all compensation controls have been prepared in  
Step 36. You must prepare a compensation control for each fluorochrome or conjugate if you are using tandem dyes.  
It may also be that you are not using the proper beads; use anti-mouse Ig  for mouse monoclonal antibodies and  





























NATURE PROTOCOLS | VOL.10 NO.9 | 2015 | 1421
Step 38
If you have clogging of the sample line while acquiring samples, the cells are probably aggregating because of poor  
viability. We recommend resuspending the cells in sorting buffer that contains EDTA and filtering the cells using 5-ml  
polystyrene round-bottom tubes with cell-strainer caps.
Step 39
If you have clogging of the sample line while sorting samples, the cells are probably aggregating because of poor  
viability. We recommend diluting the cells and filtering the sample again using a 5-ml polystyrene round-bottom tube  
with a cell-strainer cap.
 TIMING
Staining panel #1: ~3 h–5 h 30 min
Steps 1–8, fresh samples: ~2 h or Steps 13–17, frozen samples: 30 min
Steps 35 and 36A, staining: 1 h 30 min
Steps 37 and 38, acquisition: ~1–2 h
Staining panel #2: ~3 h–5 h 30 min
Steps 1–8, fresh samples: ~2 h or Steps 13–17, frozen samples: 30 min
Steps 35 and 36A, staining: 1 h 30 min
Steps 37 and 38, acquisition: ~1–2 h
Staining panel #3: 3 h 30 min–7 h
Steps 1–8, fresh samples: ~2 h or Steps 13–17, frozen samples: 30 min
Steps 35 and 36B, staining: 1 h
Steps 37 and 39, sorting: ~2–4 h
Staining panel #4: 3 h–5 h 30 min + 8 d coculture
Steps 1–8, fresh samples: ~2 h or Steps 13–17, frozen samples: 30 min
Steps 18–26, culture of mouse MS-5 stromal cells: 8d
Steps 27–34, hematopoietic differentiation on MS-5 stromal cells: 8 d
Steps 35 and 36C, staining: 1 h 30 min
Steps 37 and 38, acquisition: ~1–2 h
Staining panel #5: ~3 h–5 h 30 min + 8 d coculture
Steps 1–8, fresh samples: ~2 h or Steps 13–17, frozen samples: 30 min
Box 1, CFSE staining: 30 min
Steps 18–26, culture of mouse MS-5 stromal cells: 8d
Steps 27–34, hematopoietic differentiation on MS-5 stromal cells: 8 d
Steps 35 and 36C, for staining: 1 h 30 min
Steps 37 and 38, acquisition: ~1–2 h
ANTICIPATED RESULTS
Typically, GMDPs, MDPs and CDPs are found in the Lin− CD34+ cells, which comprise only a small and variable fraction  
of human BM cells (2–4%) and CB cells (~1%): (i) GMDPs represent 5% (BM) and 10% (CB) of CD34+ cells; (ii) MDPs  
represent 0.5% (BM) and 0.5% (CB) of CD34+ cells; and (iii) CDPs represent 2% (BM) and 0.4% (CB) of CD34+ cells14.  
Pre-cDCs, which are found in the Lin− CD34− cells, represent 0.1% (BM) and 0.008% (CB) of CD45+ cells15. Therefore,  
DC progenitors are rare cells; some variability in the number of progenitors is expected from one donor to another,  
but progenitors are consistently found in all BM and CB specimens. Variability between subjects is particularly problematic 
for BM samples that are obtained from elderly donors, in which age-related changes may affect the composition and  
the phenotype of the cells.
As this protocol is based mainly on flow cytometry, it is crucial to verify the proper function and setup of the flow  
cytometer or cell sorter by running an appropriate cytometer procedure and making sure that laser delays are properly  
adjusted24. This step is often omitted and an improper setting will give inconsistent results.
To perform a full and comprehensive evaluation of BM and CB hematopoietic progenitors using multiparametric flow  
cytometry (panels #1 and #2), an ideal number of 2 × 106 (BM) or 4 × 106 (CB) cells are required. Therefore, a small  
fraction of BM or CB is used, allowing the majority of the sample to be used for other studies. This protocol provides an  
appropriate method for BM and CB analysis that could be applied to samples from healthy or abnormal donors. Moreover,  
the same procedure could be adapted to other tissues—that is, blood, lymph node or tonsil—in order to identify and  
sort pre-cDCs for further studies and applications. Of note, the low frequency of pre-cDCs in whole blood (~15 cells per ml  





























1422 | VOL.10 NO.9 | 2015 | NATURE PROTOCOLS
To ensure successful hematopoietic differentiation of DC progenitors in MS5+FSG culture, cell sorting should be performed 
under sterile conditions, and sorting parameters such as sheath fluid pressure should be optimized for viability of the  
cells. Ideally, a maximum of 104 CD34+ HSPCs or DC progenitors are plated on top of MS-5 stromal cells for 7 d. After 2 d of 
expansion, colonies can be observed under the microscope. The proportion of CD45+ cells substantially increases over 7 d.  
For early hematopoietic progenitors such as CD34+ HSPCs, the yield of cells can be increased a little bit by extending the 
culture; however, over 14 d expansion is associated with substantially lower output of CD45+ cells because of competition  
for cytokines and nutrients, as well as stromal cell death. The efficiency of the hematopoietic differentiation is going to 
depend on the sample itself, as variability between donors exists, and the number of cells that are initially cocultured  
on MS-5 stromal cells. After the cells are sufficiently expanded, further characterization can be performed using flow  
cytometry (panels #4 and #5).
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